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1.1. EPIGENETICS  
Epigenetics is an old word that was first used by Conrad Waddington in 
the early 40's. He pointed out that there is no simple relationship between 
a gene and its phenotypic effects. Epigenetics in Waddington’s sense was 
not a synonym of developmental biology, but it could be considered a part 
of it. Waddington and others focused on understanding why many times 
genotype and phenotype variations are not associated, and phenotype 
differences do not necessary involve changes in genotype. However, the 
definition of epigenetics kept changing over time, and in 1982 a dictionary 
of biology defined it as “Pertaining to the interaction of genetic factors and 
the developmental processes through which the genotype is expressed in 
the phenotype.” In 1983, Medawar described epigenetics with this 
sentence: “Genetic proposes: epigenetics disposes”. An easily 
understandable definition of epigenetics could be something like: 
“epigenetics are changes in phenotype that do not involve changes in the 
underlying DNA”. The more relevant change in the concept of epigenetics 
emerged in the decade of 1990, when genetic and non-genetic factors 
were considered to be essential for the control of gene expression that 
produces increasing phenotypic complexity during development. It was 
emphasized that other factors apart from classical DNA code were 
necessary and relevant in the transmission of hereditary information.  
At the end of the 20th century, the word epigenetics became a synonym 
of epigenetic inheritance. Nevertheless, the main problem is that it is not 
easy to distinguish between genetic and epigenetic phenomena, although 
one can usually distinguish between DNA and non-DNA inheritance. In 
fact, there is no a general consensus about what the term epigenetics 
means, but an almost universal agreement. At present, genetics deals 
with the transmission and processing of information in DNA, whereas 
epigenetics deals with its interpretation and integration with information 
from other sources. 
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Jablonka & Lamb [1] wrote that examination of recent books and articles 
with epigenetics in their titles shows that the scope of the subject is far 
less narrow than some current definitions suggest.  
Today’s epigenetics importance is growing because private companies, 
as well as scientific community, are taking an active interest in what goes 
on beyond the DNA level and they are aware that epigenetics could 
introduce changes both in medicine and agriculture.  
Epigenetics is also relevant in hereditary diseases, and it is known that in 
some cases the inherited disorder is caused by a mutation of the gene, 
but in others the defect may be epigenetic. As epigenetic effects can be 
transmitted to offspring it could be necessary to develop an epigenetic 
epidemiology. There are other aspects of epigenetics that may be relevant 
in preventing or curing diseases. As cells have sophisticated epigenetic 
mechanisms for avoiding or destroying genomic parasites, it could be 
possible to control and use these natural, epigenetic defence mechanisms 
to silence the foreign or endogenous genes associated with various 
diseases. Epigenetics also has implications for ecology, because 
organisms interact with each other and with their abiotic environment, and 
through these interactions they acquire epigenetic information, some of 
which may be inherited.  
It is currently known that epigenetic inheritance is not limited to 
multicellular organisms; it is also found in unicellular organisms.  
In 2007 epigenetics was defined as changes in the expression of genes 
that happen without a modification in DNA sequence. This can be 
understood as a bridge between genotype and phenotype [2, 3]. 
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1.2. THE GENUS Serratia  
1.2.1. HISTORICAL OVERVIEW 
The story of this microorganism began in 1819 with the odd history of the 
bloody polenta. Bizio, a young pharmacist of the University of Padua 
named this bacterium.  The name of the genus was chosen to honour to 
Serafino Serrati, a renowned Italian physicist who developed an early 
steamship engine. Noting that the pigment faded rapidly, he added the 
descriptor marcescens, derived from the Latin word that means “to 
decay.” However, Ferdinand Cohn, a distinguished microbiologist dated 
back his origin from the 4th century BC on the basis of  Pitagoras 
credence showed in the satiric work Vitarium auctio written by Luciano de 
Samosata (170 AC). This bacterium has been related to an enormous 
quantity of miraculous due to the capacity of some S. marcescens strains 
to produce a red pigment called prodigiosin.   
It is believed that the first reference of a Serratia contamination is the one 
explained by Quinto Curcio Rufo in his “Alejandro History”, where he 
explains that some soldiers saw blood drops in the bread during their 
conquest of Tiro. This fact was interpreted as a good prediction by a 
fortune-teller. Finally the conquest was successfully. This episode was 
two centuries later confirmed by Siculus. In the middle of the 19th century, 
Christian Ehrenberg described all the miraculous related with this 
bacterium, but he used the name of Monas prodigiosa instead of S. 
marcescens. The most known miraculous event occurred in Bolsena, 
which was decisive for the celebration of Corpus Christi. Raffaello Santi 
painted the fresco “The Mass of Bolsena”, from the Stanza d’Eliodoro.  
 
Fig. 1. “The Mass of Bolsena” from the Stanza d'Eliodoro. Raffael.
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In 1393, in the church of Wilsnack (Germany), the priest left three hosts 
for sick people in the altar during eight days. The previous night was 
raining, so next morning hosts were completely dry. However, 
environment was still wet and drops similar to blood appeared in the hosts 
scaring all the population. This anecdote point at a S. marcescens 
contamination, but in that time many pilgrims went to that church to be 
cured [4]. 
In the 20th century, S. marcescens was used as a marker due to his 
pigment and the belief that this bacterium was innocuous for human 
health. For instance, in one of the experiments, M.H. Gordon put around 
an empty room some Petri dishes with medium and after gargling with a 
S. marcescens culture, he recited Shakespeare texts to check the 
importance of the speaking in the transmission of diseases.  
In 1920, Cumming contaminated with Serratia the throat, the lips and the 
gum of a group of soldiers to study the transmission of diseases. Later on, 
he recovered this bacterium from the hands and mouths of non-inoculated 
soldiers.  
In 1950, the United States Navy conducted a secret experiment named 
"Operation Sea-Spray" in which some S. marcescens were released by 
bursting balloons of it over urban areas of the San Francisco Bay Area in 
California. Although the Navy claimed that bacteria were harmless, some 
patients at a local hospital developed very rare, serious urinary tract 
infections and one of these individuals died. Cases of pneumonia in San 
Francisco also increased after S. marcescens was released [5]. 
Since 1950, S. marcescens has steadily increased as a cause of human 
infection, with many strains resistant to multiple antibiotics [6]. 
The question is now: Which will be the following surprise that this 
prodigious creature will offer to us? [5]  
1.2.2. CHARACTERISTICS OF THE GENUS  
The genus Serratia belongs to the family Enterobacteriaceae, and it is 
comprised of a group of bacteria that are related both phenotypically and 
by DNA sequence [7]. 
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Serratia are Gram-negative short rods that have a 0.5-0.8 µm in diameter 
and 0.9-2.0 µm in length. They are usually motile by peritrichous flagella 
and facultatively anaerobic having two types of metabolism: respiratory 
and fermentative. They grow well at 30 and 37 ºC. They catabolize D-
Glucose and other carbohydrates with the production of acid and often 
gas. They are indole negative except S. odorifera strains, Simmons citrate 
test positive, Voges-Proskauer test usually positive except for S.fonticola 
and most of the strains produce DNase and hydrolyze gelatin and corn oil. 
Most of the species are also lysine decarboxylase positive, arginine 
dihydrolase negative and ornithine decarboxylase positive. They are not 
able to hydrolyze urea or produce H2S and they don’t usually use 
malonate.  They have the capacity to reduce nitrates and ferment 
carbohydrates as maltose, D-mannose, salicin, sucrose and trehalose [8]. 
Figure 2 shows different images of S. marcescens from culture in Petri 
dish, scanning electron microscope, confocal microscope (dead-alive) and 
atomic force microscopy (AFM). 
 
 a)                            b)                                  c)                           d) 
 
Fig. 2. a) S. marcescens pigmented colonies growth in TSA. b) S. marcescens obtained by 
Scanning Electron Microscope. c) S. marcescens from confocal microscope after staining 
with LIFE/DEAD stain and d) S. marcescens obtained by AFM.  
 
Serratia species occupy different habitats and are mainly isolated from 
small mammals, water, plants and hospitalized patients.  
Water is probably the principal habitat of S. plymuthica. However, many 
other species have been isolated from water. The 75% of 150 Serratia 
strains isolated from river water belonged to S. marcescens (F. Agbalika, 
F. Grimont, and P.D.A. Grimont, unpublished observations). In soil, S. 
marcescens might play a role in the biological cycle of metals by 
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mineralizing organic iron and dissolving gold and copper. Most of the 
strains isolated from soil and water are prodigiosin producers. This 
pigment is toxic to protozoa, so this may be an ecological advantage for 
them.  
Plants are also a usual habitat for Serratia strains. S. ficaria is mainly find 
in figs, and S. rubidaea in coconuts. Serratia species were frequently 
found in plants (Grimont et al., 1981). Vegetables, mushrooms, mosses 
and wet plants are the most important habitats where Serratia is found. It 
is sometimes found in grasses and less in trees and shrubs. The most 
common Serratia strains isolated from plants other than figs and coconuts 
are S. liquefaciens and S. proteamaculans. S. marcescens is rarely 
isolated from plants.   
Insects are mainly associated with S. marcescens, S. proteamaculans 
and S. liquefaciens, which are considered potential insect pathogens. The 
rarity of S. rubidaea in insects might be explained by its inability to 
produce chitinase, a virulence factor for insect-associated Serratia 
species. 
Serratia strains can be isolated from many vertebrates as caws, turtles, 
birds and wild rodents. Sometimes strains have been recovered from 
healthy vertebrates, but usually Serratia has been associated with chronic 
infections. For instance, red-pigmented strains are responsible for 0.2-
1.5% of mastitis in cows. Serratia is not usually isolated from healthy 
people, whereas hospitalized patients are frequently colonized or infected. 
The opportunistic pathogen S. marcescens has been related to many 
infections. This fact will be widely described in subsequent sections [7].  
1.2.3. TAXONOMY  
The number of species that belong to the genus Serratia has increased 
from five species mentioned in the first edition of The prokaryotes to 
seven species described in Bergey´s Manual of Systematic Bacteriology 
until ten species known at present. The Serratia species are: S. 
marcescens, S. liquefaciens, S. proteamaculans, S. grimesii, S. 
                                                                                                   Introduction   
  
9
plymuthica, S. rubidaea, S. odorifera, S. ficaria, S. entomophila and S. 
fonticola.  
1.2.4. PATHOGENICITY FACTORS  
S. marcescens is an opportunistic pathogen that causes infections in 
immunocompromised patients. The possible pathogenicity factors found in 
Serratia are described below:  
Fimbriae: are proteinaceous appendages that are thinner and shorter 
than flagellum. Five types of fimbriae have been observed in Serratiae, 
and each strain can produce between one and three kinds of fimbrial 
hemaglutinin. The type 1 fimbriae produce mannose-sensitive 
hemagglutinin (MS-HA) and was found to be produced by all or almost all 
strains of S. marcescens whether environmental or clinical and also in 
some strains of other Serratia species. The production of MS-HA has 
been correlated with the ability of S. marcescens to attach to human bucal 
epithelial cells or to the human urinary bladder surface. 
The type 3 fimbriae are associated with mannose-resistant hemagglutinin 
(MR/K-HA) and are produced by almost all Serratia strains. However, this 
type of fimbriae is more frequently produced by clinical strains than 
environmental strains. The type FGH MR/PHA fimbriae produced by 
strains of all species except S. plymuthyca and S. fonticola are associated 
with mannose-resistant hemaglutinin and these fimbriae are 
immunologically related in the different species [9].  
The type F MR/P-HA fimbriae produced by some S. rubidaea are 
associated with mannose-resistant hemagglutinin and are 
immunologically unrelated with other hemagglutinins.  
The type F MR/P-HA fimbriae produced by some S. fonticola strains are 
also associated with mannose-resistant hemagglutinin.  
Siderophores: Siderophores are produced by clinical and environmental 
S. marcescens strains. Serratia strains generally produce enterobactin but 
only rarely produce aerobactin.  
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O antigens: Although O-antigens cannot be considered truly 
pathogenicity factors, they are located in LPS surface, and it is known that 
O6 and O14 serotypes of S. marcescens are predominant in infections.  
Extracellular enzymes: Enzymes that play a prominent role in the 
pathogenesis of experimental pneumonia and keratitis.  
Plasmids: They probably play no rule in the virulence in experimental 
models, but multiple drug resistance may affect the course and prognosis 
of infections. Non-pigmented strains of S. marcescens use to be more 
resistant because they often harbour resistance plasmids.   
Relatively little is known about factors that contribute to S. marcescens 
pathogenesis within its host. However, some virulence factors of the 
human opportunistic S. marcescens have been recently identified by in 
vivo screening [7, 10]. 
1.3. THE GENUS Pseudomonas  
Pseudomonas spp. are aerobic, non-spore-forming Gram-negative bacilli, 
which are usually motile by one or several polar flagella.  
Pseudomonas is a genus including species that can use a wide range of 
organic and inorganic compounds and can live under diverse 
environmental conditions. For that reason, they are ubiquitous in soil and 
water, plants, animals and humans (some isolates may infect 
immunocompromised patients). 
This genus is well known for its metabolic and genetic plasticity. They 
generally grow rapidly and are able to metabolize a huge number of 
substrates including toxic organic chemicals, such as aliphatic and 
aromatic hydrocarbons [11]. 
They possess a strictly respiratory metabolism with oxygen as the 
terminal electron acceptor; but they are capable grow anaerobically due to 
its ability to use nitrate, an alternative electron acceptor [12].  
One important consequence of its metabolic diversity is that 
Pseudomonas spp., in particular P. aeruginosa, is common throughout the 
hospital setting and persist in many types of equipment, sinks, tubes, etc. 
                                                                                                   Introduction   
  
11
This characteristic certainly contributes to the opportunistic nature of 
opportunistic infections [13].   
Pseudomonas species, particularly the human pathogen P. aeruginosa, 
not often colonize healthy humans. The throat, intact skin or stools of 
healthy individuals are densely colonized by normal flora, which do not 
include Pseudomonas species. Nevertheless, individuals that often 
received antibiotic therapies are at risk of gastrointestinal colonization with 
P. aeruginosa and consequently, due to this reservoir the patient can 
suffer septicemia caused by this microorganism. Patients undergoing anti-
cancer chemotherapy or marrow ablation for bone marrow transplantation 
and patients with cystic fibrosis or receiving mechanical ventilation have 
greater risk to develop serious Pseudomonas infections [12].  
1.3.1. TAXONOMY  
Pseudomonas is a genus that was first proposed by Migula in 1894. It has 
been subjected to many taxonomic revisions and identification 
methodologies. In the early 1970s this genus was classified into five 
unrelated groups according to RNA-DNA hibridization studies: I, 
Proteobacteria; II, Burkholderia species; III, Comamonas, Acidovorax, and 
Hydrogenophaga genera; IV, Brevundimonas species; and V, 
Stenotrophomonas and Xanthomonas genera. Currently, there are about 
160 species within Pseudomonas genus, of which few species have 
clinical significance.  
1.3.2. PATHOGENESIS  
P. aeruginosa is the most important causative agent of opportunistic 
infections among the genus Pseudomonas; this is the reason why we are 
basically going to focus on the pathogenesis of this particular 
microorganism [12,14]. It can cause both acute and chronic infections.  
P. aeruginosa is now recognized as a common source of many 
community acquired and nosocomial infections. The main infections are 
the ones that involve cornea, skin, urinary tract and respiratory tract, 
although infections may occur in essentially all anatomical locations. Host 
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immunodeficiency, combined with a high incidence of antibiotic resistant 
strains, makes treatment of P. aeruginosa a serious medical challenge.  
There are many factors involved in the pathogenesis of P. aeruginosa. 
Thus, the virulence of this opportunistic pathogen cannot be attributed to a 
single factor; it has to be considered multifactorial. Some of the factors 
relevant in Pseudomonas pathogenesis are adhesins, endotoxins, 
proteases, hemolysins and a type III secretion system. 
The virulence determinants with known roles in pathogenesis are 
summarized below:  
Adherence: The two important types of adhesins used by P. aeruginosa 
to colonize host tissues are fimbrial adhesins, such as type IV pili and type 
I fimbriae, and non-fimbrial adhesins, including lipopolysaccharide, 
flagella, outer membrane proteins and alginate.  
Exotoxin A: It is the most potent exotoxin produced by almost all clinical 
P. aeruginosa isolates.  
Proteases and phospolipases: P. aeruginosa produces several 
proteases including LasB elastase, LasA elastase, and alkaline protease. 
Las A, Las B and alkaline protease are associated with tissue damage in 
P. aeruginosa infections. Besides, it produces two homologous 
extracellular phospholipases, the hemolytic PlcH and the nonhemolytic 
PlcN, which has been demonstrated to be a virulence factor in a variety of  
P. aeruginosa infections.  
Type III secretion: This system is a major determinant of virulence in P. 
aeruginosa. It is used to deliver four toxins that act in concert to inhibit 
phagocytosis and promote tissue destruction. It is expressed in response 
to a variety of environmental signals (low Ca2+ concentrations, serum and 
contact with eukaryotic cell surfaces).  
Quorum sensing: las and rhl are the two quorum sensing systems used 
by P. aeruginosa for the coordination of gene expression with density of 
bacteria. Many of the genes regulated by quorum sensing are known 
virulence factors. However, as P. aeruginosa is considered an 
opportunistic pathogen, it is though that quorum sensing plays an 
important function in the environment.  
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Biofilms: P. aeruginosa biofilms (surface-associated bacterial 
communities encased within a polymeric matrix) are mainly formed on the 
surfaces of medical devices, and can contribute to chronic infections. 
Moreover, inherent resistance of biofilms makes them difficult to treat and 
eliminate. 
1.4. ANTIMICROBIAL AGENTS AND BACTERIAL RESISTANCE  
1.4.1. ß-LACTAMS 
ß-lactams are a group of antibiotics that contain a four-atom ring (ß-
lactam) that determine their most relevant characteristics i.e. mechanism 
of action (inhibition and synthesis of the wall), main mechanisms of 
resistance (ß-lactamases) and low toxicity (strict inhibition of wall 
biosynthesis, since the structure do not exist in eukaryote cells). ß-lactam 
antibiotics include penicillins, cephalosporins, carbapenems and 
monobactams.  
Since 1920, when penicillin was discovered, ß-lactams have been 
successfully used in the treatment of human infectious diseases. Due to 
their spectra of activity, effectiveness, low toxicity and wide therapeutic 
margin, they are the most used antimicrobial agents in the community, as 
well as in hospitals. 
1.4.1.1. PENICILLINS  
1.4.1.1.1. CLASSIFICATION AND STRUCTURE  
Penicillins are natural or semisynthetic antibiotics containing the chemical 
nucleus 6-aminopenicillanic acid. The penicillins differ from one another in 
the substitution at position 6.  
 
 Fig. 3. Penicillin core structure. 
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1.4.1.1.2. TARGETS AND MECHANISM OF ACTION 
Penicillins have the ability to inhibit a number of bacterial enzymes, 
specifically penicillin-binding proteins (PBPs) that are essential for 
peptidoglycan synthesis.  
PBPs have enzymatic activity as carboxypeptidases and transpeptidases 
being directly responsible of the incorporation of new subunits into the 
growing peptidoglycan. Activity of penicillins is usually related to their 
ability to destroy bacterial wall by the triggering of membrane-associated 
autolytic enzymes. They can also inhibit endopeptidase and glycosidase 
enzymes, which are relevant in bacterial growth.  
1.4.1.1.3. SPECTRUM OF ACTIVITY  
Penicillins are active against most Gram-positive and many Gram-
negative and on both aerobic and anaerobic organisms. Penicillin G is not 
active against enterococci, members of the family Enterobacteriaceae, 
Pseudomonas spp. or members of the Bacteroides fragilis group. 
Ampicillin and amoxicillin have similar spectra of activities than Penicillin 
G, and they are degraded by ß-lactamase and are inactive against many 
Enterobacteriaceae and P. aeruginosa. Carboxypenicillins and 
ureidopenicillins are more stable against hydrolysis by the ß-lactamases 
of Enterobacteriaceae and P. aeruginosa.  
1.4.1.2. CEPHALOSPORINS  
1.4.1.2.1. CLASSIFICATION AND STRUCTURE  
Cephalosporins belong to ß-lactam antibiotics and originally derived from 
Acremonium. They contain a 7-aminocephalosporanic acid nucleus, which 
consist of a ß-lactam ring fused. Various substitutions at positions 3 and 7 
alter their antibacterial activities and pharmacokinetic properties. The 
addition of a methoxy group at position 7 of the ß-lactam ring results in a 
new group of compounds called cephamycins, which are highly resistant 
to a variety of ß-lactamases.  
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Cephalosporins are classified in generations. The evolution of the 
generations is related with an increment of their spectrum of activity and 
intrinsic activity against Gram-negative organisms. 
Figure 4 shows the chemical structure of cephalosporins.  
 
 
Fig.4. Cephalosporin core structure.  
 
Classification of cephalosporins is shown in table 1. 
Table 1. Cephalosphorins classification 
First generation  
(narrow-spectrum) 
Second generation  
(expanded 
spectrum)  
Third generation  
(broad-spetrum) 
Fourth generation  
(extended 
spectrum) 
Cefadroxil  
Cefazolin  
Cephalexin  
Cephaloridine  
Cephalotin  
Cephapirin  
Cephradine 
Cefaclor  
Cefamandole 
Cefonicid  
Ceforanide  
Cefuroxime  
Cefprozil  
Loracarbe  
Cefmetazole  
Cefotetan  
Cefoxitin 
Cefdinir 
Cefditoren  
Cefixime  
Cefoperazone  
Cefotaxime  
Cefpodoxime  
Ceftazidime  
Ceftibuten  
Ceftizoxime  
Ceftriaxone 
Cefepime  
Cefpirome 
 
1.4.1.2.2. TARGETS AND MECHANISM OF ACTION  
Like penicillins, cephalosporins act by binding to penicillin-binding proteins 
(PBPs) of susceptible organisms, thereby interfering with synthesis of 
peptidoglycan of the bacterial wall. Cephalosporins also produce 
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bactericidal effects by triggering autolytic enzymes in the envelope of 
bacteria.  
1.4.1.2.3. SPECTRUM OF ACTIVITY  
First generation cephalosporins (narrow spectrum) have good activity 
against Gram-positive organisms and modest activity against Gram-
negative organisms.  
Second generation cephalosporins (expanded spectrum) are more active 
against Gram-negative bacteria than first generation cephalosporins 
because of their stability to ß-lactamases, and less active against Gram-
positive organisms. The activity also depends on the concrete antibiotic 
used.  
Third generation cephalosporins (broad spectrum) are generally less 
active against Gram-positive cocci than the narrow spectrum agents, but 
they are more active against the Enterobacteriaceae and P. aeruginosa.  
Four generation cephalosporins (extended spectrum) are active against 
stably derepressed class I ß-lactamase mutants of Enterobacteriaceae 
and P. aeruginosa. Besides, these antibiotics penetrate well through the 
outer membrane of Gram-negative bacteria but they are inactive against 
enterococci or anaerobes.  
1.4.1.3. MONOBACTAMS AND CARBAPENEMS 
1.4.1.3.1. CLASSIFICATION AND STRUCTURE  
Monobactams, such as aztreonam, are β-lactam compounds wherein the 
β-lactam ring is alone and not fused to another ring.  
Carbapenems are ß-lactams with a hydroxyethyl side chain in trans 
configuration at position 6 and lacking a sulphur or oxygen atom in the 
bicyclic nucleus (Figure 5). Doripenem, imipenem, meropenem and 
ertapenem are currently available for clinical use. 
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Aztreonam                     Carbapenems 
Fig. 5. Chemical structure of aztreonam and carbapenems.  
1.4.1.3.2. TARGETS AND MECHANISM OF ACTION  
Aztreozam binds to the PBP 3 of Gram-negative aerobes disrupting 
bacterial wall synthesis. It does not induce production of enzymes and it is 
not hydrolyzed by most common ß-lactamases.  
Carbapenems bind to PBP 1 and PBP 2 of Gram-negative and Gram-
positive bacteria, elongating the cell and causing lysis.  
1.4.1.3.3. SPECTRUM OF ACTIVITY  
Aztreonam has significant activity against Enterobacter spp. and S. 
marcescens. 
Carbapenems are active against aerobic Gram-positive species. More 
than 90% of Enterobacteriaceae are generally susceptible to 
carbapenems, including S. marcescens. Ertapenem is inactive against 
Pseudomonas and Acinetobacter.  Carbapenems are the most potent ß-
lactams against anaerobes. At present, there are some P. aeruginosa 
strains resistant to imipenem.  
1.4.1.3.4. RESISTANCE TO ß-LACTAM ANTIBIOTICS 
1. Penicillin-binding protein-mediated resistance 
This kind of resistance takes several forms described below:  
PBP overexpression: It is an uncommon mechanism of resistance where 
the high number of target molecules can result in resistance under the 
correct circumstances [12]. 
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2. ß-lactamase-mediated resistance 
There are two ß-lactamase classification systems currently used that are 
compared in table 2. 
Table 2. ß-lactamase classification  
Bush-Jacoby-
Medeiros system 
Major 
subgroups 
Ambler system Main attributes 
 
Group 1 
cephalosporinases 
 
 
 
Group 2 
penicillinases 
(clavulanic acid 
susceptible)  
 
 
 
 
 
 
 
 
 
 
 
Group 3 metallo-
ß-lactamase  
 
 
 
Group 4 
 
 - 
        
 
 
 
2a 
 
2b 
 
2be  
 
2br 
2c 
2e 
 
2f  
 
2d 
 
 
3a 
 
3b 
3c 
 
 - 
 
C 
(cephalosporinases) 
 
 
 
A (serine ß-
lactamases) 
A 
 
A 
 
A 
A 
A 
 
A 
 
D (oxacillin 
hydrolyzing)  
 
B (metalloenzymes)  
 
B 
B 
 
Not classified  
 
Usually chromosomal; 
resistance to all ß-lactams 
except carbapenems; not 
inhibited by clavulanate 
 
Staphylococcal penicillinases  
 
Broad-spectrum: TEM-1, 
TEM-2, SHV-1  
Extended-spectrum: TEM and 
SHV variants predominantly  
Inhibitor-resistant TEM  
Carbenicillin hydrolyzing  
Cephalosporinases inhibited 
by clavulanate  
Carbapenases inhibited by 
clavulanate  
Oxacillin-hidrolyzing (OXA)  
 
 
Zinc-dependant 
carbapenemases  
 
 
 
Miscellaneous enzymes, most 
not yet sequenced  
 
 
ß-lactamase mechanism: This mechanism has been studied in TEM-1 
and SHV-2 Class A ß-lactamase. Disruption of the amide bond is done in 
a two-step reaction where the negatively charged carboxylate group of the 
ß-lactam antibiotic is attracted to the active site by the enzymes positively 
charged residues and then, ß-lactam becomes acylated.  
ß-lactamases: These enzymes are produced in a constitutive or inducible 
manner. They can be encoded by chromosomal, plasmids, or transposon 
genes. Genes encoding ß-lactamases of all known molecular classes (A 
through D) can be found as integrons-associated.  
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Integrons are genetic elements of variable lengths that contain a 
5’conserved integrase gene (int), mobile antibiotic resistance genes 
(cassettes), and an integration site for the gene cassette, attI (att, 
attachment). Class 1, 2 and 3 integrons are common in Gram-negative 
bacteria. Integrons capture antibiotic resistance gene cassettes by using a 
site-specific recombination mechanism. They act both as natural cloning 
systems and as expression vectors [15]. The capture and spread of 
antibiotic resistance determinants by integrons underlie the rapid evolution 
of multiple-antibiotic resistance in Gram-negative clinical isolates [16]. 
Integrons carrying ß-lactamases have been found in most Gram-negative 
bacteria.  
ß-lactamases classes:  
Class A ß-lactamases (Group 2b Penicillinases): The two commonly 
class A ß-lactamases found in Enterobacteriaceae are TEM-1 and SHV-1, 
which are primarily penicillinases with diminished activity against 
cephalosporin substrates. They are the progenitors of the ESBLs and the 
inhibitor-resistant TEM ß-lactamases now common in many hospitals [12].  
Bush group 2be (ESBLs): Extended-spectrum cephalosporins (a group 
of potent ß-lactams) are poor substrates for hydrolysis by group 2b 
enzymes. Mutations at critical amino acids resulted in an expansion of the 
spectra of these enzymes enabling them to hydrolyze extended-spectrum 
cephalosporins.  The number of enteric Gram-negative rods possessing 
ESBLs has increased recently and this has obliged to modify the choice of 
antimicrobial therapies.  
Non-TEM, non-SVH ESBLs: CTX-M ß-lactamases commonly found in 
Klebsiella pneumoniae, Escherichia coli, Salmonella spp., Shigella spp., 
Citrobacter freundii, Enterobacter spp., and S. marcescens are the most 
important non-TEM, non-SHV ß-lactamases. They hydrolyze cefotaxime 
and ceftriaxone better than they do ceftazidime. They are more readily 
inhibited by tazobactam than they are by clavulanic acid.   
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Inhibitor-resistant class A ß-lactamases (Bush group 2br): This group 
is formed by amino acid mutated TEM and SHV conferring resistance to 
inhibition by ß-lactamases inhibitors.  
Class B ß-lactamases (Bush group 3 enzymes): This class of ß-
lactamases is formed by metallo-enzymes that require zinc or another 
heavy metal for catalysis; their activities are inhibited by chelating agents 
such as EDTA. These ß-lactamases confer resistance to a wide variety of 
ß-lactam compounds, including carbapenems and cephamycins. They are 
resistant to inactivation by clavulanate, sulbactam and tazobactam. Some 
of them hydrolyse aztreonam. The majority of ß-lactamases are 
chromosomally encoded, and their expression may be constitutive or 
inducible. VIM and IMP class B ß-lactamases are active against most ß-
lactams and have been found in various Gram-negative clinical isolates. 
The majority of these enzymes are mobilized on integrons, transposons 
and mobile common regions. 
Class C ß-lactamases (Bush-Jacoby-Medeiros group 1): ß-lactamases 
chromosomally encoded by almost all Gram-negative bacteria except 
Salmonella and Klebsiella. These enzymes are important in Gram-
negative clinical isolates, including S. marcescens. Class C ß-lactamases 
hydrolyze cephalosporins and penicillins. Most of them are resistant to 
inhibition by clavulanate, sulbactam and tazobactam. Some class C ß-
lactamases of Gram-negative bacteria are plasmid mediated.  
Class D ß-lactamases (oxacillin-hydrolyzing): OXA enzymes ß-
lactamases are included in this group. They confer resistance to a wide 
variety of penicillins and are weakly inhibited by clavulanic acid and totally 
inhibited by sodium chloride. The frequent location of class D genes on 
mobile genetic elements (plasmid or integrons) facilitates its spread. 
Several OXA ß-lactamases are associated with an ESBL phenotype, and 
are important because some of them are capable to hydrolyze 
carbapenems. Although OXA carbapenases hydrolyze imipenem 
inefficiently, their presence in an organism with an active efflux pump or a 
porin mutation may confer clinically significant levels of resistance.  
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1.4.2. AMINOGLYCOSIDES  
1.4.2.1. CLASSIFICATION AND STRUCTURE  
Streptomycin was the first aminoglycoside introduced in 1944 for the 
treatment of serious Gram-negative infections. Structurally, each of this 
aminoglycosides contains two or more amino sugars linked by glycosidic 
bonds to an aminocyclitol ring nucleus.  
There are two different groups of aminoglycosides. Streptomycin, 
neomycin, kanamycin, tobramycin and gentamicin belong to the group of 
natural aminoglycosides, and amikacin and netilmicin belong to the group 
of semisynthetic aminoglycosides (Figures 6 and 7). 
 
    
                           Streptomycin                                             Neomycin 
  
Kanamycin 
 
                          Tobramycin                                            Gentamicin  
Fig. 6. Chemical structures of natural aminoglycosides. 
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                                         Amikacin                                    Netilmicin   
Fig. 7. Chemical structures of semisynthetic aminoglycosides. 
 
1.4.2.2. TARGETS AND MECHANISM OF ACTION 
These bacterial agents inhibit bacterial protein synthesis by binding 
reversibly to the bacterial 30S ribosomal subunit preventing mRNA 
translation during protein synthesis and leading bacteria to death. 
Bacterial uptake of these agents is facilitated by ß-lactams and 
vancomycin, which inhibit bacterial wall biosynthesis.  
1.4.2.3. SPECTRUM OF ACTIVITY  
Aminoglycosides are generally active against aerobic Gram-negative rods 
(Enterobacteriaceae, P. aeruginosa and Acinetobacter spp.) and 
Staphylococcus aureus (not recommended as single agents). They are 
not active against anaerobes.  
Certain differences in antimicrobial spectra among the various 
aminoglycosides do exist (table 3).  
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Table 3. Differences in antimicrobial spectra among aminoglycosides.  
Aminoglycoside Resistant to : Other particularities: 
Kanamycin  
 
 
P. aeruginosa  
Plasmid-mediated inactivating 
enzymes among other Gram-
negative bacilli. 
Used in mycobacterial infections 
in combination with other 
antimicrobial agents. 
Streptomycin  
 
 
 
Some Enterobacteriaceae. 
 
Used as a single agent in 
Francisella tularensis and 
Yersinia pestis. 
Used in combination with 
tetracycline for brucellosis.  
Used in combination with 
penicillin or vancomycin for 
streptococci or enterococci 
infective endocarditis.  
Gentamicin  
 
Bacteria that produce modifying 
enzymes (except 6-
acetyltransferase and 4’-
adenyltransferase). 
Active against Mycobacterium  
tuberculosis.  
Very active against Serratia spp.  
Tobramycin  Bacteria that produce modifying 
enzymes (including 6-
acetyltransferase and 4’-
adenyltransferase). 
Variable resistance to 3-
acetyltransferase producers.  
Very active against P. 
aeruginosa.  
 
Netilmicin  Many of the aminoglycoside-
modifying enzymes.  
Most gentamicin-resistant 
Serratia, Proteus, Providencia 
and Pseudomonas isolates.  
Active against most gentamicin 
and tobramycin-resistant 
Enterobacteriaceae.  
Less active against P. 
aeruginosa than gentamicin and 
tobramycin.  
Amikacin  Some aerobic Gram-negative 
bacillus and S. aureus.  
Active against most gentamicin 
and tobramycin-resistant 
Enterobacteriaceae. 
Used when tobramycin and 
gentamicin resistances are 
prevalent.  
Active against many 
Mycobacterium spp. and 
moderately active against 
Haemophilus spp. and Neisseria 
spp.  
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1.4.2.4. RESISTANCE TO AMINOGLYCOSIDES  
There are three known mechanisms of resistance to aminoglycosides:  
1. Reduction of intracellular aminoglycosides accumulation due to outer 
membrane permeability alteration, inner membrane transport decrease or 
active efflux increase.  
2. Modification of the target site by mutation in the ribosomal proteins or 
16S RNA.  
3. Enzymatic modification of the drug.  
All S. marcescens produce chromosomal AAC(6’)-Ic enzyme that may 
slightly affect the activity of all aminoglycosides except streptomycin and 
gentamicin.  
Gentamicin is the most active aminoglycoside against Serratia. However, 
other aminoglycosides can be used when isolates do not produce 
aminoglycoside-modifying enzymes.  
Resistance to aminoglycosides in P. aeruginosa usually results from drug 
inactivation by plasmid or chromosome-encoded enzymes harbored by 
resistant strains.  
Enzyme-independent resistance can be due to defects in 
uptake/accumulation of the drug [17]. 
1.4.3. QUINOLONES  
1.4.3.1. CLASSIFICATION AND STRUCTURE 
The era of quinolones began in the early 1960s when Lesher and 
associates discovered nalidixic acid during the synthesis of the 
antimalarial agent chloroquine [18,19].  
Quinolones are a class of wide-spectrum agents which are usually 
classified by generations taking into account their spectrum of activity and 
clinical indications.  
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 Table 4. Classification of quinolones by generations  
First 
generation 
Second 
generation 
Third 
Generation 
Four 
generation 
Five generation 
Nalidixic acid  
Pipemidic acid  
Cinoxacin 
Flumequine 
Ofloxacin  
Enoxacin 
Lomefloxacin 
Ciprofloxacin  
Pefloxacin 
Levofloxacin  
Sparfloxacin 
Grepafloxacin 
Gatifloxacin 
Trovafloxacin 
Moxifloxacin 
Gemifloxacin 
Sitafloxacin 
Clinafloxacin 
Garenofloxacin  
DX-619, WCK-
771, WCK-
1153,DW-286 
 
The chemical structure of fluoroquinolones (Fig. 8) is based on the 1,4-
dihydro-4-oxo-pyridine molecule, which has a carboxylic acid substituent 
at position 3. This substituent with the carbonyl group at position 4 
appears to be essential for the activity of these antimicrobial agents. First 
generation quinolones (except flumequine) lack the fluorine atom at 
position 6. The second-generation quinolones have a cyclic diamine at the 
position 7 and fluorine atom at position 6 in the quinolone nucleus, and 
the third generation differs from the previous generation in the 
substituents located at positions 1, 7 and 8 of the quinolone nucleus [17, 
20].  
 
Fig. 8. Basic structure of quinolones. 
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1.4.3.2. TARGETS AND MECHANISM OF ACTION  
DNA gyrase and topoisomerase IV are the protein targets of quinolones. 
On the one hand, DNA gyrase is a tetrameric enzyme with two A subunits 
and two B subunits that catalyzes the negative supercoiling of DNA. The 
energy required for this process is obtained from the hydrolysis of ATP. 
DNA gyrase is known to play a significant role in both transcription and 
replication of DNA. On the other hand, topoisomerase IV is a tetrameric 
enzyme with two A subunits and two B subunits encoded by the ParC and 
ParE genes. It seems to be involved in decatenating daughter replicons 
following DNA replication. 
At present, the mechanism of action of quinolones is not fully understood. 
There are some controversies, despite the fact that the mechanism of 
action has been carefully studied. It is accepted that quinolones have two 
binding domains, one interacting with DNA and the other with DNA 
gyrase. Complex formation of the DNA gyrase-quinolone-DNA has been 
associated to inhibition of DNA replication.  
1.4.3.3. SPECTRUM OF ACTIVITY  
First generation quinolones are substantially less potent in vitro and have 
narrower antibacterial spectra than newer generations, having enhanced 
activities against Gram-negative bacilli, except P. aeruginosa. They lack 
activity against Gram-positive cocci and anaerobes. These quinolones 
reach high concentrations in the urinary tract and subsequently they are 
widely used to treat urinary tract infections [17, 21].   
Second generation quinolones exhibit striking potency against enteric 
Gram-negative bacilli, less activity against non-enteric Gram-negative 
bacilli, including P. aeruginosa, and generally marginal activity against 
staphylococci and anaerobes [18, 20]. These quinolones are mainly used 
to treat urinary tract infections, pyelonephritis, skin and soft tissue 
infections and sexually transmitted diseases [21].  
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The third generation quinolones have improved activity against Gram-
positive cocci and anaerobic bacteria. They are mostly used for the 
treatment of chronic bronchitis, acute sinusitis and community pneumonia.  
The fourth generation quinolones have similar spectrum of activity than 
third generation quinolones. They exhibit activity against anaerobes. They 
are used for the treatment of nosocomial pneumonia, intraabdominal and 
gynecologic infections and the same infections to which the previous 
generations are used but urinary tract infections.  
Finally, some of the fifth generation quinolones have antimicrobial activity 
against the same microorganisms than those of fourth generation, 
whereas others are specifically designed to fight against infections caused 
by multidrug-resistant bacteria [20].  
1.4.3.4. RESISTANCE TO QUINOLONES  
Both chromosomal and plasmid-mediated quinolone resistance have been 
described. Chromosomal mutations comprise mutations in the 
topoisomerase genes (gyrA, gyrB, parC and ParE) and mutations that 
produce a reduction in drug accumulation (decrease uptake or increase 
efflux).  
There are many factors that can promote the emergence of resistance to 
quinolones, not only in the target pathogen, but also in the normal flora 
(gut, skin and throat). These factors can be categorized in three groups: 
dependent on the drug, dependent on the bacterium or dependent on the 
host and others. Table 5 shows the relevant factors to be considered in 
each group [17].  
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Table 5. Relevant factors favoring emergence of resistance to quinolones.  
                                                                 Factors dependent on the:  
Drug Bacterium   Host and others 
Concentration of the 
drug achieved in the 
infection site or 
epithelium. 
 
Time of exposure 
(concentration of the 
drug above the MIC).  
 
Mutagenesis  
Higher inoculum increase probability 
of spontaneous mutations. 
 
Quorum sensing. (Control of virulence 
factors expression, the entry into 
stationary phase, the conjugal factor 
of transfer DNA, and spore formation 
and transformation competence). 
 
Hypermutability.  
 
Capability and capacity to form 
biofilm. (Bacterial density determines 
the gradients of nutrients and oxygen 
availability within the biofilm structure; 
bacteria located in deeper parts of 
biofilm have worst access to nutrients 
and oxygen; bacteria located in zones 
of the biofilm with high metabolic 
activity and oxygen concentration are 
better killed by antimicrobial agents). 
 
Facility to acquire quinolone 
resistance. (Slow or no growth 
bacteria have increased resistance 
than exponential ones). 
Pharmacokinetics of the 
drug at the infection or 
colonization sites. 
 
Immune status. 
  
Environment at the site 
infection such as pH, 
oxygen, nutrients, etc. 
 
Many authors have shown that in S. marcescens, like in other 
Enterobacteriaceae (but E.coli) a single substitution in the quinolone-
resistance determining region (QRDR) is enough to produce high level 
resistance. However, higher levels of fluoroquinolone resistance can be 
achieved when there is cooperation between QRDR alterations and low 
permeability (or active extrusion) limiting the intracellular accumulation of 
the drug  [22].    
It was also demonstrated that when the Omp1 porin was absent in clinical 
isolates of S. marcescens, there was a prominent decrease in quinolone 
accumulation. Thus, porins play a key role in S. marcescens quinolone 
resistance [23]. 
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Puig et al. indicated that susceptibility to antibiotics in S. marcescens was 
modified by analgesics, suggesting that when analgesics such as 
acetylsalicylate and antibiotics are administered together, their interaction 
can change the response of microorganisms to antibiotics [24]. 
Furthermore, it was shown that when concentration of salicylic acid 
augments, there is a diminishing in ciprofloxacin accumulation and a 
reduction in the porin content of the outer membrane. Resistance to 
ciprofloxacin and nalidixic acid was enhanced when bacteria grew in the 
presence of salicylic acid, supporting the idea that salicylate induces 
phenotypic resistance to quinolones in S. marcescens [25].  
Subsequently, Begic and Worobec  evidenced that high salicylate and 
sucrose concentrations, increased temperature and an acidic acid pH 
reduce the porins uptake and availability of norfloxacin (hydrophilic 
fluoroquinolone), leading to an increased resistance of S. marcescens to 
this antibiotic. Nevertheless, nalidixic acid (hydrophobic quinolone) 
susceptibility was not affected by the same conditions [26].  
Mechanisms of quinolone resistance in non-fermentative Gram-negative 
bacteria are similar to the ones described for Enterobacteriaceae. The 
quinolone susceptible strains of P. aeruginosa (also Acinetobacter 
baumannii and Stenotrophomonas maltophilia) usually show higher 
baseline MICs for quinolones when compared with Enterobacteriaceae. In 
P. aeruginosa, the decreased permeability of the outer membrane 
together with several efflux pumps such as MexAB-OprM, MexCD OprJ, 
MexEF-OprN, MexXY-OprM and MexVW-OprM can affect fluoroquinolone 
susceptibility. The genome of this microorganism revealed the presence 
of more efflux pumps, although their potential role in antibacterial 
resistance has not been fully elucidated.  Mutations in gyrA and parC 
genes can also contribute to increasing the level of resistance to 
quinolones. Fluoroquinolone minimal inhibitory concentration (MIC) can 
be modulated by overexpression of one or more efflux pumps in 
collaboration with mutations in the gyrA and parC genes [17].  
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1.4.4. POLYMYXINS 
1.4.4.1. CLASSIFICATION AND STRUCTURE  
Polymyxins are cationic peptides antimicrobials (Fig. 9) originally derived 
from Bacillus polymyxa. Only polymyxins B and E (colistin) are available 
for therapeutic use in humans.  
Colistin is available since 1959 for the treatment of infections caused by 
Gram-negative bacteria. However, when early clinical reports suggested a 
high level of toxicity in the early 1970s, its use was reduced since less 
toxic aminoglycosides and other anti-pseudomonal agents were available. 
This is the reason for the reduced number of studies between 1970s until 
the mid-1990s [27].  
There are two forms of colistin available: colistin, which is usually used as 
the sulphate salt, and colistimethate, which is used as sodium salt [28, 
29].  
Cationic peptides are amphipathic molecules that have both a 
hydrophobic face, comprising non-polar amino acid side-chains, and a 
hydrophilic face of polar and positively charged residues.  
 
   
                      Polymyxin E (Colistin)                                                 Polymyxin B                                                  
 
Fig. 9. Molecular structure of  polymyxin E (colistin) and polymyxin B.  
 
1.4.4.2. TARGETS AND MECHANISM OF ACTION 
Polymyxins interact with LPS on the surfaces of Gram-negative bacteria, 
and are subsequently taken up via the self-promoted uptake pathway.  
Firstly, these cationic peptides interact with divalent cation binding sites 
on LPS and competitively displace native divalent cations (Ca2+ or Mg2+). 
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This displacement disrupts the normal barrier property of the outer 
membrane which permits the passage of molecules such as hydrophobic 
compounds, small proteins and/or antimicrobial agents. Moreover, it is 
promoted the uptake of the perturbing peptide itself (Fig. 10.a).  
Bacteria are killed as a result of insertion of peptides into cytoplasmic 
membrane leading to channels formation and leakage of cytoplasmic 
molecules (Fig. 10.b). It is remarkable the fact that channels formation is 
favored by the large transmembrane potentials, high content of negatively 
charged lipids and lack of cationic lipids and cholesterol [30, 31]. 
   
Fig. 10. a) Uptake of polymyxins across outer membrane of Gram-negative bacteria. b) 
Mechanism of bacterial killing by polymyxins [30]  
 
1.4.4.3. SPECTRUM OF ACTIVITY  
Polymyxins are only active against Gram-negative rods, particularly 
Pseudomonas spp. 
Proteus, Providencia, Serratia, and Neisseria are generally resistant [12].  
Colistin does not exhibit a wide antibacterial spectrum. It is basically 
active against common Gram-negative clinical isolates, including 
Enterobacteriaceae species and Aeromonas, but not Vibrio species, or 
some non-fermentative and fastidious Gram-negatives. Some bacteria are 
resistant to this antimicrobial, such as Proteus spp., Providencia spp., 
Morganella morganii and S. marcescens. However, the non-fermentative 
Gram-negative bacteria P. aeruginosa and Acinetobacter species are 
mainly susceptible, although some strains have recently developed 
resistance.  
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It is also noteworthy that many authors have shown that colistin sulphate 
has lower antimicrobial activity than sodium colistin methanesulphonate 
[28].  
1.4.4.4. MECHANISM OF RESISTANCE  
Although resistance is not as common as resistance to other families of 
antimicrobial agents, probably due to its low use over the past 50 years, 
some polymyxin resistant-bacteria have been identified. Modifications of 
LPS are the most common mechanisms of resistance to colistin, which is 
the initial site of action of this antimicrobial agent. Other mechanism of 
resistance to colistin have been described, for instance, tolerance to 
colistin in P. aeruginosa biofilms has been associated to metabolically 
active bacteria and controlled by pmr and mexAB-oprM [27].  
A recent study showed that the opportunistic pathogen P. aeruginosa is 
able to become resistant in the presence of subinhibitory levels of 
polymyxins and certain antimicrobial peptides. It is believed that the 
PhoP-PhoQ and PmrA-PmrB two-component systems, which control this 
modification under low-Mg2+ conditions, are irrelevant in peptide mediated 
adaptive resistance. In 2010, a novel P. aeruginosa two-component 
regulator affecting polymyxin adaptive resistance, ParR-ParS (PA1799-
PA1798) was identified and characterized by Fernández et al. [32]. They 
also demonstrated that this system is required for activation of the 
arnBCADTEF LPS modification operon in the presence of subinhibitory 
concentrations of colistin, leading to increased resistance to various 
polycationic antibiotics, including aminoglycosides. 
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1.5. EPIGENETIC INHERITANCE AND EVOLUTION OF ANTIBIOTIC 
RESISTANCE IN BACTERIA 
In terms of epigenetic inheritance and evolution it is important to have in 
mind the concept of fitness or adaptedness of a given microorganism [33] 
and the concept of environment, which has been almost ignored for a long 
time in clinical microbiology.  
Antibiotic resistance has to be understood as a multifactorial process 
where biochemical and genetic mechanisms as well as environmental 
processes involved in the selection and diffusion of genes of resistance 
and organisms have to be taken into account.  
Baquero et al. considered that the term of antibiotic pressure should be 
understood within the larger concept of selective environment [34]. 
DNA mutations and plasmid uptake are not the only factors related to 
antibiotic resistance. It is necessary to bear in mind that evolution of 
antibiotic resistance by bacteria is, at least in part, the result of natural 
selection acting on variant phenotypes.  
The phenotype is determined not only by the strict base sequence of 
DNA, but also by the variable expression patterns of the genes present.  
In bacterial populations, phenotypic diversity is due to heritable epigenetic 
variations. That is, natural selection arises from differences in gene 
expression patterns.  
A clear example of this selection is the exposure of an isogenic population 
to different antibiotics, where it can be observed how some individuals 
survive and form colonies while genetically identical neighbors die. In that 
case, it is necessary to look for other factors apart from stable DNA 
mutations to explain the high rate of survivors.  
Several variables that have influence on the probability of appearance of 
individuals resistant to antimicrobial agents have been identified, including 
the number of target genes and the number of positions within those 
genes that can be mutated to confer resistance.  
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A few studies show that bacterial survival rates ramp higher by successive 
exposures to increasing concentrations of antibiotics, indicating the lack of 
stable mutations that confer resistance.  
Only bacteria that have the capacity to epigenetically inherit the gene 
expression pattern of antibiotic resistance are able to divide and form 
colonies. In contrast, bacteria without this capacity would eventually die.  
Unlike genetic mutations, epigenetic alterations are much more unstable. 
For that reason, epigenetic inheritance, such as maintenance of certain 
chromatin configuration and/or DNA methylation states, would give much 
higher reversion rates to antimicrobial sensitivity than mutations.  
Stability of antibiotic resistance by bacteria depends on the antibiotic 
concentration and the time under selection. In other words, instability of 
antibiotic resistance state can disappear as the time under selection and 
antibiotics concentrations are increased.  
Selective pressure and phenotypic diversity created by heritable 
epigenetic variation plays a key role in the evolution of antimicrobial 
resistance.  
Adam et al. proposed that evolution of antibiotic resistance in 
microorganisms depend on two processes. The first is the variation in 
gene expression patterns, and the second is related to the epigenetic 
memory mechanisms that are able to maintain the gene expression state 
for numerous generations after a gene expression is established. Both 
DNA methylation patterns and DNA modifications inherited by bacteria are 
factors that can mediate transcriptional memory.  
Natural selection is presumably provided by several mechanisms that are 
capable of performing heritable phenotypic variation. In the mentioned 
study it was also emphasized that epigenetic inheritance based evolution 
could be of medical relevance. It is though that when bacteria within a 
patient are exposed to a low dose of antibiotics, a subpopulation of 
bacteria survives. These survivors with low level resistance could then 
divide and form new bacteria for a sufficient period of time to accumulate 
more stable mutations in DNA resulting in an increase of the antibiotic 
resistance level [35].  
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1.6. ADAPTATIVE RESISTANCE  
In contrast to intrinsic and acquired resistances, which are characterized 
by an irreversible phenotype and are independent of the presence of 
antibiotic or the environmental conditions, less is known about adaptative 
resistance. Fernández, et al. [36] defined this type of resistance as the 
induction of resistance to one or more antimicrobial agents in response to 
the presence of a specific signal. Mawer and Greenwood [37] showed that 
increase of resistance generally reverts upon removal of the triggered 
factor, although original level of resistance is not usually restored. This 
adaptation response is not only triggered by antibiotics, other signals such 
as pH, anaerobiosis or biofilm formation may play significant roles in 
determining antibiotic resistance and, they could be involved in a clinical 
failure of some antibiotic administration.  
Although molecular mechanisms involved in adaptative resistance are not 
well understood, it is necessary a better comprehension about their role in 
the slow but constant increase in baseline MIC values to design more 
effective antibiotic strategies.  
It is known that bacteria respond to changes in environment by 
modulating their gene expression and these changes can induce antibiotic 
resistance. Anaerobiosis is one of the important factors that trigger 
adaptative resistance. For instance, adaptation to anaerobic conditions 
allows P. aeruginosa to maintain a chronic infection and become more 
persistent and resistant to a broad range of antipseudomonal agents. 
Furthermore, some authors have demonstrated that aminoglycoside 
activity is reduced under anaerobic conditions. Thus, variation of oxygen 
concentration in the environment can have a great impact on adaptative 
responses.  
Another important factor in microbial adaptative resistance is the cation 
concentration in the surrounding milieu. The presence of divalent cations, 
which have a role in stabilizing the outer membrane, can limit the self-
promoted uptake of aminoglycosides, cationic peptides and polymyxins. 
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Other environmental factors that can modify antibiotic resistance in 
pathogenic bacteria are carbon source, pH and osmolarity.  
Under certain environmental conditions, microorganisms exhibit 
coordinated multicellular behaviors that require cell-to-cell communication 
and are often controlled in part by quorum sensing signals. Microbes 
when forming biofilms give the best relevant example of social behavior. 
In this case, bacterial show phenotypic and transcriptional differences 
compared to their planktonic counterparts, and they mimic more the 
behavior of a multicellular organism [38]. One of the major complications 
associated with resistance and biofilms in the clinical environment is their 
high resistance to antibiotics and detergents, as well as to the immune 
system. Some studies seem to indicate that the conditions of biofilm 
production facilitate the acquisition of inheritable resistance traits. Many 
mechanisms are implicated in biofilms resistance such as restricted drugs 
penetration, antimicrobial destroying enzymes limited or anaerobic growth 
at the base of biofilms, specific quorum sensing regulated resistance 
mechanisms for individual classes of antibiotics, the presence of persister 
bacteria and general stress responses.  
In general, biofilms constitute a major threat in the clinical environment by 
acting as reservoirs of multidrug resistant pathogenic bacteria. There are 
evidences that the increase resistance of microorganisms in biofilms is 
due, at least in part to the characteristics and adaptations to the biofilm 
state. Swarming is also considered a social phenomenon that may 
contribute to failure of antimicrobial therapy due to adaptative resistance.  
Brazas and Hancock [39] showed that bacterial gene expression can be 
regulated by the presence of certain concentrations of antimicrobial 
compounds. It is well known that antimicrobial susceptibility decreases 
after the first exposure to the antibiotic as a consequence of one or more 
adaptative changes.  
Phenomenon of adaptative antimicrobial resistance affects almost all 
antibiotic families by different mechanisms. In the case of 
aminoglycosides, the mechanisms involved in this type of resistance are 
still not well understood. Recently, it has been demonstrated that genes 
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encoding the efflux pump MexXY are induced by aminoglycosides, but 
mutations in these genes do not lead to adaptative resistance.  
Several studies have demonstrated that during the administration of 
fluoroquinolones in clinical use, its concentration often decrease causing 
the appearance of adaptative mutations. These subinhibitory 
concentrations reached during therapy are reflected in an increase of 
resistance and a possible therapeutic failure. 
Bacteria have also developed mechanisms of adaptative resistance to ß-
lactams, mainly triggered by the presence of ß-lactams themselves. For 
instance, in many Gram-negative bacteria, the chromosomally encoded ß-
lactamase is inducible by particular ß-lactam antibiotics, and the 
expression of genes involved is lower in the absence of these antibiotics. 
When there is certain ß-lactams in the environment, transcription of ampC 
and ß-lactamase production is higher and there is an increase of drug 
degradation [40]. Moreover, ß-lactam adaptative resistance is also 
affected by the exposure of a microorganism to subinhibitory 
concentrations of the drug, which allow the microorganism to adapt and 
become resistant against killing, by a follow-up exposure.  
Bacteria can become more resistant due to environmental conditions and 
different physiological states (biofilms and swarming). It is necessary to 
pay attention to the small increases in resistance observed in clinic, 
because this probably indicates the emergence of adaptative resistance 
during the infection and possible troubles in the treatment.  
1.7. BACTERIAL ENVELOPE  
Bacterial envelope is a complex multilayered structure that serves to 
protect these organisms from their unpredictable and often hostile 
environment. There are principally two groups: Gram-negative envelope is 
formed by a thin peptidoglycan wall of bacteria, which itself is surrounded 
by an outer membrane (OM) containing lipopolysaccharide; Gram-positive 
envelope lacks an outer membrane and is surrounded by thick layers of 
peptidoglycan linked via teichoic acids. The characteristic shape of 
bacteria is due to the very large polymer called peptidoglycan. The OM is 
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essentially stapled to the underlying peptidoglycan by lipoproteins 
(Fig.11). 
The periplasm is an aqueous compartment delimited by outer and inner 
membranes. Cellular compartmentalization allows Gram-negative bacteria 
to sequester potentially harmful degradative enzymes such as RNAse or 
alkaline phosphatase. 
The inner membrane (IM) in bacteria is a phospholipid bilayer with several 
proteins involved in energy production, lipid biosynthesis, protein 
secretion and transport of nutrients or waste products [41]. 
The outer membrane plays a key role in the physiology of Gram-negative 
bacteria in making them resistant to host defense factors. It also acts as 
an effective permeability barrier to many antibiotics. Although the 
presence of OM decelerates the diffusion of antibiotic, the small amount of 
antibiotic that penetrate can be inactivated by bacteria, and thus very high 
levels of resistance are easily established in Gram-negative bacteria [42, 
43]. 
Due to the relevancy of this structure, it will be described in great detail in 
the following section.  
 
  
 
Fig. 11. Schematic representation of the envelopes of Gram-negative bacteria. 
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1.7.1. OUTER MEMBRANE OF GRAM-NEGATIVE BACTERIA  
Gram-negative bacteria are surrounded by a thin peptidoglycan wall, 
which itself is surrounded by an outer membrane containing 
lipopolysaccharide. Biological membranes are constituted by lipid 
components and specific proteins that make each membrane unique. 
Bacteria survive thanks to the complex bacterial envelope that at the 
same time protects them and allows selective entry of nutrients and 
expulsion of waste products. Membranes do not simply serve to 
segregate different types of molecules, but also function as surfaces on 
which reactions can occur. 
The OM is a distinguishing feature of Gram-negative bacteria, since 
Gram-positive bacteria lack it.  
The OM contains phospholipids, but it is not a phospholipid bilayer.  
The outer leaflet of the OM is composed of glycolipids, principally 
lipopolysaccharide (LPS) [44]. 
OM also contains proteins. There are basically two classes of OM 
proteins: lipoproteins and β-barrel proteins. 
Almost all OM transmembrane proteins (OMPs) assume a β-barrel 
conformation. OMPs allow the passive diffusion of small molecules such 
as mono- and disaccharides and amino acids across the OM. LPS are 
molecules avidly bound especially if cations like Mg2+ are present to 
neutralize the negative charge of phosphate groups. They play a key role 
in the OM barrier function for hydrophobic molecules. This coupled with 
the fact that porins limit diffusion of hydrophilic molecules larger than 700 
Daltons, making OM a very effective yet, selective permeability barrier. 
1.7.2. PORINS  
In 1976, Taeji Nakae working in the laboratory of Hiroshi Nikaido 
discovered the outer membrane nonspecific channel proteins and 
proposed the word “porin” to describe them. There are two classes of 
proteins depending on their permeability properties for hydrophobic 
solutes: porins that have a certain solute specificity (not acting as specific 
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diffusion pores) and diffusion porins that form large-water filled channels 
through which solutes pass depending on their molecular mass or 
physicho-chemical properties (acting as general diffusion pores) [45]. 
It has been described that expression profiles of porins are usually 
regulated by environmental conditions such as pH, temperature or 
nutrients [46].  
Porin structures generally contain 14 (less common), 16 or 18 ß-sheets 
depending on the protein family, and are typically closed by loops or cork-
domain-like structures (α-helix). Most of the bacterial porins are oval-
shaped and are laterally 3-3.5 nm in size and 5 nm in height for the 
monomer. The motif of structural architecture is the closure of the barrel 
by pairing of the first and the last ß-strand in an anti-parallel way. The 
strands are connected by eight or nine long loops, facing the extracellular 
side, with seven or eight small turn-like structures in the periplasmic 
space. There are also aromatic girdles with tyrosine and phenylalanine 
residues in the outer and inner membrane boundaries, which could 
interact with lipid head groups or LPS molecules [47].  
Structures of different porins of outer membrane are shown in figure 12.  
 
Fig.12. Structures of different porins of outer membrane. a) TolC protein of K. oxytoca. [88] 
b) OmpA porin of S. marcescens [82] c) FepA porin of E. coli [48] 
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1.7.3. EFFLUX SYSTEMS  
There are five families of bacterial efflux pumps which are ATP-binding 
cassette (ABC) superfamily, the major facilitator superfamily (MFS), the 
multidrug and toxic compound extrusion (MATE) family, the small 
multidrug resistance (SMR) family, and the resistance-nodulation-division 
(RND) superfamily, the most important efflux system in clinically-resistant 
Gram-negative bacteria. The latest, function as proton/drugs antiporters, 
and catalyze the active efflux of a wide variety of antibacterial substrates 
such as antibiotics and chemotherapeutic agents.  
The main characteristic of RND transporters is that have large periplasmic 
domains and form tripartite complexes with the periplasmic adaptor 
proteins or membrane fusion proteins (AcrA and MexA) and OM channels 
(TolC and OprM).  
Figure 13 shows the schematic drawing of tripartite RND multidrug efflux 
system of a Gram-negative bacterium.  
 
Fig. 13. Schematic drawing of tripartite RND multidrug efflux system of a the Gram-negative 
bacterium showing the OMP, the RND Protein and the MFP [49]. 
 
Membrane fusion proteins (MFPs) are essential domains in the assembly 
and function of the tripartite complex and may play an important role in the 
direct activation of the pump. They work as adaptor proteins in systems 
containing RND (AcrAB-TolC), MFS (EmrAB-TolC) and ABC (MacAB-
TolC) pumps.  
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Outer membrane channel proteins are trimeric proteins represented by 
TolC and OprM. These proteins interact with other efflux components i.e. 
AcrA-TolC, AcrA-AcrB-TolC, AcrB-TolC, MexA-OprM and chimeric.  
The importance of efflux pumps in Gram-negative bacteria is due to its 
relationship with antimicrobial resistance. Overexpression of efflux pumps 
and deficiencies of OMPs have a key role in bacterial drug-resistance and 
may be necessary for adaptative resistance to some antimicrobial agents 
such as aminoglycosides. Efflux pumps can also contribute to resistance 
in bacteria of animal and environmental origin, and efflux-mediated 
resistance has been usually found in animal pathogens and has been 
evident in environmental isolates.  
Another role of efflux pumps has been described in biofilm resistance, 
where bacteria growing in biofilms seem to be more resistant or tolerant to 
antimicrobial agents than planktonic counterparts.  
Drug efflux pumps can also be affected by different stimulus, including 
stress responses, colonization, virulence and quorum sensing, among 
others. Moreover, they can be phenotypically induced by small molecules, 
or substrates of efflux pumps and the expression of their genes can vary 
depending on the phases of growth [50].  
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1.7.4. LIPOPOLYSACCHARIDES (LPS) 
The outer membrane of Gram-negative bacteria consists of an 
asymmetric double layer of polyanionic lipopolysaccharide molecules 
(outer leaflet) and glycerophospholipids (inner leaflet). Structurally, LPS is 
composed of three domains: lipid A, core oligosaccharide and the distal O 
antigen (Fig. 14). 
 
Fig. 14.  General structure of Gram-negative LPS [51]. 
 
The outer core OS has a unique feature; it exists in two structurally 
distinct glycoforms, called “uncapped or smooth” and “capped or rough”.  
The smooth glycoform is covalently attached to O-Ag, whereas the 
uncapped glycoform cannot be substituted with O-Ag.  
To appreciate the complexity and heterogeneity of LPS, it is noteworthy 
that heterogeneity exists in the chain length of the O-Ag. 
In general, core OS, which is the linker region between O-Ag and lipid A 
can be divided into two regions, namely the inner and the outer core.  
LPS molecules are electrostatically linked by divalent cations (e.g., Mg2+ 
and Ca2+). This structure can be weakened by removing divalent ions or 
replacing them with other cationic agents. This results in an increase of 
outer membrane permeability and sensitizes the bacteria to hydrophobic 
antibiotics, detergents, or dyes.  
Beyond their structural role, LPSs mediate the interaction of bacteria with 
their environment and act as a protection against harmful molecules. 
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Moreover, LPSs acts as a major virulence factor. Some studies have 
pointed out that modification of lipid A of lipopolysaccharide (LPS) is a key 
component of adaptive antimicrobial resistance, such as peptide 
resistance [52, 53, 54].  
1.8. INTEGRONS 
Integrons were firstly described in the eighties as DNA elements that 
function as gene-capture and expression systems that incorporate open 
reading frames (ORFs) and convert them into functional genes [55, 56].  
These genetic elements are able to acquire a variety of individual and 
unconnected genes via a site-specific recombination.  
Integrons provide an integration site (attI) for the site specific integration of 
gene-cassettes, an integrase to mediate excision and orientation-specific 
integration of gene-cassettes, and a promoter Pc to ensure the expression 
of the operon [57, 58].  
1.8.1. GENE CASSETTES: STRUCTURE AND FUNCTION 
Gene cassettes are the smallest known form of mobilizable DNA. In 
contrast to other mobile DNA elements, gene cassettes are inserted at 
specific locations in the host genome defined by the presence of an 
integron [59, 60]. Although they may contain several genes, the main 
characteristic of these elements is that they all share a common structure.  
A gene cassette is comprised of a single gene and a recombination site 
known as 59 base element (59-be or attC site), which is located 
downstream of the gene coding region. The 59-be sites vary in length and 
structure, but they are all bounded by a core site (GTTRRRY) at the 
recombinant crossover point and an inverse core site (RYYYAAC) at the 
3′ end of the inserted gene (Fig. 15) [61, 62].  
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G-TTRRRY Gene cassette RYYYAAC
attI
Variable region
54-135 nt G-TTRRRY
attC
Invers Core Core
 
Fig. 15. Structure of a gene cassette. attC consist of Invers Core and Core, and are 
separated by a variable region. Extremes of the cassette are defined by two cores, attI (on 
the left) and attC (on the right). Recombination takes place between G of the fisrt core and T 
of the second core.  R= purine  and Y= pyrimidine. 
 
Cassettes vary considerably in total length from 262 to 1549 bp. This is 
largely because of differences in the size of the gene, as in most 
cassettes little non-coding sequence flanks the gene. Integrons of 
different isolates vary with regard to the type, number and order of genes 
cassettes they contain.  
Site-specific recombination of a gene cassette is catalyzed by an 
integrase. In class 1 integrons the integrase gene intI1 is located in the 5’ 
conserved-segment (CS) of the integron, and it interacts with two 
recombination sites (be-59 of gene cassette and the attI site located in the 
5’CS of the integron. Integrated cassettes are always in the same 
orientation of 5’end of the gene closest to the 5’CS of the integron. The 
insertion of additional cassettes may result in multi-cassette arrays 
containing two or more cassettes. Although gene cassettes are generally 
found inserted into an integron, they also transiently exist as free covalent 
circular molecules, very important in cassettes dissemination [63]. 
Class 1 integrons are the most common and well-characterized class of 
integrons, and are widely disseminated in animal and human clinical 
strains of the family Enterobacteriaceae [64]. Class 1 integrons are also 
common in clinical isolates of P. aeruginosa, but not in environmental 
strains [65].  
Class 1 integrons contain the attI1 recombination site, integrase gene and 
the promoter Pc. They are bounded by terminal inverted repeats, 
designated IRi and IRt. IRi is located at the 5’ end of class 1 integrons and 
IRt is located at the 3’end [57].  
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Class 1 integrons contain a specific recombination site attI1, located near 
the intI1 gene that is recognized by the integrase IntI1 and a promoter Pc 
that lies within the intI1 gene that directs the transcription of inserted 
genes cassettes. Most class 1 integrons possess two CSs that flank either 
end of the gene cassette region. The 5’CS contains the intI1 gene and a 
promoter Pc directed towards the integration site (Fig. 16).  
The 3’CS usually contains the quacE∆1 and sul1 genes and an ORF of 
unknown function (orf5).  
intI15’
Pc
Gene cassette qacE 1 sul1 orf5 3’
attI1
5’ conserved segment 3’ conserved segment 
 
Fig 16. Basic structure of a class 1 integrons showing the 5’ and 3’ conserved segments.  
The IntI1 gene (open box) and the attI1 recombination site (grey box) are located in the 
5’CS. The qacE∆1 gene encoding resistance to the quaternary ammonium compounds, the 
sul1 gene encoding sulphonamide resistance and the ORF orf5 are found in the 3’CS. The 
gene cassette is represented by a bold line and the associated 59-be by a filled circle. The 
direction of gene transcription and the promoted region Pc, directed toward the integration 
site, are indicated.  
 
1.8.2. ROLE OF INTEGRONS IN BACTERIAL DRUG RESISTANCE 
Increasing attention has been given to integrons in the context of 
resistance to antimicrobials. In particular, much research effort has been 
devoted to integrons belonging to classes 1, 2 and 3, the classes most 
commonly associated with the spread of antibiotic resistance in 
pathogens. Surveys examining the prevalence of various genetic 
elements in multidrug-resistant strains invariably show a high correlation 
between the presence of a class 1 integron and particular antimicrobial 
resistance profiles. Integrons that contain gene cassettes provide a 
powerful vehicle for the rapid horizontal transfer of resistance across 
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bacterial populations and thus could contribute to the sudden increase in 
the prevalence of multidrug-resistant infections in a community. The 
distribution of identical genes in organisms isolated from people living in 
disparate geographic regions indicates that they were more likely infected 
by organisms already harboring such gene cassettes than originate in 
non-human reservoirs. 
The variety of structures found amongst class 1 integrons after more than 
half a century of antibiotic usage bears testament to the genetic flexibility 
and adaptability of the bacterial genome under environmental stress, 
characteristics that make these microorganisms ultimate survivors [65]. 
Several studies in European hospitals have demonstrated that integron-
positive isolates were statistically more likely to be resistant to 
aminoglycoside, quinolone and beta-lactam compounds, including third-
generation cephalosporins and monobactams, than integron-negative 
isolates. Integron-positive isolates were also more likely to be multi-
resistant than integron-negative isolates [66]. 
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Resistance to antimicrobials is a well-known phenomenon leading to 
difficulties in the treatment of infectious diseases. The genetic 
determinants of such resistance are in general well understood: plasmids, 
transposons, insertion sequences and integrons are the most frequently 
related genetic elements.  
The word epigenetics refers to changes in the phenotype or in the gene 
expression caused by mechanisms other than underlying DNA sequence. 
In some cases these changes can remain for generations.  
S. marcescens is an enterobacterium characterized by their ability to 
produce prodigiosin (a linear tripyrrolic pigment) which was, in former 
times extensively studied in our laboratory [67, 68, 69, 70]. In the last few 
years a renewed interest on prodigiosin due to its antitumor activities has 
emerged [71]. 
This bacterium can also produce other pigments derived from the 
catabolism of aromatic compounds [72, 73]. A prominent characteristic of 
Serratia is its natural (intrinsic) resistance to most antibiotics. At the same 
time S. marcescens is a relevant opportunistic pathogen which has been 
involved in several pathologies such as urinary tract infections prostheses 
infections, cellulitis, bacteremia and others. Virulence factors were 
investigated several years ago in part by our group [67, 74, 75, 76, 77].   
On the other hand, P. aeruginosa is a Gram-negative bacterium 
considered one of the major nosocomial pathogens worldwide. It causes 
several infections such as wound and burn infections as well as 
respiratory tract infections mostly affecting cystic fibrosis patients. Our 
group has studied resistance in this bacterium since many years ago [14, 
65]. 
Moreover, an increasing prevalence of infections caused by multidrug-
resistant (MDR) isolates has been reported in many countries and is 
actually a cause of concern. Both, P. aeruginosa and S. marcescens are 
relevant nosocomial pathogens. 
Some of the classic antimicrobials used to treat these pathogens are out-
of-date and several of the new drugs available have already become 
targets for bacterial mechanisms of resistance. 
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The mechanisms leading to antimicrobial resistance have been 
investigated in our laboratory from many years ago [22, 65, 78, 79, 80, 
81].  The role of the outer membrane as well as proteins involved have 
been also the focus of our research [82, 83, 84, 23, 85, 86, 87, 88, 89].  
AIMS 
Environmental conditions exert high pressure not only in the selection of 
genes encoding resistance to antibiotics or integron fixation in bacterial 
genomes or plasmids and other mobile elements transmission, but also in 
the expression of these potentialities that leads to resistance. Thus the 
role of epigenetics remains to be investigated. In addition it is well known 
that bacteria causing infections are naturally forming part of biofilms 
instead the planktonic way of life normally assumed to be in laboratory 
conditions.  
The aim of this project was to explore unconventional mechanisms of 
antimicrobial resistance contributing to MDR phenotypes in both Gram-
negative bacteria. The research itself has conditioned a series of new 
partial objectives which can be summarized as follows:  
 Exploration of antimicrobial susceptibilities of three extensive groups 
of S. marcescens strains, a Gram-negative bacterium that belongs to 
Enterobacteriaceae family and which has a cosmopolitan distribution. 
The first group is formed by strains isolated and lyophilized in 1940/50 
by Robert P. Williams’s in Houston (Robert P. Williams Serratia 
Collection; UB); the second group is a collection of current Serratia 
isolated from environment, and finally, the third group is formed by 
clinical isolates of Serratia after 2000.  
 Exploration of integron presence, and in the case, determination of 
their sequences and identification of genes encoding antimicrobial 
resistance. Also exploration of the eventual presence of ESBLs 
(Expanded Spectrum Beta-lactamases) in S. marcescens. 
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 Development of an experimental method to measure functionality of 
efflux pumps when bacteria grow in biofilm conditions and comparison 
with planktonic cultures.  
 Evaluation of the actual role of efflux pumps in antimicrobial 
resistance of bacteria forming part of the biofilm to explore the 
importance of epigenetics on these proteins involved in antimicrobial 
resistance. 
 Exploration of antimicrobial susceptibilities in multidrug-resistant P. 
aeruginosa, including colistin-resistant strains.  
 Development of a bioassay to compare meropenem accumulation P. 
aeruginosa growth without antibiotic and P. aeruginosa treated with 
meropenem.  
 Detection of eventual presence of integrons in multidrug-resistant P. 
aeruginosa and determination of sequences and identification of the 
genes encoding antimicrobial resistance.  
 Study of the effects of drug-selective pressure in MDRPA and colistin-
resistant P. aeruginosa.  
 Evaluation of efflux pumps in MDRPA when synergic combinations of 
antimicrobial agents are used.   
 Exploration of the contribution of outer membrane proteins in P. 
aeruginosa multidrug-resistance.   
 Comparison of outer membrane proteins and lipopolysaccharide 
profiles of colistin-resistant and colistin-susceptible clinical isolates of 
P. aeruginosa. 
 Investigation of the role of oprD porin in imipenem heteroresistance 
among clinical isolates of P. aeruginosa.  
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3.1. BACTERIAL STRAINS  
3.1.1. S. marcescens 
A total of 79 strains of Serratia were examined. There were distributed 
into tree different groups depending on their origin. The first group (G1) 
included 14 strains of Serratia isolated between 2007 and 2008 from 
environment, mainly from water samples, but also from vegetables and 
soil in the suburbs of Pallars Jussà, and the region surrounding 
Barcelona. The second group of Serratia (G2) consisted in 41 strains 
isolated and freeze-dried many years ago (1940/50) by Professor Robert 
P. Williams at Baylor College of Medicine (BCM), Houston Tx. These 
isolates were preserved and after Dr. Williams death donated by BCM to 
our laboratory. (Robert P. Williams Serratia Collection; BCM-UB); finally, 
the third group (G3) consisted in clinical strains isolated from patients at 
Laboratory Clinic L’Hospitalet (Barcelona).  
Identification and preliminary antibiotic susceptibility testing was 
accomplished by using the Microscan system (Sacramento, CA, USA). 
S. marcescens 2170 was used in experiments of efflux and biofilms [90].  
Groups of Serratia strains used in this study are described in tables 6-8. 
Table  6. List of environmental strains. 
G1: Environmental Serratia strains (2007 and 2008). Own culture collection. 
Strain: Source:  
ES001  River water from Catalonia 
ES002 Catalonia Irrigation channel 
ES005 River water from Catalonia 
ES007 Soil from Guatemala 
ES008 River water from Catalonia 
ES009 Soil from Guatemala 
ES013 Pipe from Catalonia 
ES014 Catalonia Irrigation channel 
ES015 Pond from Catalonia 
ES016 Stream from Catalonia 
ES018 Spring from Catalonia 
ES019  Fountain from Catalonia 
ES020 Onion 
ES021 Water from Metlini (Algeria) 
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Table  7. List of old strains. 
G2: Robert P.Williams Serratia Collection; BCM-UB. 
Strain: Source: 
8PW Unknown. University of Visconsin 
10PW Unknown .University of Visconsin 
33PW Unknown 
34PW Unknown 
36aPW Unknown. Texas (USA) 
41PW Soil from USA 
42b PW  Environmental. Soil. 1956. Dept. Agriculture 
44a PW Environmental. Eggs. 1956. Dept. Agriculture 
46b PW  Environmental. Eggs. 1956. Dept. Agriculture 
49a PW Environmental.Eggs. Dept. Agriculture 
51b PW Environmental.Eggs. Dept. Agriculture 
54b PW Environmental.Isolated from eggs. Dept. Agriculture 
56b PW  Environmental. Fly. 1956 
57a PW  Clinical. Throat. 1956 
58a PW  Clinical. Sputum. 1958 
59a PW  Clinical. Blood. 1958 
60 PW  Clinical. Bronchial washing. 1956 
62 PW  Clinical. Bronchial washing. 1956 
63 PW  Clinical. Urine. 1956 
65 PW  Clinical. Paracentesis fluid. 1956 
66 PW  Clinical. Blood. 1956 
73PW Ulcer from a University Hospital 
74aPW Milk from Hygienic Inst. Kiln. 1927. Lister Institute, London 
75PW Hospital bread isolated in 1926 
American Type Culture Collection, Chicago 
76aPW Human case of spinal meningitis. American Type Culture Collection. 
77bPW Water from a paper mill 
80bPW Cheese from Ithaca (USA) 
82PW Unknown. Received from American Type Culture Collection, Chicago in 
1925 
83PW Unknown. Received from Oswaldo Cruz Institute (Brazil) in 1928 
86PW Unknown. Received from Kluyver of the Technische Hoogeschool 
Laboratory Voor Microbiologii et Delft. Holland in 1929 
87PW Unknown. Received from Kluyver of the Technische Hoogeschool 
Laboratory Voor Microbiologii et Delft. Holland in 1929 
88PW Unknown. Received from Kluyver of the Technische Hoogeschool 
Laboratory Voor Microbiologii et Delft. Holland in 1929 
90aPW Unknown 
119 PW Environmental. Wine. 1956 from Dr. Breed’s collection 
121 PW  Environmental.Sugar cane. 1956 
132 PW Environmental. Tap water. 1956 
137 PW Environmental. Fruit fly. 1956 
147 PW  Clinical. Hospital clothes. 1956 
159a PW  Environmental. Sea water. 1956 
230 PW  Clinical. Sputum. 1957 
248aPW Unknown 
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Table 8. List of current clinical strains.  
G3: Clinical strains isolated after 2000. Laboratory Clinic L’Hospitalet (Barcelona). 
Strain: Source: 
1JO  Unknown 
2JO Unknown 
3JO Unknown 
4JO Exudate 
5JO Ulcer 
6JO Blood culture 
7JO Sputum 
9JO  Sputum 
10JO  Sputum 
11JO  Exudate 
12JO  Sputum 
13JO Exudate 
14JO  Sputum 
15JO  Ulcer 
16JO  Ulcer 
17JO  Ulcer 
18JO Urine 
19JO Urethral smear 
20JO  Exudate 
21JO Exudate 
22JO Ulcer 
23JO Sputum 
24JO Blood culture 
26JO Ulcer 
 
3.1.2. ISOLATION AND IDENTIFICATION OF ENVIRONMENTAL 
STRAINS 
Environmental samples (mainly water and soil) were taken and stored at 4 
ºC until their processing in the laboratory. Samples were pre-enriched in 
nutrient broth with 4% NaCl, and incubated overnight at room temperature 
(about 20 ºC) with shaking. Then, caprylate-thallous (CT) agar medium 
was used for selective isolation of Serratia species. This CT agar, derived 
from M70 minimal medium (Véron, 1975) [91]. A volume of 0.1 mL of the 
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pre-enrichment culture was streaked onto CT agar and then incubated at 
30 ºC for seven days.  
Isolated colonies were streaked onto TSA to achieve the identification. 
Identification of the isolates was done by using standard microbiological 
methods such as colonies shape and pigmentation, typical morphology of 
Gram-negative rod-shaped in Gram staining, negative reaction to oxidase, 
ability for gelatine liquation, production of DNase, citrate degradation 
(Simmons Citrate), inability to hydrolyze urea  (Christensen’s Urea Agar), 
inability to form indole from tryptophan and positivity to Voges-Proskauer 
test.  
3.1.3. MULTIDRUG-RESISTANT P. aeruginosa 
Four isolates of multidrug-resistant P. aeruginosa (MDRPA) from Hospital 
del Mar, Barcelona (Spain), were used. Identification and preliminary 
antibiotic susceptibility testing was accomplished by using the Microscan 
system (Sacramento, CA, USA). P. aeruginosa ATCC 27853 was used as 
a control strain.  
These strains were used to explore the mechanisms of resistance leading 
to multidrug-resistance in P. aeruginosa.  
Clinical isolates are described in the table below.  
Table  9. Multidrug-resistant P. aeruginosa (MDRPA).  
Strain: Abbreviation: Source: 
2404459 459 Surgical wound 
1449133 133 Sputum 
2908162 162 Urine 
1169527 527 Blood culture 
 
Several colistin-resistant clinical isolates of P. aeruginosa from Hospital 
del Mar patients (Barcelona, Spain) were explored for mechanisms of 
resistance to colistin. As described previously, identification and 
preliminary antibiotic susceptibility testing was done by using the 
Microscan system.  
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Strains 5150328S (328S) and 5150328R (328R) were isolated from 
sputum of the same patient. Strain 5150328S was colistin-susceptible 
whereas 5150328R was colistin-resistant.  
Table 10. Colistin resistant P. aeruginosa 
Strain: Abbreviation: Source: 
4811296 296 Urine 
442362 362 Bronchial aspirate 
1820017 017 Urine 
2473493 493 Urine 
1138264 264 Urine 
2882025 025 Bronchial aspirate 
5181401 401 Pharynx 
5116732 732 Urine 
4769780 780 Sputum 
5150328R 328R Sputum 
 
Two more P. aeruginosa clinical isolates were explored. These strains 
were isolated from the same patient at the “Servei de Microbiologia” of the 
Hospital Universitari de Bellvitge (Barcelona, Spain). The strain PA110514 
was isolated before the treatment with imipenem whereas strain 
PA116136 was isolated once the treatment was finished. Both isolates 
gave identical pulsed field gel electrophoresis (PFGE) profile and 
biochemical tests, suggesting their close relationship. 
3.2. CULTURE MEDIA  
3.2.1. TRYPTONE SOY AGAR (TSA) 
Tryptone Soy Agar is a solid nutritive medium useful for cultivation of a 
wide variety of organisms. 
Composition in g/L:  
Peptone from casein ............................................................ 15.0 
Peptone from soymeal ........................................................... 5.0  
Sodium chloride ..................................................................... 5.0 
Agar .................................................................................... 15.0 
 
40g/liter; adjust pH to 7.3 ± 0.2 at 25 °C. boiled and autoclaved. 
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3.2.2. TRYPTONE SOY BROTH (TSB)  
Tryptic Soy Broth was also used in experiments in molecular genetics.  
Composition in g/L:  
Peptone from casein ............................................................ 17.0 
Peptone from soymeal  .......................................................... 3.0  
Sodium chloride ..................................................................... 5.0 
Dipotassium phosphate ......................................................... 2.5 
Glucose ................................................................................. 2.5 
 
Suspended 30 g/liter (broth), autoclaved (15 min at 121 °C), adjusted pH 
to 7.3 ± 0.2 at 25°C.  
3.2.3. MUELLER-HINTON BROTH (MHB)  
Muller-Hinton Broth is a nutritive medium used for microdilution antibiotic 
susceptibility testing.  
Composition in g/L:  
Peptone from casein ............................................................ 17.5 
Starch .................................................................................... 1.5 
Meat extract .......................................................................... 4.0 
 
21 g of powder to 1 L of distilled water sterilized by autoclaving at 121°C 
for 15 minutes. 
For experiments with P. aeruginosa, the medium used was BBLTM 
Mueller-Hinton II broth cation adjusted (20-25 mg/L of calcium and 10-
12.5 mg/L of magnesium). 
3.2.4. MUELLER-HINTON AGAR (MHA)  
Mueller-Hinton agar is a microbiological growth medium that is 
recommended for the disk diffusion method of antibiotic susceptibility 
testing.  It is recommended by FDA, World Health Organization and 
NCCLS for testing most commonly encountered aerobic and facultative 
anaerobic bacteria in food and clinical material. 
Composition in g/L:  
Beef extract powder ............................................................... 2.0 
Acid digest of casein  ........................................................... 17.5 
Starch .................................................................................... 1.5 
Agar .................................................................................... 17.0 
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3.2.5. LURIA BROTH (LB)  
Luria broth is standard and rich nutrient media used to grow bacteria. 
Composition in g/L:  
Pancreatic digest of casein .................................................. 10.0 
NaCl ...................................................................................... 5.0 
Yeast extract ......................................................................... 5.0 
Glucose ................................................................................. 1.0 
 
3.2.6. SUPPLEMENTED MINIMAL BROTH DAVIS WITHOUT 
DEXTROSE (DMBSUP)  
Minimal Broth Davis without dextrose and supplemented with 0.05% 
glucose and 0.05% casamino acids is the medium that was used in 
biofilm’s experiments.  
Composition in g/L:  
Dipotassium Phosphate ......................................................... 7.0 
Monopotassium Phosphate .................................................... 2.0 
Sodium Citrate ....................................................................... 0.5 
Magnesium Sulphate ............................................................. 0.1 
Ammonium Sulphate .............................................................. 1.0 
Glucose ................................................................................. 0.5 
Casamino Acids ..................................................................... 0.5 
  
3.2.7. PRE-ENRICHMENT MEDIUM FOR Serratia ISOLATION 
This medium was used to pre-enrich environmental samples (mainly 
water) for the isolation of the Serratia strains.  
Composition in g/L: 
NaCl ...................................................................................... 4.0 
Peptone from meat ................................................................ 5.0 
Meat extract .......................................................................... 3.0 
 
3.2.8. CAPRYLATE-THALLOUS AGAR SELECTIVE FOR Serratia (CT) 
This medium was used for the selective isolation of Serratia species. This 
CT agar, derived from M70 minimal medium (Véron, 1975) [91].  
CT agar has the following composition and mode of preparation:  
Two solutions designated A and B were prepared, autoclaved separately 
and mixed aseptically to yield a liter of the final medium.  
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Solution A contained: 
Calcium Chloride Dihydrate .......................................... 0.0147 g 
Magnesium Sulphate Heptahydrate ................................ 0.123 g 
Potassium Dihydrogen Phosphate .................................. 0.680 g  
Dipotassium Phosphate Anhydrous ................................ 2.610 g 
Trace element solution ..................................................... 10 mL  
Caprylic (n-octanoic) acid ................................................ 1.1 mL 
Yeast extract 5% wt/vol solution ......................................... 2 mL  
Thallous sulphate ............................................................. 0.25 g  
Distilled water up to ........................................................ 500 mL 
The pH was adjusted to 7.2 with NaOH using a pH-meter and the solution 
was autoclaved at 110 ºC for 20 min.  
Solution B contained:  
Sodium Chloride .................................................................... 7 g  
Ammonium Sulphate ............................................................. 1 g  
Agar .................................................................................... 15 g  
Trace element solution (Véron, 1975) contained the following components 
in g/L:  
Phosphoric Acid .................................................................. 1.96  
Ferrous Sulfate Heptahydrate .......................................... 0.0556 
Zinc Sulphate Heptahydrate ............................................ 0.0287  
Manganese Sulphate Tetrahydrate .................................. 0.0223  
Copper Sulfate Pentahydrate........................................... 0.0025  
Cobalt Nitrate Hexahydrate ............................................... 0.003 
Boric Acid ........................................................................ 0.0062  
This solution was stored unsterilized at 4º C.  
The pH was adjusted to pH 7.2, and this agar base (solution B) was 
autoclaved at the same time and under the same conditions as solution A.  
After autoclaving, solution A and B were mixed aseptically and the 
resulting CT agar medium was poured into sterile plastic Petri dishes. The 
dishes were stored at 4 ºC until used.  
3.2.9. BRAIN HEART INFUSION BROTH WITH 10% GLYCEROL (BHI) 
This medium was used for the growing of Serratia and Pseudomonas 
strains previous to the DNA extraction for the search of integrons. 
Glycerol was added afterwards.  
Composition in g/L:  
Brain and heart infusion ....................................................... 17.5 
Peptone ............................................................................... 10.0 
Glucose ................................................................................. 2.0 
Sodium Chloride .................................................................... 5.0  
Disodium phosphate .............................................................. 2.5  
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3.2.10. CRYOPRESERVATION MEDIUM  
This medium was used for the cryopreservation of bacterial strains at -80 ºC.  
It was prepared by dissolving 3g of TSB in 80 mL of distilled water plus 20 
mL of glycerol. The solution was autoclaved at 121 °C for 15 minutes. 
3.3. SOLUTIONS AND OTHER COMPOUNDS USED  
3.3.1. PHENOL SOLUTION 
This solution was used for extraction of nucleic acids. Liquid phenol was 
equilibrated with an equal volume of buffer (usually Tris-HCl pH 8 at room 
temperature). Then, the mixture was stirred on a magnetic stirrer for 15 
min and when the two phases were separated, the upper (aqueous) 
phase was aspirated. Afterwards, an equal volume of 0.1 M of Tris-HCl 
pH 8.0 was added to the phenol and the mixture was stirred as described 
previously. Extractions were repeated until the pH of the phenolic phase 
was >7.8. 
Phenol solution was stored in a light-tight bottle for periods of up to 1 
month [92].  
3.3.2. CHLOROFORM-ISOAMYL ALCOHOL  
This mixture was used in the extraction of chromosomal DNA. It consisted 
of 24:1 v/v that means the addition of 1 mL of isoamyl alcohol each 24 mL 
of chloroform.  
3.3.3. SALINE-SODIUM CITRATE BUFFER 20X (SSC)  
This solution was used in the extraction of chromosomal DNA, and 
contained:  
Sodium Chloride ............................................................. 175.3 g  
Sodium citrate ................................................................... 88.2 g  
Distilled water....................................................... up to 1000 mL 
All the ingredients were dissolved and pH was adjusted to 7.0 with a few 
drops of a 14N solution of hydrochloric acid. Then, solution was sterilized 
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by autoclave. Final concentrations were 3.0 M of sodium chloride and 0.3 
M of sodium citrate.  
3.3.4. PHOSPHATE-BUFFERED SALINE (PBS) PH 7.5 
This buffer was used to maintain the correct osmolarity and keep the 
bacteria in an isotonic state.  
The stock was prepared 10X concentrated, and the working solution was 
1X.  
Composition of the 10X concentrated solution in g/l was:  
Sodium Chloride .................................................................. 80.0 
Potassium Phosphate Monobasic .......................................... 2.0 
Di-Sodium Phosphate ........................................................ 11.44 
Potassium Chloride .............................................................. 11.0 
Distilled water...................................... Up to a final volume of 1L  
3.3.5. GLYCINE SOLUTION PH 3  
This solution was used in fluorometry experiments to allow bacterial lysis.  
The composition was: 
Glycine ............................................................................... 0.1 M   
Hydrochloric acid ............................................................. 24 mM 
It was prepared by mixing 50 mL of a 0.2 M glycine solution with 12 mL of 
a 0.2 M HCl solution and distilled water up to a final volume of 100 mL.  
3.3.6. TRIS-ACETATE-EDTA 50X (TAE) 
This solution was used in the preparation of agarose gels to determine the 
presence of integrons and as buffer in electrophoresis.  
The stock was prepared 50X concentrated, and the working solution was 
1X.  
The composition was:  
Tris................................................................................ 242.28 g  
Acetic acid glacial .......................................................... 57.1 mL 
0.5M EDTA (pH 8.0) ........................................................ 100 mL     
Distilled water up to ................................................................ 1 L 
All the components were mixed until complete dissolution.  
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3.3.7. TRIS-BORATE-EDTA 50X (TBE) 
This solution was used in the preparation of agarose gels to analyze 
amplicons obtained from the oprD gene region from several P. aeruginosa 
strains and as buffer in electrophoresis.  
The stock was prepared 50X concentrated, and the working solution was 
1X.  
The composition was:  
Tris.................................................................................. 108.0 g  
Boric acid ............................................................................. 55 g 
0.5M EDTA (pH 8.0) .......................................................... 40 mL     
Distilled water up to ................................................................ 1 L 
All the components were mixed until complete dissolution.  
3.3.8. TRIS-GLYCINE SDS GEL RUNNING BUFFER (5X) AND 30% 
ACRYLAMIDE STOCK SOLUTION  
Tris-glycine SDS gel running buffer was used in SDS-PAGE analysis of 
LPS or OMPs.  
Tris ..................................................................................  15 g/L  
Glycine .............................................................................. 72 g/L  
SDS .................................................................................... 5 g/L  
This buffer was equilibrated to a pH 8.3 and stored at 4 ºC until its use. 
30% acrilamide stock solution was used in SDS-PAGE gel 
electrophoresis.  
Acrylamide ........................................................................... 30 g  
N,N'-methylbisacrylamide .................................................... 0.8 g  
Distilled H2O .................................................................... 100 mL 
This stock was stored at 4 ºC in dark until its use. 
3.3.9. SILVER STAINING SOLUTION 
This solution was used in the silver staining protocol. It was prepared by 
mixing A and B solutions under constant shaking. Silver staining solution 
was discarded if argent precipitates were observed.  
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A SOLUTION: 
AgNO3  ................................................................................ 0.5 g   
Distilled H2O ..................................................................... 2.5 mL  
B SOLUTION: 
NaOH 1 N  ....................................................................... 1.4 mL   
NH3 30%   ........................................................................... 1 mL  
Distilled H2O ...................................................................... 70 mL 
3.3.10. SILVER STAIN DEVELOPER 
The silver stain developer was used in the silver staining protocol. 
Citric acid 10%  .................................................................. 50 µL  
Formaldehyde    ................................................................. 50 µL  
Distilled H2O ........................................................... up to 100 mL  
3.3.11. STOPPING SOLUTION 
This solution was used in the silver staining protocol. 
Glacial acetic acid 10%  .................................................... 10 mL    
Methylamine   ................................................................. 3 drops   
Distilled H2O ........................................................... up to 100 mL  
3.3.12. PRESERVING SOLUTION 
This solution was used in the silver staining protocol. 
Ethanol  ......................................................................... 30% v/v    
Glycerol    ......................................................................... 5% v/v    
Distilled H2O ................................................................... 65% v/v   
3.3.13. PROTEINASE K 
Proteinase K was used in bacterial DNA extraction.  
The stock was prepared at 20 mg/mL:  
Proteinase K ..................................................................... 20 mg  
Ultrapure H2O ..................................................................... 1 mL 
All the compounds were added in the indicated order and shacked until 
complete dissolution. 50µL aliquots were stored at -20 ºC.  
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3.3.14. RNase (10 mg/mL) 
RNase was used in bacterial DNA extraction. 
RNase ............................................................................. 0.010 g  
Tris-HCl.............................................................................. 10 µL  
5M Sodium Chloride ............................................................. 3 µL  
Ultrapure H2O .................................................................. 987 µL  
All the ingredients were dissolved and sterilized at 100 ºC for 15 min. The 
solution was cooled on ice and 20 µL aliquots were stored at -20 ºC.  
3.3.15. PIV SOLUTION  
This solution was used in experiments of bacterial strain typing by PFGE.  
Tris 1M pH 8 ..................................................................... 10 mL 
NaCl 5M .......................................................................... 200 mL 
Distilled water  ................................................................. 790 mL   
Solution was sterilized by autoclave.  
3.3.16. ST SOLUTION (LYSIS SOLUTION)  
This solution was used in experiments of bacterial strain typing by PFGE.  
Tris pH 8 .......................................................................... 0.6 mL  
NaCl 5M ............................................................................ 20 mL 
EDTA 0.5 M pH 8 .............................................................. 20 mL 
10% Sodium deoxycholate .................................................. 2 mL 
10% Sarkosyl  ....................................................................  5 mL 
Distilled water  ................................................................ 52.4 mL   
Solution was sterilized by autoclave.  
3.3.17. ES SOLUTION (FOR PROTEINASE K INCUBATION)  
This solution was used in experiments of bacterial strain typing by PFGE.  
EDTA 0.5 M pH 8 .............................................................. 90 mL  
10% Sarkosyl  ................................................................... 10 mL 
Solution was sterilized by autoclave.  
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3.3.18. TE SOLUTION 
This solution was used in experiments of bacterial strain typing by PFGE.  
Tris 1M pH 7.5 .................................................................. 10 mL  
EDTA 0.5 M pH 8  ............................................................... 2 mL 
Distilled water  ................................................................. 988 mL   
Solution was sterilized by autoclave.  
3.3.19. RESTRICTION SOLUTION  
This solution was used in experiments of bacterial strain typing by PFGE.  
SpeI restriction enzyme ...................................................... 2.5 U  
Bovin seric albumin (BSA) ................................................ 0.4  µL   
Spe I buffer 1X 
3.3.20. 6X GEL-LOADING BUFFER 
Gel-loading buffer was used to suspend samples for analysis of agarose 
gel analysis of DNA.   
Bromophenol blue ............................................................. 0.25% 
Xylene cyanol.................................................................... 0.25% 
Ficoll or glycerol ................................................................ 30.0% 
Distilled water  .......................................................... Up to 10 mL  
3.3.21. MARKERS  
Lambda DNA/HindIII is a marker suitable for sizing and quantifying linear 
double-stranded DNA molecules of between 125 bp and 23.1 kb. The 
marker is prepared by completely digesting lambda DNA (cl857, Sam7) 
with HindIII.  
Gene Ruler 1 kb DNA Ladder is a marker suitable for sizing and 
quantifying linear double-stranded DNA molecules of between 250 bp and 
10000 bp. 
SDS-PAGE Molecular Weight Standard, Low Range is a marker suitable 
for sizing protein molecules of between 14400 and 97400 Da.  
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3.3.22. DYES  
 Ethidium bromide: It was used to stain DNA in agarose gels, and 
prepared by adding 1 g of ethidium bromide in 100 mL of distilled 
water. It was kept at room temperature and dark conditions.  
 Silver nitrate: It is an inorganic compound used for silver staining of 
proteins and LPS in SDS PAGE gels.  
 LIVE / DEAD BacLight Bacterial Viability Kit for microscopy and 
quantification assays L7011: This kit that provides a two-colour 
fluorescence assay of bacterial viability was used to stain biofilms and 
analyzed them by Confocal Laser Scan Microscopy (CLSM). The 
working solution was prepared dissolving 1.5 µL of SYTO 9 dye 3.34 
mM solution in dimethyl sulfoxide (DMSO) plus 1.5 µL of propidium 
iodide, 20 mM solution in DMSO in 997 mL of distilled water.  
3.3.23. BACTERIAL EFFLUX PUMPS INHIBITORS 
 Carbonyl cyanide m-chlorophenylhydrazone (CCCP): It is an energy 
uncoupler that collapses the membrane energy and is able to collapse 
the energy required for drug transport [93,94]. It reduces the viability 
of the bacterium and cause death of bacteria via the dissipation of the 
proton-motive force of the membrane. CCCP is highly noxious and 
cytotoxic and is a substrate of bacterial efflux pumps [95]. It was used 
in the efflux experiments of P. aeruginosa or S. marcescens strains. 
The stock was prepared at a concentration of 10 mg/mL in methanol, 
and stored at -20 ºC until its use.  
 MC207,110 or phenylalanine arginyl ß-naphthylamide (PAßN): It is a 
peptidomimetic that have the ability to inhibit the efflux of one or more 
antibiotics and restore antibiotic susceptibility of resistant bacteria. 
This molecule can be considered to exhibit a broad spectrum activity 
of efflux pump inhibition. However, not all antibiotic substrates for a 
given pump are potentiated by PAßN. Mechanism of action of this 
compound has indicated that PAßN is itself a substrate of efflux 
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 pumps. It is assumed that different antibiotics have dissimilar binding 
pockets within the transporter protein and that PAßN compete with 
antibiotics for binding in the substrate pocket to the potentiated 
antibiotic, but not to the binding site for the non-potentiated antibiotic 
(substrate-dependent inhibition) [96]. It was used in the efflux 
experiments of P. aeruginosa. Stock of PAßN was prepared at a 
concentration of 50 mg/mL in methanol and stored at -20 ºC until its 
use.  
3.3.24. OTHERS  
 Ethylenedinitrilotetraacetic acid (EDTA): It is a chelator of divalent 
cations. It was used in experiments of colistin-resistant P. aeruginosa. 
Since lipopolysaccharides (LPS) molecules present in the outer 
membrane of Gram-negative bacteria are electrostatically linked by 
divalent cations such as Mg2+ and Ca2+, EDTA interferes with the Ca2+ 
and increases the permeability of the outer membrane, therefore 
sensitizing Gram-negative bacteria to certain antimicrobial agents 
such as colistin.  
 LPS extraction kit: (Gentaur). It is a kit designed for the extraction of 
LPS from small volume of bacteria. It was used to analyze LPS of 
several colistin-resistant P. aeruginosa and control strains following 
manufacturer’s instructions.  
 Pierce®BCA Protein Assay Kit: (Thermo Scientific). It is a detergent-
compatible formulation based on bicinchoninic agent (BCA) for the 
colorimetric detection and quantification of total protein. This method 
combines the reduction of Cu2+ to Cu1+ by protein in an alkaline 
medium (biuret reaction) with the sensitive and colorimetric detection 
of the cuprous cation (Cu1+) using a reagent that contains 
bicinchoninic agent. This kit was used to equal total protein of bacteria 
used in the bioassay for the measurement of meropenem 
accumulation in P. aeruginosa.  
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3.4. DETERMINATION OF BACTERIAL SUSCEPTIBILITIES TO 
ANTIMICROBIAL AGENTS 
The three methods described in sections 3.4.2, 3.4.3 and 3.4.4 were used 
indistinctly for drug susceptibility testing.   
3.4.1. PREPARATION OF ANTIMICROBIAL STOCKS 
Antimicrobial agents used are shown in table 11. 
Table 11.  Stock solutions of antimicrobial agents.  
Antibiotic Concentration Solvent [97] 
ß-lactam 
Penicillin  
Ampicillin 
Amoxicillin  
Cefoxitin  
Ceftazidime 
Cefotaxime  
Ceftriaxone  
400 µg/mL 
1 mg/mL  
1000 µg/mL  
100 mg/mL 
2000 µg/mL  
2000 µg/mL  
100 mg/mL 
Sterile distilled water  
Phosphate buffer pH 8; 0.1 M  
Buffer phosphate pH 6; 0.1 M  
Sterile distilled water  
Ca2CO3 (10% of the ceftazidime used) 
Sterile distilled water  
Sterile distilled water  
Aminoglycosides  
Kanamycin  
Gentamicin 
Streptomycin 
Tobramycin  
100 mg/mL  
100 mg/mL 
100 mg/mL 
10 mg/mL 
Sterile distilled water  
Sterile distilled water 
Sterile distilled water 
Sterile distilled water 
Rifampicin  6.25 mg/mL  Methanol  
Tetracycline 500 µg/mL Sterile distilled water  
Carbapenems    
Meropenem 5,000 mg/L  Methanol, 0.1mmol/L NaOH  
Imipenem  5,000 mg/L  Phoshate buffer pH 7.2; 0.1 M  
Quinolones    
Ofloxacin  
Ciprofloxacin  
20 mg/mL 
100 mg/mL  
½ volume of water, then 0.1 mol/L NaOH  
Sterile distilled water 
Polymyxins    
Colistin  1000 mg/L Cold Sterile distilled water 
 
All the antibiotic stocks were stored at -20 ºC until their use.  
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3.4.2. MINIMAL INHIBITORY CONCENTRATION (MIC) BY BROTH 
MICRODILUTION METHOD 
Broth Microdilution test is a quantitative method to determine the minimal 
inhibitory concentration of each antibiotic. This procedure involves a 
microtiter tray containing standard twofold dilutions of antimicrobials 
agents to be inoculated with standardized microbial suspensions. Each 
microtiter tray can be prepared with several antimicrobial agents or with 
only a single agent.  
The method used is the one described below [98]:  
 
 Bacterial cultures were incubated at 30 ºC (Serratia) or 37 ºC 
(Pseudomonas) for approximately 18 hours. 
 The cultures were then diluted 1:100 in  Mueller-Hinton broth 
(OD625nm=0.08-0.1) 
 5 µL of the diluted culture (5x105 CFU/mL) were inoculated using a 
multi-channel pipette in each of the microtiter wells containing serial 
dilutions of the antimicrobial agent.  
 Microtiter plates were incubated at 30 ºC (S. marcescens) or 37 ºC (P. 
aeruginosa) for 18 hours.  
 MICs were determined as the lowest concentration of drug that 
inhibits more than 99% of the bacterial population. 
Based on breakpoints defined by European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) [99] or Clinical Laboratory and Standards 
Institute (CLSI) [98] bacterial strains were classified as sensible (S), 
intermediate (I) or resistant (R) to the tested antimicrobial agent.  
3.4.3. DETERMINATION OF BACTERIAL SUSCEPTIBILITIES BY DISK 
DIFFUSION METHOD  
Antimicrobial disk susceptibility test is a well standardized method for 
determining susceptibility of bacteria to antimicrobials [100]. 
Bacterial cultures were incubated at 30 ºC (Serratia) or 37 ºC 
(Pseudomonas) for approximately 18 hours. 
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 Inoculum was prepared by diluting the cultures 1:100 in Mueller-
Hinton broth (OD625nm=0.08-0.1, equivalent to 1-2 x 108 CFU/mL).  
 Bacterial inoculum was applied to the surface of a large (150 mm 
diameter) Mueller-Hinton agar plate. 
 Up to 12 commercially-prepared, fixed concentrations, paper antibiotic 
disks were placed on the inoculated agar surface. 
 Plates were incubated for 16-24 h at 30 ºC (S. marcescens) and 37 ºC 
(P. aeruginosa) prior to determination of results.  
 The zones of growth inhibition around each of the antibiotic disks 
were measured to the nearest millimeter. The diameter of the zone is 
related to the susceptibility of the isolate and to the diffusion rate of 
the drug through the agar medium. 
 The zone diameters of each drug were interpreted using the criteria 
published by the Clinical and Laboratory Standards Institute CLSI or  
EUCAST  
 It is important to note that the results of the disk diffusion test are 
“qualitative,” in that a category of susceptibility (i.e., susceptible, 
intermediate, or resistant) is derived from the test rather than a MIC.  
3.4.4. DETERMINATION OF BACTERIAL SUSCEPTIBILITIES BY DOUBLE 
DILUTION AGAR METHOD  
The method of double dilution agar was used for drug susceptibility testing 
and is the one specified by CLSI [101]. It is described below: 
 Bacterial cultures were incubated at 37 ºC for approximately 18 hours. 
 The cultures were then diluted 1:100 in Mueller-Hinton broth 
(OD625nm=0.08-0.1). 
 The Mueller-Hinton agar plates with appropriate antibiotic 
concentrations were inoculated using a Steers replicator, depositing 
0.001 mL of a suspension of each adjusted culture (5×105 CFU/mL). 
 Plates were incubated at 37 ºC for 18-24 h.  
 MICs were determined as the lowest concentration of drug that 
inhibits more than 99% of the bacterial population. 
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3.4.5. STATISTICAL ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITIES 
FOR THE THREE GROUPS OF Serratia STRAINS  
Comparison of antimicrobial MICs between the three groups of S. 
marcescens strains were statistically analyzed using Kruskall-Wallis (K-W) 
test with Bonferroni correction for multiplicity, following the Holm 
sequential procedure.  
Antimicrobials that showed significant differences in K-W test were 
analyzed by U Mann-Whitney test to check differences between couples 
of strain groups. 
3.4.6. MICS OF COLISTIN WITH AND WITHOUT EDTA 
MICs of colistin alone and in combination with EDTA were determined by 
twofold standard broth microdilution method (section 3.4.2). Colistin was 
tested at 11 concentrations (128-0.25 µg/mL), and EDTA at the 
concentration of 1 mM, based on previous studies [102] 
3.5. ANALYSIS OF PRESENCE/ABSENCE OF INTEGRONS  
The technique described by Lévesque et al. [58] was used to detect the 
presence or absence of class 1 integrons in Serratia or Pseudomonas 
strains.  
The protocol followed is described below:  
3.5.1. DNA EXTRACTION  
 Serratia and Pseudomonas strains were grown O/N in 4 mL of brain 
heart infusion (BHI)-10% glycerol. Serratia was incubated at 30 ºC 
and Pseudomonas at 37 ºC.  
 200 µl of the culture was added to 800 µl of distilled water and boiled 
for 10 min. 
 Bacterial suspension was then centrifuged at 12,000 x g for 2 min, 
and the supernatant was used for PCR. 
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3.5.2. POLYMERASE CHAIN REACTION (PCR) 
PCR was carried out in 100 µL volumes containing 30 µl of template DNA 
and 70 µL of mix.  
Components for 100 µL of mix:  
Oligonucleotides ........................................................... 2.5 pmol 
Taq DNA polymerase ............................................................. 1U 
Deoxynucleoside triphosphate ............................... 200 µM each 
MgCl2 ................................................................................. 3 mM  
Tris-HCl pH 8 ................................................................... 10 mM  
KCl Sulphate .................................................................... 50 mM  
Gelatin ............................................................................ 0.001% 
Distilled water......................................................................... QS  
 
Primers: 
Primers used were described by Lévesque et al. [58] and are designed 
from conserved segments in integrons allowing only the amplification of 
the integrated gene cassettes.  
These are the sequences of the primers used:  
Primer  Nucleotide Sequence ( 5´ to 3´) 
5´CS GGC ATC CAA GCA GCA AG 
3´CS AAG CAG ACT TGA CCT GA 
Primers were purchased from Invitrogen (USA). 
DNA amplification:  
Previously to the amplification, DNA was pre-denaturalized using the hot 
start method:  
 12 min at 94 ºC 
To amplify the DNA in the thermal cycler, a three-step profile was used:  
 1 min of denaturation at 94 ºC 
 1 min of annealing at 55 ºC 
 5 min of extension at 72 ºC  
Total of cycles: 35. Five seconds were added to the extension time in 
each cycle.  
All completed reactions were maintained at 4 ºC.  
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3.5.3. VISUALIZATION OF PCR PRODUCTS 
The PCR products were visualized in 0.7% (w/v) agarose gels in 1X TAE 
at 100 volts for 1.30 hours.  
Composition of agarose gel 0.7% (w/v):  
Agarose ...................................................................... 0.7 g 
TAE ......................................................................... 100 mL  
3.5.4. GEL STAINING   
Agarose gel staining is described in section 3.15.2. 
3.6. DETECTION OF EXTENDED-SPECTRUM ß-LACTAMASES 
(ESBLS) BY BORONIC ACID (BA) DISK TEST AND THE CLSI 
CONFIRMATORY TEST 
The method used for the detection of ESBLs in S. marcescens strains 
was the one described by Seok Hoon Jeong et al. [103]:  
 Disks containing BA were prepared using commercially available 
antibiotic-containing disks (Oxoid Ltd., Basingstoke, Hampshire, 
England) as described by Coudron PE [104].  
 20 µL of the phenylboronic acid (BA) solution (20g/L; Sigma-Aldrich 
Chemie GmbH, Germany) was dispensed onto each disk containing 
cefotaxime (CTX) (30 µg) and ceftazidime (CAZ) (30 µg) with and 
without clavulanic (CLA) (10µg).  
 Disks were allowed to dry for 60 min and used immediately or stored 
in airtight vials with desiccant at 4 ºC.  
 Similar to the CLSI ESBL confirmatory test, a ≥5mm increase in the 
zone diameter of CTX/CLA and/or CAZ/CLA disks tested in 
combination with BA (CTX/CLA/BA and/or CAZ/CLA/BA) versus CTX 
and/or CAZ disks containing BA (CTX/BA and/or CAZ/BA) was 
considered positive for ESBLs. CTX, CTX/CLA, CAZ and CAZ/CLA 
disks with BA were spaced over the Mueller–Hinton agar surface. 
Inoculated plates were incubated overnight at 30 ºC in ambient air. 
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 The CLSI confirmatory test for ESBL production was also carried out 
on Mueller–Hinton agar using CTX and CAZ alone and with CLA. 
3.7. BIOFILMS 
3.7.1. FORMATION OF BIOFILMS  
The strain used for the studies of biofilms was S. marcescens 2170.  
Biofilms were obtained in the following conditions: 
 Nutritional conditions: Davis minimal broth without dextrose, 
supplemented with 0.05% glucose and 0.05% of casamino acids.  
 Material for biofilm formation:  a methacrylate piece of 1 mm thickness 
and size of 1 x 1 cm2. 
 Procedure: submersion of methacrylate pieces in Petri dishes with 25 
mL of DMBsup and inoculation of the medium with 100 µL of an ON 
bacterial culture.  
 Environmental conditions: incubation at 30 ºC for 24 or 48 hours 
without shaking.  
3.7.2. QUANTIFICATION OF BIOFILMS  
The determination of the number of bacteria forming biofilms was a 
previous condition to measure both intake and efflux of antibiotics. 
Quantification of biofilms was done by following the method described 
below:  
 Methacrylate pieces were withdrawn with sterile tweezers and 
cleaned three times by immersion in 1X PBS pH 7.4 for 10 seconds to 
eliminate planktonic bacteria.  
 PBS was discarded in order to remove bacteria loosely attached to 
the methacrylate. 
 Methacrylate pieces where the biofilm was formed were put into 
Eppendorf tubes and sonicated on ice (3x3 min) to aid dispersal of 
attached bacteria. 
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 To check the sonication efficiency, images of the methacrylate pieces 
were taken by AFM (Fig. 17).  
 
 
 
 
Fig. 17. Two AFM images of sonicated methacrylate pieces to check biofilm removal. 
Visualization in air by using the Atomic Force Microscope XE-70 (Park Systems) previously 
air dried at RT in a dust-free environment. Images were collected in Non-contact mode using 
pyramidal-shaped silicon cantilevers. 
 To estimate the amount of bacteria in biofilms, optical densities at 550 
nm were measured followed by serial dilution and TSA plating.   
 After the counting of colonies, a relationship between absorbance 
(OD) and microbial concentration was established.  
3.7.3. VISUALIZATION OF BIOFILMS  
3.7.3.1. ATOMIC FORCE MICROSCOPY (AFM) 
In order to check that bacteria were attached to the surface of the 
polymer, pieces of methacrylate were visualized in air by using the Atomic 
Force Microscope XE-70 (Park Systems). For visualization of biofilms 
under AFM, they were previously air dried at RT in a dust-free 
environment. All images were collected in Non-contact mode using 
pyramidal-shaped silicon cantilevers. The acquired data were converted 
into images and analysed by using XEP and XEI softwares (Park 
Systems). 
Figure 18 shows AFM images of Serratia biofilms formed in methacrylate 
pieces and incubated at different times.  
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 c)    b)   a)  
 
Fig. 18. AFM images of Serratia biofilms formed in methacrylate pieces and incubated at 
different times. Biofilms were visualized in air by using the Atomic Force Microscope XE-70 
(Park Systems) previously air dried at RT in a dust-free environment. All images were 
collected in Non-contact mode using pyramidal-shaped silicon cantilevers. a) 24 h biofilm-
formation. b) 48 h biofilm-formation. c) 72 h biofilm-formation 
3.7.3.2. CONFOCAL MICROSCOPY  
In order to check viability of bacteria in biofilms, they were prepared for 
confocal scanning laser microscopy (CLSM) by staining with the 
LIVE/DEAD Baclight viability probe, prepared according to manufacturer’s 
specifications. Microscopic observation and image acquisition of biofilms 
was performed by using the Basic Scanning using AxioPlan 2 LSM 510 
equipped with an argon ion laser at 483 nm of excitation and 543 nm 
band-pass filter for emission. 
Figure 19. shows confocal microscopy images of S.marcescens biofilms. 
 
 
a)  b)  c)  
 
Fig. 19. Confocal images of S. marcescens biofilm at different times of incubation. Basic 
Scanning using AxioPlan 2 LSM 510 equipped with an argon ion laser at 483 nm of 
excitation and 543 nm band-pass filter for emission. X100 magnification. Stained 15 min in 
dark conditions and RT with 50 µL LIVE/DEAD, and rinsed three times with PBSx1 pH 7.4. 
a) 24 h biofilm-formation. b) 48 h biofilm-formation. c) 96 h biofilm-formation. 
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3.8. EFFLUX EXPERIMENTS  
3.8.1. GROWTH AND INHIBITION ASSAYS 
3.8.1.1. BACTERIAL GROWTH CURVES 
Bacterial growth curve was done for P. aeruginosa and S. marcescens. 
The protocol is described below:  
 Bacterial strains were inoculated in flasks containing 100 mL of TSB. 
 The spectrophotometer was set to 550 nm and calibrated.  
 The spectrophotometer was blanked inserting a test tube containing 
TSB into the sample holder.  
 Incubation was at 37 ºC for P. aeruginosa and 30 ºC for S. 
marcescens. Cultures were shacked at 250 rpm until the OD was 
between 0.2-0.3.  
 Every hour, a sample of 1 mL of each culture was removed and OD of 
the cultures were read and recorded. 
 For direct growth measurements, serial dilutions and standard plate 
counts of each sample were done. A volume of 20 µL of each dilution  
(10-1, 10-2, 10-3, 10-4 and 10-5) were spread onto TSA and incubated at 
the appropriate temperature.  
 The number of CFU/mL of the original culture for each of the time sets 
was determined by counting the plates containing between 30 and 
300 CFU. Numbers were averaged and recorded only one for each 
time set. 
 Counting of CFU growth in TSA allowed us to establish the 
relationship between OD and bacterial concentration.  
3.8.1.2. INHIBITION ASSAYS WITH EFFLUX INHIBITORS 
Growth inhibition assays for S. marcescens and P. aeruginosa were 
performed as described by Beyer et al. [105] with some modifications:   
 Strains were inoculated at 1x107 to 2x107 CFU/mL (OD = 0.2 to 0.3) 
into flasks with 20 mL of TSB.  
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 Antibiotics were added at a concentration of one-fourth the 
determined MIC, either alone, with 10 µg/mL carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) or 40 µg/mL Phe-Arg-naphthylamide 
(PAßN). All strains were also grown with neither antibiotic nor 
CCCP/PAßN, with 10 µg/mL of CCCP alone or with 40 µg/mL of 
PAßN alone. Ciprofloxacin was the antibiotic tested for MDRPA 
strains, and colistin for colistin-resistant P. aeruginosa strains.  
 Cultures were incubated at 37 ºC (P. aeruginosa) or 30 ºC (S. 
marcescens) and optical densities were determined at intervals of one 
hour at 550 nm (OD550 nm).   
 OD550 nm was plotted on the Y axis and incubation times on the X axis. 
3.8.1.3. QUINOLONE AND COLISTIN RESISTANCE 
To determine the prevalence of efflux pump-mediated quinolone 
resistance in the MDRPA strains and efflux pump-mediated colistin 
resistance in colistin-resistant P. aeruginosa, MIC determinations were 
carried out in 96-well microtiter plates by twofold standard broth 
microdilution method in Mueller-Hinton broth either with or without a fixed 
concentration of the efflux pump inhibitor (EPI) Phe-Arg-naphthylamide 
(PAßN) using the method described by Kriengkauykiat et al. [106].  
Ciprofloxacin concentration ranged between 128-0.25 µg/mL and colistin 
concentration ranged between 256-0.5 µg/mL. PAßN was used at a fixed 
concentration of 40 µg/mL based on previous studies [96].  
Inoculums were adjusted to OD625 nm = 0.08-0.1 equivalent to 1-2x108 
CFU/mL and diluted 1:10 (for inoculation volume of 5 µL) to get a final 
concentration of 5x105 CFU/mL. Microtiter plates were incubated at 37 ºC 
for periods of 18/24 hours.  
3.8.1.4. MEXXY-OPRM EFFLUX PUMP 
To determine the presence of a functioning MexXY-OprM efflux pump in 
the MDRPA strains, MIC of the aminoglycoside tobramycin was carried out 
in 96-well microtiter plates using a twofold standard broth microdilution 
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standard method in Mueller-Hinton broth in the absence and in the 
presence of 40 µg/mL of PAßN.  
Tobramycin was tested at 11 concentrations (0.25-256 µg/mL).  
3.8.1.5. ROLE OF EFFLUX PUMPS IN SYNERGIC COMBINATIONS OF 
ANTIMICROBIAL AGENTS 
To determine the role of efflux pumps in the MDRPA strains when 
synergic combinations of antibiotics are used interaction between 
ceftazidime plus tobramycin and meropenem plus tobramycin alone and 
in combination with 40 µg/mL of the EPI PAßN were studied. 
Meropenem and ceftazidime were tested at 11 concentrations (0.125 to 
128 µg/mL) and these antibiotics were combined with different 
concentrations of tobramycin (0, 8, 16, 32, 64 and 128 µg/mL). Microtiter 
plates were incubated at 37 ºC between 18 and 24 hours.  
3.8.2. FLUOROMETRY EXPERIMENTS  
3.8.2.1. CIPROFLOXACIN ACCUMULATION: SENSITIVITY OF THE 
METHOD  
To explore if ciprofloxacin accumulation vary depending on the amount of 
bacteria, planktonic cultures of S. marcescens 2170 were used. The 
accumulation of quinolones was measured spectrofluorometrically by 
using the method described by Mortimer and Piddock [107] with some 
modifications [108].  
The method used is described below:  
 A volume of 100 mL of DMBSUP was inoculated with 3 colonies of S. 
marcescens and incubated at 30 ºC until OD600 was 1.5.  
 Bacteria were harvested by centrifugation at 8,000 rpm at room 
temperature for 15 min.  
 The sediment was suspended in 100 mL 1X PBS pH 7.5 and 
centrifuged at 8,000 rpm at room temperature for 15 min.  
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 Sediment was suspended in 10 mL 1X PBS pH 7.5 and 2-fold serial 
dilutions were made. These dilutions were kept at 4 ºC until his use.  
 Number of bacteria (CFU) in each dilution was determined by serial 
dilutions from 1x10-1 to 1x10-6, platting out 0.1 mL of the aliquots onto 
TSA.  
 Bacterial dilutions were incubated at 30 ºC for 10 min and 1 mL 
sample was removed (time 0).  
 Ciprofloxacin was added to a final concentration of 10 µg/mL and 1 
mL samples were removed at different time intervals. Incubation times 
with the antibiotic were 3 and 6 min.  
 The samples were immediately diluted in 1 mL of ice-cold 1X PBS 
and centrifuged for 1 min at 4 ºC and 11,000 rpm.  
 Pellets were suspended in 1 mL of 0.1M glycine buffer at pH 3.0 and 
incubated at room temperature and dark conditions overnight to allow 
bacterial lysis.  
 Thereafter, the suspensions were centrifuged at 20 ºC for 15 min to 
remove bacterial debris.  
 The fluorescence of supernatant was measured using the Fluoromax-
4 spectrofluorometer at excitation and emission wavelengths of 279 
and 447 nm, respectively.  
 The concentration of ciprofloxacin in the supernatant was calculated 
by comparison with a standard curve for ciprofloxacin (0.02 to 10 
µg/mL) in 0.1 M glycine hydrochloride (pH 3.0). Ciprofloxacin 
accumulation was expressed in ng of ciprofloxacin/mg bacteria. 
 The experiment was repeated at least three times. 
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3.8.2.2. CIPROFLOXACIN ACCUMULATION/EFFLUX IN PLANKTONIC 
BACTERIA 
The accumulation and efflux of ciprofloxacin was measured 
spectrofluorometrically by using the method described previously with the 
following modifications: 
 A volume of 20 mL of DMBSUP was inoculated with 3 colonies of S. 
marcescens and incubated at 30 ºC ON.  
 Then, the ON culture was diluted until the OD550 was equaled to the 
OD550 obtained for 24 h or 48 h biofilms formed in 1cm x 1cm 
methacrylate pieces. 
 For both accumulation and efflux experiments, ciprofloxacin was 
added to a final concentration of 10 µg/mL and 1 mL samples were 
removed at different time intervals. Incubation times with the antibiotic 
or antibiotic plus CCCP were 0, 3 and 7.5 min.  
 For efflux experiments, CCCP was added after 3 min of ciprofloxacin 
addition, at a final concentration of 10 µg/mL.  
 The samples were immediately diluted in 1 mL of ice-cold 1X PBS 
and centrifuged for 1 min at 4 ºC and 11,000 rpm.  
 Pellets were suspended in 1 mL of 0.1M of glycine buffer at pH 3.0 
and incubated at room temperature and dark conditions overnight to 
allow bacterial lysis.  
 Thereafter, suspensions were centrifuged at 20 ºC for 15 min to 
remove bacterial debris.  
 The fluorescence of supernatant was measured using the Fluoromax-
4 spectrofluorometer at excitation and emission wavelengths of 279 
and 447 nm, respectively.  
 The concentration of ciprofloxacin in the supernatant was calculated 
by comparison with a standard curve for ciprofloxacin in 0.1 M glycine 
hydrochloride (pH 3.0). Ciprofloxacin accumulation was expressed in 
ng of ciprofloxacin/mg bacteria. 
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 The experiment was performed at least three times to make sure of 
the reproducibility. 
3.8.2.3. CIPROFLOXACIN ACCUMULATION/EFFLUX IN BIOFILMS  
This experiment was designed to explore if active expulsion of antibiotics 
is or not dependent on the way that bacteria grow.   
The method used is described below:  
 10 mL of TSB were inoculated with 3 colonies of the isolates and 
incubated overnight at 30 ºC.  
 100 µL of the overnight cultures were used to inoculate Petri dishes 
containing 25 mL of DMBSUP and sterile methacrylate pieces 1cm x 
1cm x 0.1 cm in horizontal position. Cultures were incubated statically 
at 30 ºC for 24 or 48h. 
 Thereafter, methacrylate pieces where bacteria were attached 
forming the biofilm were gently removed by sterile tweezers and 
rinsed in a new Petri dish containing 25 mL of 1X PBS. This step was 
repeated three times.  
 To determine the average of attached bacteria (CFU/cm2) in the 
methacrylate pieces at the beginning of experiment, 3 biofilms were 
sonicated for 3 min in tubes with 5 mL of 1X PBS. The OD550 was 
measured and serial dilutions were made platting out 0.1 mL of the 
aliquots onto TSA.  
 Washed biofilms were put in a new Petri dish containing 25 mL of 
sterile DMBsup and 1 of them was removed (time 0).  
 For both accumulation and efflux experiments, ciprofloxacin was 
added to a final concentration of 10 µg/mL and 1 mL samples were 
removed at different time intervals. Incubation times with the antibiotic 
or antibiotic plus CCCP were 0, 3 and 7.5 min. 
 For efflux experiments CCCP was added after 3 min of ciprofloxacin 
addition, at a final concentration of 10 µg/mL.  
 The samples were immediately put into tubes with 1 mL of ice-cold 1X 
PBS placed on ice.  
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 Tubes were gently inverted 3-4 times to wash biofilms, and 1X PBS 
was then removed.  
 1 mL of 0.1M of glycine buffer at pH 3.0 was added and incubated at 
room temperature and dark conditions overnight to allow bacterial 
lysis. 
 Afterwards, tubes were sonicated for 3 min  at room temperature and 
suspensions were replaced in 1 mL Eppendorf tubes and centrifuged 
at 20 ºC for 15 min to remove bacterial debris. 
 The fluorescence of supernatant was measured using the Fluoromax-
4 spectrofluorometer at excitation and emission wavelengths of 279 
and 447 nm, respectively.  
 The concentration of ciprofloxacin in the supernatant was calculated 
by comparison with a standard curve for ciprofloxacin in 0.1 M glycine 
hydrochloride (pH 3.0). Ciprofloxacin accumulation was expressed in 
ng of ciprofloxacin/mg bacteria.  
3.9. EFFECT OF DRUG-SELECTIVE PRESSURE IN ANTIMICROBIAL 
RESISTANCE 
3.9.1. BIOASSAY FOR MEASUREMENT OF MEROPENEM 
ACCUMULATION IN MDRPA 
 Long rod-shaped bacteria of P. aeruginosa formed in the presence of 
4X meropenem MIC and short rods from cultures without antibiotic 
were washed with PBS pH 7.4 and resuspended in 30 mL of the 
same buffer.  
 The total protein of both samples was equaled by BCA™ Protein 
Assay Kit and meropenem was added to a final concentration of 1 
µg/mL while bacteria were centrifuged at 13,000 rpm for 1 min.  
 The supernatant was used for the measurement of the meropenem 
unable to penetrate inside bacteria.  
 Measures were done using a meropenem susceptible strain of E. coli. 
The standard curve ranged from 25 to 0 ng/mL of meropenem.  
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 After incubation of samples at 37 ºC for approximately 2 hours, the 
optical density at 550 nm was measured. Optical densities of 
unknown samples were extrapolated to the standard curve to obtain 
the amount of meropenem inside and outside of long or short P. 
aeruginosa. 
3.9.2. EFFECT OF DRUG-SELECTIVE PRESSURE IN COLISTIN 
RESISTANCE  
To check if drug-selective pressure plays an important role in colistin 
resistance, several P. aeruginosa strains described in table 10 were 
chosen:  
 In vitro experiments with strains 5181401, 4769780, 5150328R and 
2473493 were done to explore the ability of bacteria to adapt to deficit 
of antibiotic and recover fitness on serial passage. Adaptation 
experiments were performed in 20 mL of MHB by subsequent serial 
passages in the absence of antibiotic for at least 20 times.  
 The colistin-susceptible strain 5150328S and the colistin-resistant 
strains 5150328R and 2473493 were used to explore the ability of 
bacteria to adapt to higher concentrations of colistin. Adaptation 
experiments were performed in 20 mL of MHB and the concentration 
of colistin was doubled every passage. At the end of the experiment, 
colistin susceptibility of all the strains was indistinctly tested by using 
the method of broth microdilution method (section 3.4.2) or double 
dilution agar method (section 3.4.4).   
3.9.3. EFFECT OF DRUG-SELECTIVE PRESSURE IN IMIPENEM 
RESISTANCE  
To check if drug-selective pressure plays an important role in imipenem 
resistance, strain PA116136 was explored:  
 Adaptation experiments were performed in 20 mL of MHB by 
subsequent serial passages in the absence of antibiotic.  
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 After 30 antibiotic-free passages antibiotic susceptibility was 
indistinctly tested by using the method of broth microdilution method 
(section 3.4.2) or double dilution agar method (section 3.4.4).  
3.10. ANALYSIS OF OUTER MEMBRANE PROTEINS (OMPs) 
3.10.1. OMPS ISOLATION  
OMPs were obtained as described by Puig et al. [82]  
 P. aeruginosa strains were grown in 10 mL of TSB at 37 ºC O/W.  
 The O/W cultures were added to 100 mL of TSB flasks and incubated 
at 37 ºC with shaking (250 rpm) O/N.  
 Cultures were centrifuged for 15 minutes at 7000 rpm and room 
temperature.  
 Sediment was resuspended in 30 mL of ringer ¼ to wash bacterial 
cells.  
 Cells were centrifuged at 7000 rpm for 15 min at room temperature. 
 Pellet was resuspended in 30 mL HEPES 10 mM pH 7.4.  
 Cells were disrupted at a pressure of 30 KPa (Constant cell disruption 
systems). 
 Sedimentation of whole cells was done at 5,000 rpm for 15 min at 21 
ºC.   
 Sedimentation of total membranes was done at 30,000 rpm for 1.30 h 
(ultracentrifuge) at 21 ºC.  
 Pellets were resuspended in 2 mL of SLS 1% in HEPES 10 mM pH 
7.4  
 Suspensions were incubated at RT for 20 min. 
 Sedimentation of outer membranes was done at 30000 rpm for 60 
min.  
 Sediments were resuspended in 50 µL of sample buffer (4.0 mL of 
distilled water, 1.0 mL 0.5 M Tris-HCl pH 6.8, 0.8 mL of glycerol, 1.6 
mL of 10% (w/v) SDS).  
 Aliquots of 20 µL were kept at –20 ºC.  
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 To remove lipids excess, 20 µL of each sample were resuspended in 
200 µL of 10% SDS and centrifuged at 13000 rpm for 99 min.  
 Pellets were resuspended in 50 µL of sample buffer with blue 
bromophenol and mercaptoethanol (4.0 mL of distilled water, 1.0 mL 
0.5 M Tris-HCl pH 6.8, 0.8 mL of glycerol, 1.6 mL of 10% (w/v) SDS, 
0.4 mL mercaptoethanol and bromophenol blue).  
 For SDS-PAGE electrophoresis samples were boiled for 10 min and 
cooled 10 more min.  
3.10.2. SDS-PAGE ANALYSIS OF OMPs  
Sodium sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was carried out according to Laemmli's method [109] as modified 
by Ames et al. [110] The stacking and resolving gels were 4 and 12% 
acrylamide, respectively. Samples were loaded and run at RT in a Tris-
glycine SDS gel running buffer (section 3.3.8). An Atto vertical 
electrophoresis cell was used.  The gel was run at 70 V (10 mA) until 
stacking gel was finished and 110 V (15 mA) until the end. 
RESOLVING GEL (12% acrylamide):  
Distilled H2O .................................................................. 1.67 mL  
Tris-HCl 1.5 M, pH 8.8 ................................................... 1.25 mL  
Acrylamide stock solution (section 3.3.8) ............................ 2 mL 
SDS 10% ........................................................................... 50 µL 
Ammonium persulfate (APS) 10% ..................................... 25 µL 
TEMED ............................................................................. 15 µL 
 
STACKING GEL (4% acrylamide):  
Distilled H2O .................................................................. 3.05 mL  
Tris-HCl 0.5 M, pH 6.8 ................................................... 1.25 mL 
Acrylamide stock solution (section 3.3.8) ....................... 0.65 mL 
SDS 10% ........................................................................... 50 µL 
Ammonium persulfate (APS) 10% ..................................... 25 µL 
TEMED ............................................................................... 5 µL 
 
Both solutions were degassed by vacuum for 15 minutes before APS and 
TEMED were added. Oxygen is a strong inhibitor of polymerization and it 
is better to remove it from the solutions.  
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3.10.3. OMPs STAINING PROTOCOL  
 The gel was removed from the supports and stained with A solution 
(methanol, acetic acid and distilled water (5:1:5) + 1 g Coomasie blue) 
for 1 hour at 55 ºC or O/N at RT.  
 The gel was immersed in B solution (methanol, acetic acid and 
distilled water (5:1:5) until bands appeared.  
 Gel was preserved in C solution (methanol, acetic acid and distilled 
water (1:1:18) until it was dried by vacuum using the Gel dryer model 
543 (Bio-Rad).  
3.10.4. OBSERVATION OF RESULTS  
To compare OMPs profiles between strains, observation of results were 
done by visual analysis of the gels. 
3.11. ANALYSIS OF LIPOPOLYSACCHARIDES (LPS) 
LPS analysis was performed by using indistinctly the two methods for 
extraction described below: 
3.11.1. LPS PREPARATION BY THE PROTEINASE K METHOD  
The method of Hitchcock and Brown [111] was used to prepare LPS 
extracts with minor modifications: [112] 
 All the isolates were grown overnight at 37 °C 
 Bacteria were harvested by centrifugation at 13,000 x g for 2 min and 
resuspended in 50 µL of sample buffer which contained 66.6% H2O, 
16.6% Tris pH 6.8, 0.5 M, 13% glycerol and 6,6% 2-mercaptoethanol. 
 After boiling for 10 min, 50 µL of proteinase K at 10 mg/mL were 
added.  
 This was followed by incubation at 56 °C for a minimum of 3 h. This 
produced reasonably concentrations of LPS, except in a few cases in 
which the cell pellet was significantly small.  
 Extracts were stored at -20 °C and thawed immediately before use.  
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3.11.2. MICROSCALE EXTRACTION OF LPS FROM BACTERIA  
The LPS extraction kit (Gentaur, Belgium) was used to extract LPS from 
small volume of bacteria following the manufacturer’s instructions.  
 Bacterial cells were lysed by organic solution to disrupt and release in 
solution phospholipids and protein components of cell membrane.  
 Purification of LPS among the released cell components was done 
with high salt concentration solution.  
 Salts were briefly removed by a washing step for the obtaining of high 
quality LPS.  
3.11.3. ANALYSIS OF LPS (SDS-PAGE) 
SDS-PAGE was carried out according to Laemmli's method as modified 
by Ames et al. The stacking and resolving gels were 4 and 15% 
acrylamide, respectively. Samples (30 µL) were loaded and run at RT in a 
Tris-glycine SDS gel running buffer (section 3.3.8). An Atto vertical 
electrophoresis cell was used. Constant current (10 mA) was applied for 
stacking gel and constant current (15 mA) for resolving gel.  
RESOLVING GEL (15% acrylamide):  
Distilled H2O .................................................................... 2.4 mL  
Tris-HCl 1.5 M, pH 8.8 ..................................................... 2.4 mL  
Acrylamide stock solution (section 3.3.8) ......................... 5.0 mL 
SDS 10% ......................................................................... 100 µL 
Ammonium persulfate (APS) 10% ..................................... 50 µL 
TEMED ............................................................................. 10 µL 
 
STACKING GEL (4% acrylamide):  
Distilled H2O .................................................................. 3.05 mL  
Tris-HCl 0.5 M, pH 6.8 ................................................... 1.25 mL  
Acrylamide stock solution (section 3.3.8) ....................... 0.65 mL 
SDS 10% ........................................................................... 50 µL 
Ammonium persulfate (APS) 10% ..................................... 25 µL 
TEMED ............................................................................... 5 µL 
 
Both solutions were degassed by vacuum for 15 minutes before APS and 
TEMED were added.  
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3.11.4. SILVER STAINING PROCEDURE  
LPS were visualized by using previously described silver staining protocol 
[111] with minor modifications:  
 After SDS-PAGE electrophoresis gel was removed from glass and 
placed for at least 2 hours (occasionally O/N) in a rinse solution of 5% 
v/v glacial acetic acid, 35% v/v absolute ethanol and 60% v/v distilled 
water shaking gently. 
 Gel was treated with rinse solution plus sensitizer (0.7% of periodic 
acid) for 7 min. 
 Sensitizing solution was replaced with distilled water and washed 3 
times for 15 min with gently shaking.  
 Water was replaced with silver staining solution (section 3.3.9). This 
solution was prepared immediately before its use, and gel was left for 
10 min with shaking.  
 Gel was washed with distilled water 3 times for 5 min.  
 Silver stain developer solution (section 3.3.10) was added and left 
until sharp LPS bands appear.  
 Development was stopped covering the gel with stopping solution for 
10 min. (section 3.3.11)  
 The silver stained gel was kept immersed into the preserving solution 
(section 3.3.12) until it was dried by vacuum using the Gel dryer 
model 543 (Bio-Rad).  
3.11.5. OBSERVATION OF LPS PROFILES  
To compare LPS profiles between strains, observation of results were 
done by visual analysis of the gels. 
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3.12. PULSED-FIELD GEL ELECTROPHORESIS 
PFGE was performed by using the method described by Maslow et al. 
[113] and Schwartz et al. [114] with some modifications. Chromosomal 
DNA restriction patterns produced by pulsed-field gel electrophoresis 
were interpreted by criteria described elsewhere [115]. 
3.12.1. CHROMOSOMAL DNA EXTRACTION  
 Microorganisms were growth in blood-agar at 37 ºC for 18-24 hours. 
Colonies were resuspended in 200 µL of PIV and 5 µL were added to 
1 mL of PIV solution to measure OD at 620 nm. Bacterial suspensions 
were adjusted in 1.5 mL Eppendorf tube with PIV solution by the 
following equation: PIV volume = (OD at 620 nm * 40 * 210) -210.  
 A volume of 100 µL of melted 1.0% Megabase agarose kept at 70 ºC 
was added to new Eppendorf tube with 100 µL of the adjusted 
bacterial suspensions.  Samples were mixed thoroughly by gently 
vortexing.  
 20 µL of the agarose-bacterial suspension mixture were dispended on 
the top of an slide and covered by another slide. 
 The agarose plugs were allowed to solidify at 4°C for 5 min. 
 For the lysis of bacteria, the plugs were transferred to 10-mL tubes 
containing 1 mL of the cell lysis buffer (ST). Lysis was allowed to 
proceed for 5 hours at 37 ºC.  
 Lysis solution was discarded and samples were treated with 
proteinase K by adding 1 mL of ES solution prepared just before its 
use. Samples were then incubated at 50 ºC in a water bath for 
approximately 18 hours (overnight).  
 After lysis, the plugs were washed four times (30 min/wash) with TE, 
pH 8 with shaking. TE was discarded after each wash.  
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3.12.2. DNA DIGESTION 
 Plugs were transferred to a tube containing 1X restriction buffer 
solution 
 Then, the restriction enzyme mixture containing 2.5 U of SpeI (Roche) 
was added to each tube. 
 The plug slices were incubated at room temperature (23 to 25 °C) for 
5 h. 
3.12.3. ELECTROPHORESIS 
 The electrophoresis conditions used during the developmental stage 
of this PFGE protocol consisted of a switch time of 0.25 s and a final 
switch time of 15 s (gradient of 6 V/cm and an included angle of 120).  
 The gels were electrophoresed for 20 h at 14 ºC (CHEF Mapper), in 
0.5X TBE. After the electrophoresis run was completed, the gels were 
stained with 400 mL of ethidium bromide solution (50 µg/mL), and the 
band pattern was observed under UV illumination.  
3.13. PLANAR BILAYER ASSAYS 
The basic methods have been reported previously [116, 117, 175].  
Membranes were made from 1% lipid (1% diphytanoylphosphatidylcholine 
(DiphPC) in n-decane or 0.2% diphytanoylphosphatidylglycerol (PS) plus 
0.8% (DiphPC) in n-decane). Bilayers were painted across a 0.8 mm2 hole 
in a Teflon divider separating two compartments containing 5 mL each of 
a bathing solution of 1 M KCl. Voltages were applied across this 
membrane through Ag/AgCl electrodes connected by a salt bridge, and 
the resultant current was boosted 109-1010 fold by a current amplifier, and 
recorded on a Rikadenki strip chart recorder. 
3.14. DNA EXTRACTION  
Two methodologies were indistinctly used for the extraction of 
chromosomal DNA of S. marcescens or P. aeruginosa.  
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3.14.1. CHROMOSOMAL DNA EXTRACTION ( LARGE SCALE) 
The Marmur’s method for bacterial DNA extraction was used for each 
strain as described below: [118] 
 First, strain was inoculated in 5 mL of LB O/N at 30 ºC without 
shaking.  
 Then, 1 mL of the previous subculture was used to inoculate 50 mL of 
LB and incubated for 18 hours at 30 ºC with shaking. 
 Bacteria were pelleted by centrifugation at 10,000 rpm for 10 min at 4 
ºC and resuspended in 5 mL of 0.15 M NaCl and 0.01 M Tris pH 8. 
Mixture was kept on ice for 10 min.  
 1 mL of proteinase K (10 mg/mL) was added and sample was gently 
mixed. Lysis of bacteria was achieved by the addition of 263 µL of 
SDS 20% concentrated (1% final concentration) and incubated at 75-
85 ºC for 15 min shaking the mixture occasionally. Complete lysis was 
indicated by a rapid change in viscosity.  
 Sample was cool at room temperature and 1.316 µL of sodium 
perchlorate 5M (final concentration 1 M) was added. Then the mixture 
was shaken and 3.29 mL of chloroform:isoamyl alcohol ) 24:1 was 
added. After transferred it to glass-stoppered flasks, it was swirl to mix 
the two phases together, and shacked on a wrist-action shaker for 30 
min at sufficient speed to get an emulsion.  
 Emulsion was centrifuged at 10,600 rpm for 10 min in a refrigerated 
centrifuge at 4 ºC.  
 The upper aqueous layer was carefully pipetted from each tube, being 
careful not to collect any of the white precipitate (protein) at the 
interfaces between the two phases. The lysate extraction steps were 
repeated until the substantial protein layer at the surface had 
disappeared.  
 The aqueous phase was placed in a beaker and slowly overlaid with 
cold 95% ethanol (an amount equal to about 2 volumes of the 
aqueous phase). The precipitated DNA was collected with glass 
stirring rod by gently stirring the two phases while spinning the rod. 
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The excess of ethanol was removed pressing the rods against the 
side of the beaker, and then the rod was placed in test-tube kept on 
ice.  
 Spooled DNA was dissolved in 1,500 µL of 0.1X SSC 
 85 µL of 20X SSC  was added to adjust the concentration to 1X.   
 17 µL of RNase mixture (5 mg/mL) was added and incubated at 37 ºC 
for 30 min (final concentration 50 µg/mL) 
 The mixture was transferred in a polypropylene flask, and 850 µL of 
phenol was added. Then, the mixture was shaken.  
 850 µL of chloroform:isoamyl alcohol was added and the mixture was  
shaken again. The emulsion was centrifuged at 5,000 rpm for 10 min 
(Sorvall RC 5C Plus Superspeed Centrifuge), and the aqueous phase 
was drawn off. The chloroform-isoamyl alcohol extractions were 
repeated until very little protein was observed between the two 
phases. 
 In the aqueous phase (≈1.6 mL), 180 µL of 3 M sodium acetate 
(NaOAc 0,1125 vol.s) and 111 µL of isopropanol (0,625 vol.s) were 
added  and the mixture was kept on the freezer for at least 2 hours.  
 After that time, samples were centrifuged at 5,000 rpm for 10 min at 4 
ºC (Sorvall RC 5C Plus Superspeed Centrifuge) 
 Supernatant was decanted and the soft pellet was washed with 3 mL 
of chilled ethanol. The sample was immediately centrifuged at 5,000 
rpm for 10 min at 4 ºC and supernatant decanted.  
 Pellet was briefly dried by air drying or in a vacuum (5-10 min.). 
 Pellet was resuspended by adding 2 mL of sterile distilled water.  
 The DNA concentration was measured using the NanoDrop ND-1000 
Spectrophotometer or a spectrophotometer (A 260/0,020 = [ ] µg/mL) 
3.14.2. RAPID CHROMOSOMAL DNA EXTRACTION 
The commercial kit DNeasy® Blood & Tissue kit (Quiagen) was used for 
fast extraction of DNA. 
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Bacteria were grown in 10 mL of LB O/N at 30 ºC (S. marcescens) or 37 
ºC (P. aeruginosa) without shaking, harvested by centrifugation for 10 min 
at 7,500 rpm. Pellet was suspended in 180 µL of tissue lysis buffer (ATL) 
included in the kit. Extraction was done following the manufacturer’s 
instructions.  
3.15. DNA METHODS  
3.15.1. MEASUREMENTS OF DNA CONCENTRATION 
Two methods were employed to asses both quantity and quality of DNA 
templates: the NanoDrop ND-1000 Spectrophotometer (improvement of 
the basic UV/Vis spectrophotometer) and agarose gel electrophoresis.  
3.15.1.1. MEASUREMENTS OF PURITY OF DNA 
NanoDrop ND-1000 spectophotometer uses the surface properties of the 
sample to hold the sample in place during the measurement cycle, 
eliminating the need for cuvettes or capillaries. During each measurement 
cycle, the sample is assessed at two different path lengths (1.0 mm and 
0.2 mm), resulting in a broad dynamic range (2ng/µL to 3700 ng/µL). The 
0.2 mm path allows very concentrated absorbance measurements, so it is 
necessary to consume only 1 µL of the sample [119]. 
Measurements were made following this protocol:  
 After nucleic acid extraction, the instrument was calibrated with 1 µL 
of ultrapure water.  
 1 µL of the sample was pippeted directly onto the lower optical 
(measurement) surface, and an upper optical fiber automatically 
engaged the sample, forming a liquid column of mechanically 
controlled path length (1 mm) that was hold in place by the sample’s 
surface tension. Light diffraction was reduced by direct contact of the 
sample with the optical surfaces. Measurement was then made and 
the NanoDrop software automatically determined the estimated DNA 
concentration in ng/µL.  
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 The sample was cleaned off with a lab wipe before loading the next 
sample.  
3.15.1.2. AGAROSE GEL ELECTROPHORESIS 
The method used is the one described by Sambrook et al. [92] with some 
modifications: 
 The edges of a clean and dry plate were sealed with tape to make a 
mold. The mold was set on a horitzontal section of the bench.  
 The solution of agarose in TAE or TBE electrophoresis buffer was 
prepared by adding the amount of powdered agarose appropriate for 
the particular size fragments expected in DNA samples.  
 The agarose solution was heated until the agarose was dissolved and 
cooled to 50 ºC 
 The desired comb was positioned above the plate to form the wells 
and warm agarose solution was poured into the mold.  
 The gel was completely set at room temperature, and a small amount 
of electrophoresis buffer was poured on the top of the gel.  
 Carefully the comb and the tape were removed and the gel was 
mounted in the electrophoresis tank.  
 Enough electrophoresis buffer was added to cover the gel to a dept of 
approximately 1 mm.  
 DNA samples were mixed with 0.20 volume of the desire 6X gel-
loading buffer.  
 Samples mixtures were slowly loaded in the slots of the submerged 
gel using a disposable micropipette. Size standards were loaded into 
slots on both the right and left sides of the gel.  
 The lid of the gel tank was closed and the electrical leads attached. 
The constant applied voltage was between 50 and 100 V. The 
electrophoresis time varies with the size of DNA fragments and the 
applied voltage.  
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3.15.2. GEL STAINING 
 The gel was stained in an aqueous ethidium bromide solution (0.5 
µg/mL) for about 15-30 min in the dark, at room temperature.  
 Then, the gel was rinsed in water plus MgCl2 for 10-15 minutes. 
 Finally, the gel was examined under UV light (302 nm) and 
photographed.  
3.16. oprD IN CLINICAL ISOLATES OF P. aeruginosa  
3.16.1. oprD AMPLIFICATION 
To obtain genomic DNA of P. aeruginosa PA110514, AS1-4, AR1-4, 
PA116136 and the control strain ATCC 27853, the protocol used is 
described below: 
 A single colony was used to inoculate 20 mL of LB and incubated ON 
at 37 ºC and 250 rpm. 
 Bacteria in 1 mL of the ON culture were harvested by centrifugation at 
7,500 rpm at RT for 10 min.   
 The pellet was suspended in 180 µL of ATL buffer of the DNeasy® 
Blood and Tissue kit (Quiagen, Germany) which was used to purify 
DNA following the manufacturer’s instructions.  
 oprD amplification was performed using a modified PCR assay 
previously described [120]. Reactions mixture of a volume of 50 µL 
contained 2 µL (1/10th volume) of genomic DNA, 0.5 µM of the 
OprDSEQF1 forward primer (5’-CTACGCAGATGCGACATGC-3’) and 
0.5 µM of the OpdRSEQR1 reverse primer (5’-
CCTTTATAGGCGCGTTGCC-3’) (Invitrogen, EE.UU), 1 U of Taq 
DNA polymerase (Fermentas, Lithuania) and 0.2 mM each 
deoxynucleoside  triphosphate (Fermentas, Lithuania), 1X PCR buffer 
and 2 mM MgCl2. Amplification was achieved in a Techne (United 
Kingdom) thermocycler model TC-312 as follows: 25 cycles, each 
consisting of 30 s at 95 ºC, 30s. at 56 ºC and 2 min at 72 ºC. Final 
extension was performed at 72 ºC for 10 min.  
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3.16.2. VISUALIZATION  
PCR products were separated in agarose gels (1.5% w/v) in Tris-Borate 
buffer (TBE) at 150 volts for 1.5 h and visualized. 
3.17. DNA SEQUENCING  
3.17.1. DETERMINATION OF GENE SEQUENCES  
DNA sequencing was performed by using an automated system, which 
use fluorescent-labeled dideoxynucleotides in dideoxynucleotide 
sequencing reactions.  As the newly synthesized DNA strands are 
electrophoresed through a gel, they pass through a laser beam that 
excites the fluorescent label.  The resulting emitted light is then detected 
by a photomultiplier and a computer collects and analyzes the data. The 
protocol is described below: 
 PCR products were purified with a MinElute® PCR Purification Kit 
(Qiagen, Germany) prior to sequencing. 
 An ABI PRISM BigDye® Terminator v.3.1 Cycle Sequencing Ready 
Reaction Kit and ABI PRISM® 3700 DNA Analyzer (Applied 
Biosystems, USA) were used for DNA sequencing. This PCR was 
performed for both primers (reverse and forward) in order to obtain a 
single strand in each tube.  
3.17.1.1. PCR SEQUENCING 
PCR was carried out in 20 µL volumes containing 3 µL of purified DNA 
and 17 µL of mix.  
Components for 20 µL of mix:  
Terminator reaction Mix........................................................ 4 µL 
PCR product (10-30 ng/µl) ................................................... 3 µL 
Primer diluted 1/10 ............................................................... 1 µL 
Distilled water..................................................................... 12 µL 
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3.17.1.2. DNA AMPLIFICATION 
After 2 min of denaturalization at 96 ºC, the following three-step profile 
was used: 
 0.5 min of denaturation at 96 ºC 
 15 s of annealing at 50 ºC 
 4 min of extension at 60 ºC  
Total of cycles: 25 
All completed reactions were maintained at 4 ºC.  
3.17.1.3. PRECIPITATION OF DNA 
When the amplification reaction finished, a rapid spin of the samples was 
performed, followed by precipitation of DNA:  
 63 µL of 95% ethanol were added to the sequencing reaction. The 
final volume was 100 µL. 
 For DNA precipitation samples were mixed and left at RT for 15 min  
 Samples were centrifuged at 14,000 rpm for 20 min 
 The precipitate obtained in the previous step was washed two times 
with 70% ethanol and let it dry.  
 Samples were stored at -20 ºC until used.   
Nucleotide sequencing was carried out at the Serveis Cientifico‐Tècnics 
of the University of Barcelona on an ABI PRISM 3700 DNA analyser (PE 
Biosystems). Sequence chromatograms were analyzed with Chromas 
software (version 1.34).  
3.17.21.4. COMPARISON AND ANALYSIS OF SEQUENCES 
For comparison and identification of homologous sequences several 
bioinformatics programs were used.  
The Basic Local Alignment Search Tool (BLAST) [121] and FASTA [122] 
were used for comparative analysis of nucleotide sequences against 
known sequences. ExPASy [123] (Expert Protein Analysis System), the 
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proteomics server of the Swiss Institute of Bioinformatics (SIB), was used 
to translate nucleotide sequences to protein sequences. ClustalW [124] 
was used for multiple sequence alignment of nucleotide sequences.   
List of bioinformatics programs are in the table 12.  
Table. 12. Bioinformatics programs used for the analysis and comparison of sequences. 
Program: Web page: 
BLAST  National Center for Biotechnology Information, Bethesda, USA 
(http://www.ncbi.nlm.nih.gov)  
EXPASy software Swiss Institute of Bioinformatics, Geneva, Switzerland 
(http://www.expasy.org) 
CLUSTALW v2 European Bioinformatics Institute, Hinxton, UK 
(www.ebi.ac.uk/Tools/msa/clustalw2/)  
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4.1. COMPARISON OF ANTIBIOTIC SUSCEPTIBILITY OF OLD AND 
CURRENT S. marcescens  
All the strains resulted to be sensitive to ceftazidime, cefotaxime, 
kanamycin, gentamicin, ofloxacin and ciprofloxacin and resistant to 
rifampicin, penicillin, ampicillin, amoxicillin and tetracycline. Among them, 
95% were found to be sensitive to ceftriaxone, and 54% resistant to 
cefoxitin. Old Serratia strains showed reduced susceptibility to 
streptomycin compared with their current relatives (Fig. 20).  
It should be noted that cefotaxime and streptomycin were the only 
antimicrobials to show significant differences in the K-W test, so the U-
Mann-Whitney test was applied to check differences between couples of 
strain groups. On the one hand, cefotaxime susceptibility had significant 
differences between G2 (old) and G3 (clinical). However, in both groups 
all Serratia strains were clinically sensitive. Furthermore, streptomycin 
showed significant differences between G1 (environmental) and G2 
strains and those of G2 and G3 (Tables 13 and 14). 
All strains studied were resistant to penicillin G, ampicillin, amoxicillin-
clavulanic acid, cefazolin, cefamandole, polymixin B, rifampicin, 
glycopeptides, fusidic acid, lincosamides, streptogramins, colistin, 
daptomycin, linezolid and cefuroxime. Furthermore, they were susceptible 
to the third generation cephalosporins ceftazidime and cefotaxime. As the 
5% resistance to ceftriaxone suggested the occurrence of Extended 
Spectrum ß-lactamases (ESBL), we performed experiments to detect 
ESBL. None of the strains studied presented ESBL.  
Several studies have shown that evolution of bacteria after the initial use 
(sometimes abuse) of antibiotics showed a constant tendency to increase 
MIC values. This was, at least in part, attributed to the emergence of new 
molecular mechanisms of resistance. Thus, it seemed to us pertinent to 
explore whether such mechanisms were already present in “old” strains. 
Most of the Serratia strains, especially those in G2, were streptomycin 
resistant, so we checked for the presence of integrons in the “old” strains 
isolated from 1940-1950. PCR amplification followed by gel 
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electrophoresis to visualize the amplification product showed that none of 
the strains examined presented class 1 integrons. However, when testing 
modern isolates (G1 and G3) they also completely lack class 1 integrons, 
this is consistent with the hypothesis that such mechanisms have arisen in 
response to the selective pressure of antibiotics. However, the lack of 
integrons in newer strains (G1 and G3) was relatively surprising since 
several reports have shown the occurrence of class 1 integrons in Serratia 
[125, 126]. It could be possible that such integrons are restricted to ESBL 
and CTX-M producing Serratia and they occur mostly in isolates from 
Asia. In Europe and US the occurrence of ESBL-producing S. 
marcescens carrying integrons is rare, although an outbreak of such a 
clone was described in an Italian Intensive Care unit with a mortality of 86 
% [127]. Moreover, a singular clinical isolate SCH88050909 has been 
extensively studied [128]. This strain was isolated in Greece and 
presented three integrons. It was studied owing to its wide 
multiresistance, and has been used to explore several mechanisms of 
insertion and to demonstrate that the ant(299)-Ia S.ma.I2 gene cassette is 
a recombinationally active element [129].  
The tendency to increase resistance has been demonstrated for 
Streptococcus pneumoniae and penicillin (from 0.04 µg/mL in 1940 to 
0.12-1 µg/mL in 1980); S. aureus and vancomycin (from 0.25-0.5 µg/mL in 
1986 to 32 µg/mL in 2002); P. aeruginosa and tobramycin (from < 2 
µg/mL in 1980 to > 16 µg/mL in 2000) among others [36]. By contrast, in 
this study we found that resistance to antimicrobials was not so different in 
Serratia when old strains, isolated before the discovery of most of the 
antibiotics used nowadays, and current strains are compared. In other 
words, the proportion of strains exhibiting a given value of MIC is similar in 
groups G1, G2 and G3, although it is clear that MIC values are slightly 
higher in clinical isolates (Fig 20). In some cases, the resistance 
determinants becomes apparent much earlier than antibiotic discovery; for 
example, half of the strains had a MIC for cefoxitin of 16 µg/mL in both G1 
(environmental) and G2 (old) groups despite this antibiotic was first used 
in 1977, almost 30 years after the isolation of the G2 microorganisms. 
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When other non-cell-wall active antimicrobials were considered, again our 
results indicate that overall susceptibility has not changed drastically over 
the last 50 years.  This is true for all the antimicrobials tested except 
streptomycin. In this case old strains, isolated when the use of 
streptomycin was widespread, were much more resistant than the newer 
strains (Fig. 20). It also appears that the percentage of resistant Serratia 
strains has decreased since streptomycin was virtually withdrawn. Indeed, 
this has also occurred in other situations. For instance, in P. aeruginosa 
the resistance to imipenem (due to the loss of the only porin able to 
transport imipenem through the outer membrane) is reversible when 
selective pressure due to the presence of the antibiotic disappears. A 
case of an imipenem-resistant strain isolated from a patient in the course 
of a second episode after a recent treatment with imipenem gave us the 
possibility to explore and reproduce the phenomenon at laboratory scale. 
An insertion sequence ISPa133 was found.  When the susceptible isolate 
(first episode) was cultured in the presence of imipenem, a resistant clone 
was detected. This clone had the ISPa133 inserted into the gene 
encoding OprD, but after repeated subcultures in absence of imipenem, 
the susceptible phenotype was restored [130]. These results indicate that, 
despite the multiple molecular mechanisms involving bacterial resistance, 
withdrawing the antibiotics tends to restore the original phenotypes, 
possibly since they are more effective in antibiotic-free conditions. 
However, when large families of antibiotics are considered, this advantage 
could be counteracted by cross-resistance. For instance, susceptibility to 
penicillin has not been recovered in most species, despite the fact that 
penicillin is no longer widely used. One reason could be that bacteria are 
selected by many modern cephalosporins that share the mechanisms of 
resistance with the old relatives. To a greater extent than most Gram-
negative bacteria, S. marcescens exhibits characteristic patterns of 
antibiotic resistance within an individual hospital environment. Often, the 
resistance pattern of such “home strains” correlates with local antibiotic 
usage policy. This indicates that drug resistance plays a crucial role in 
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determining the biological success of this relatively noninvasive bacterium 
in hospital settings. 
Metagenomics studies have demonstrated that antibiotic resistance genes 
are widely disseminated, which seems to be inconsistent with the idea 
that resistance to antibiotics is a new emergent phenomenon. On the 
contrary they suggest a long natural history of antimicrobial resistance. 
D’Costa et al. [131] analyzed DNA bacterial sequences recovered from 
Pleistocene and developed a study of the diversity of ancient antibiotic 
resistance sequences. Furthermore, they did a comparison of 
tridimensional structural models of ancient and contemporary enzymes 
responsible for vancomycin resistance.  
Genomics (the bacterial resistome) has allowed exploring the presence of 
genes encoding for antimicrobial resistance in the past. However, it is 
feasible that environmental conditions affecting antimicrobial susceptibility 
have not change significantly during the long lapse of time elapsed from 
Pleistocene to the first moiety of 20th Century.  Therefore, studies based 
on phenotypical susceptibility, despite are not so frequent because the 
difficulty in having cultures, have a great interest, since as it has been 
pointed out, in many cases, the presence of the gene underlying a given 
function is necessary but not enough to ensure the expression of such 
function. In other words, when we have to study unculturable bacteria, 
metagenomics is undoubtedly the gold standard (and perhaps the unique 
method), but when bacteria can be cultured, interpretation of data can be 
made on the basis of both gene presence and phenotypic expression. 
In fact isolates of G2 were obtained, cultured, identified and lyophilized at 
the beginning of antibiotic era before the discovery of most antimicrobials. 
The present work could be seen as a confirmation of the conclusion that 
resistance to antibiotics already existed in ancient times [132].  
When results of MIC are evaluated in detail it becomes apparent that G3 
isolates (modern and clinical) had slightly higher values of MIC i.e. 100% 
of isolates had a MIC of ampicillin higher than 128 mg/L, whereas in group 
G2 (ancient) 60 % had a MIC of 64 mg/L and only 35 % were higher than 
128 and the additional 5% had a MIC of 32 mg/L. In summary, although 
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all isolates are clinically resistant to ampicillin, MIC values seemed to 
have a tendency to increase. A similar conclusion can be obtained when 
we evaluate data concerning other antimicrobials that do not act on the 
bacterial wall such as ciprofloxacin. In this case, all isolates were 
susceptible but among G1 MICs ranged from 0.002 to 0.04 mg/L, whereas 
G2 ranged from 0.002 to 0.08 and finally G3 had MICs higher than 0.004; 
the lower value in this group was 0.01 and maximal value reached 0.32 
mg/L. This makes sense since clinical isolates include nosocomial 
populations submitted to antibiotic pressure.  
The origin and spread of antimicrobial resistance is a main cause of 
concern and will be a research subject for many more years. It has been 
pointed out that control in antibiotic use has a great impact in delaying the 
emergence of resistance and even allows populations to evolve from 
resistance to susceptibility. This field of research has to be based on 
genomics since we lack original strains in many cases, but when 
available, old populations have to be phenotypically analyzed, as the role 
of heteroresistance, as well as adaptative responses of microorganisms 
(epigenetics) to antimicrobials, seem to play a key role in the process of 
resistance. 
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Fig. 20. Minimal inhibitory concentrations of tested antimicrobials showed as percentage of 
strains in the three groups of isolates studied. 
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Table 13. Kruskall-Wallis Tests 
  
     chi-quadrat p-valor tests Sequencial 
Ceftriaxone 3.37016819 0.18542884 4 0.0125000 
Cefotaxime 11.7698671 0.00278103 10 0.0050000 
Cefoxitin 9.64345693 0.00805286 9 0.0055556 
Ceftazidime 0.4677243 0.79147091 1 0.0500000 
Ciprofloxacin 2.6782656 0.26207284 3 0.0166667 
Gentamicin 6.1227156 0.04682407 7 0.0071429 
Kanamycin 2.01085276 0.36588859 2 0.0250000 
Ofloxacin 4.70536536 0.09511366 5 0.0100000 
Rifampicin 5.0652131 0.07945166 6 0.0083333 
Trimethoprim 9.37447766 0.00921209 8 0.0062500 
Streptomycin 13.2119967 0.00135223   11 0.0045455 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. U-Mann-Whitney Test 
Cefotaxime P.value 
G1 vs G3 0.0974 
G1 vs G2 0.1414 
G2 vs G3 0.0008 
Streptomycin 
 
G1 vs G3 0.7087 
G1 vs G2 0.0049 
G2 vs G3 0.0009 
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4.2. Serratia BIOFILM FORMATION AND FUNCTIONALITY OF 
EFFLUX PUMPS DEPENDING ON THE MODE OF BACTERIAL 
GROWTH 
It is well known that sessile bacteria (those individuals forming part of 
biofilms) are phenotypically more resistant to antibiotics than planktonic 
bacteria [133, 134, 135, 136]. Despite in recent years the understanding 
of the molecular mechanisms involved in biofilm formation has greatly 
increased, there are still many details that remain unknown.  
There is no a general agreement concerning a standard method adequate 
for the study of susceptibility in biofilms. In fact it is very difficult, if not 
impossible to compare results obtained from biofilm-growing bacteria. 
This is also true when bacteria are cultured and assayed under vastly 
different conditions [137]. Furthermore, we lack a widely accepted model 
for biofilm formation in the laboratory. Thus, we developed a laboratory 
procedure to obtain biofilms of Serratia. 
Efflux pump activity can be measured by determining the accumulation 
rates of antimicrobials that can be extruded by the pump. Ciprofloxacin 
(and in general fluoroquinolones) are useful for this purpose since 
fluorescence allows to easily measure by spectrofluorimetry. Rates of 
ciprofloxacin accumulation in planktonic Serratia have been critically 
determined whereas almost nothing is known concerning accumulation of 
ciprofloxacin by bacteria growing in biofilm.  
This part of our work was devoted to search an experimental procedure to 
check and evaluate efflux active mechanisms involved in fluoroquinolone 
resistance when bacteria live as biofilm. This can contribute to the 
understanding of the degree of involvement of efflux systems in 
antimicrobial resistance, as well as to compare data from planktonic and 
biofilm-forming bacteria.  
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4.2.1. BIOFILMS OF S. marcescens  
4.2.1.1. SESSILE BACTERIA 
S. marcescens biofilms formed on methacrylate pieces by using the 
method herein described (3.7) contained approximately 1x107 
bacteria/cm2 of methacrylate after 24 h incubation. For 48 h biofilms the 
average amount was 2x107 bacteria/cm2 of methacrylate. 
4.2.1.2. SENSITIVITY OF THE METHOD TO MEASURE 
CIPROFLOXACIN ACCUMULATION  
To explore antibiotic uptake by bacterial biofilms, a preliminary study was 
done to check the sensitivity of the method used to measure ciprofloxacin 
accumulation in planktonic cultures of S. marcescens. The method 
analyzed is the one described in section 3.8.2.1.  
The objective was to determine if ciprofloxacin accumulation changes 
depending on the density of microorganisms. Ciprofloxacin accumulation 
was determined at increasing bacterial densities (S. marcescens 2170) by 
sampling at 0, 3 and 6 min and subsequently by spectrofluorometry 
measurements.  
Figures 21.a and 21.b show the rates of accumulation of ciprofloxacin by 
different densities of wild-type S. marcescens 2170. 
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Fig. 21. Fluoroquinolone accumulation by S. marcescens 2170 (wild type). a) From 3.4x109 
to 3.3x106 CFU/mL; b) From 1.6x105 to 6.5x103 CFU/mL  
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Fluorescence values of the supernatants collected from different 
concentrations of bacteria revealed that accumulation of ciprofloxacin (ng 
ciprofloxacin/mg bacteria) depends on the density of microorganisms in 
the assay. Although it is well known that planktonic Serratia accumulates 
ciprofloxacin proportionally to time [22, 79] the total amount of 
accumulated ciprofloxacin decreases as the bacterial number increases. 
In other words, accumulation of antibiotic in diluted bacterial cultures is 
higher than in more dense cultures. Then it becomes clear that in order to 
compare antibiotic uptake by planktonic and sessile bacteria, the 
achievement of isonomic populations should be established first.  
This is consistent with the idea that small populations will have higher 
availability of the drug at identical concentrations.  
4.2.1.3. MEASUREMENT OF CIPROFLOXACIN ACCUMULATION IN 
PLANKTONIC AND SESSILE S. marcescens  
Standard bacterial suspensions from both planktonic and sessile forms 
were prepared as indicated in 3.7.  
Ciprofloxacin accumulation by planktonic and sessile S.marcescens 2170 
is shown in figures 22.a and 22.b.   
Both demonstrate that ciprofloxacin accumulation is higher in planktonic 
than in sessile forms and that it takes place during the first three minutes.  
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 Fig 22. Fluorometric assay for ciprofloxacin accumulation in S. marcescens 2170. a) 
Ciprofloxacin accumulation in 24 h biofilms and planktonic bacteria. b) Ciprofloxacin 
accumulation in 48 h biofilms and planktonic bacteria. 
Piddock et al. [164] suggested that accumulation of most quinolones in 
bacteria proceed by simple diffusion, thus the apparent saturation of 
ciprofloxacin after 3 minuts could be attributed to a fast diffusion of this 
antibiotic through Serratia envelopes.  
It has also been described that ciprofloxacin easily penetrates into 
bacterial biofilms [138], furthermore the efficiency of antimicrobials can be 
modified since a certain rate of deactivation of biological activity in the 
biofilm could take place. Data reported here suggest that the rate of 
ciprofloxacin deactivation could be higher in biofilms than in planktonic 
bacteria, leading to a smaller accumulation of the antibiotic in bacterial 
biofilms. This also reinforces the idea that antibiotic uptake could be under 
a certain degree of control by some epigenetic mechanism.  
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4.2.1.4. MEASUREMENT OF CIPROFLOXACIN EFFLUX IN 
PLANKTONIC AND BIOFILM S. marcescens 2170 
Preliminary experiments performed to measure ciprofloxacin accumulation 
in both planktonic and sessile bacteria demonstrated the different 
capability to accumulate this antimicrobial (Fig. 22). Subsequently, in 
order to quantify efflux activity, a set of experiments was performed using 
the efflux pump inhibitor CCCP. 
Since ciprofloxacin accumulation was different in biofilms and planktonic 
bacteria, the evaluation of ciprofloxacin efflux in the presence and 
absence of an EPI was performed. It has been demonstrated that de-
energized bacteria (by CCCP) have the efflux mechanisms partially 
inactivated, thus, accumulation of antimicrobials increases [139, 79]. 
However the final outcome depends not only on the efflux and entry but 
also on the effective inhibition of the target enzymes [56, 140]. 
CCCP was able to increase ciprofloxacin accumulation in planktonic 
cultures to a much higher extend than in bacterial biofilms (Fig. 23). In 
fact, it seems that effect of CCCP is negligible in biofilms.  
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Fig 23. Fluorometric assay for ciprofloxacin efflux in biofilms and planktonic cultures of S. 
marcescens 2170 with and without the efflux pump inhibitor CCCP.   
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This showed that differences in susceptibility of planktonic and sessile 
bacteria, could be due, at least in part to differences in efflux pumps 
expression i.e. they play a crucial role in planktonic but they are irrelevant 
in sessile forms. On the contrary, Kvist et al. [141] proposed that efflux 
pumps are highly active in biofilms. In fact up to twenty efflux and 
transport genes were upregulated during biofilm growth. These authors 
also observed significant reductions in biofilm formation when they added 
EPIs. Several different EPIs had this capacity. However, they did not 
measure the antimicrobial efflux. Thus, one can assume that efflux pumps 
role in increasing antimicrobial resistance in liquid is directly due to the 
extrusion activity. On the contrary the role of efflux pumps on resistance of 
sessile bacteria could be due to the key role that extrusion machineries 
play in the building of biofilm itself, and individual resistance to 
antimicrobials is due in biofilm to the particularities of bacterial life in 
biofilms more than a truly extrusion activity.  
The knowledge on the exact role of efflux pumps on biofilm growth is still 
limited and many studies of Gram-negative bacteria efflux mechanisms 
have produced discordant results. For instance, some studies have 
related efflux pumps with antibiotic resistance in biofilms and specific 
mechanisms of resistance [142,143], whereas others have found that 
pumps do not play a significant role [144]. Lay et al. [145] have explored 
the eventual association between swarming and widespread antimicrobial 
resistant phenotype by using several Gram-negative bacteria including S. 
marcescens. They found that in general swarm bacteria are more 
resistant to antimicrobials than their planktonic counterparts, but RND-
type efflux pumps (MexAB-OprM, MexCD-OprJ, MexEF-OprN and 
MexXY-OprM) did not appear to be relevant for the resistance of swarm 
cells. Consequently, they suggested that antimicrobial resistance is a 
general feature of bacterial multicellularity and proposed swarming motility 
(a form of social behavior like biofilm) as a useful model to investigate 
biofilm antibiotic resistance.  
Moreover, it has been pointed out that the expression of bacterial efflux 
pumps is probably controlled by multiple factors such as growth rate, 
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accumulation of metabolites, deficient nutrition and altered permeability 
(huge amount of protective extracellular polysaccharides among others). 
Accurate measurements of efflux by bacteria living in biofilms remains 
unavailable, thus, the need of improvements of the methods should be 
envisaged.  
4.3. CARBAPENEM RESISTANCE IN CLINICAL ISOLATES OF P. 
aeruginosa 
4.3.1. DRUG SUSCEPTIBILITY  
Values of MIC for ATCC 27853 and MDRPA strains of several 
antimicrobial agents are shown in Table 15. Clinical breakpoints are listed 
below the table in accordance with the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) recommendations. 
Table 15. MICs (mg/L) of ATCC 27853 and MDRPA determined by microdilution method.  
 
 Strains  
Drug Family  459 133 162 527 ATCC27853 
  MIC (mg/L) 
Meropenem Carbapenem 8 8 8 8 1 
Imipenem Carbapenem 8 8 8 8 2 
Ciprofloxacin Fluoroquinolone 64 64 64 64 0.5 
Tobramycin Aminoglycoside 32 64 64 64 0.5 
Ceftazidime  Cephalosporin 128 64 64 64 4 
 
Clinical breakpoints, according to European Committee on Antimicrobial Susceptibility Testing 
(EUCAST): Meropenem, susceptible ≤2 mg/L, resistant >8 mg/L; Imipenem, susceptible ≤4 
mg/L, resistant >8 mg/L; Ciprofloxacin, susceptible ≤0.5 mg/L, resistant >1 mg/L; Tobramycin, 
susceptible ≤4 mg/L, resistant >4 mg/L; Ceftazidime, susceptible ≤ 8 mg/L, resistant >8 mg/L. 
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4.3.2. PFGE ANALYSIS  
PFGE analysis showed that there was a remarkable homogeneity among 
the isolates and had very closely related SpeI patterns (Fig. 24).  
 
                   M    459  133  162 527 
 
 
Fig 24. Pulse Field Gel Electrophoresis of MDRPA 
 
4.3.3. OUTER MEMBRANE PROTEINS (OMPs) 
OMPs were visualized in all the strains. No noticeable differences in OMP 
electrophoretic profiles were found between the MDRPA strains and ATCC 
27853. However, MDRPA strains showed a reduction of OprD porin (46 
kDa) expression when compared with that of ATCC 27853 (Fig. 25). 
 
 
 
Fig. 25. SDS-PAGE of OMPs of P. aeruginosa. M: standard molecular mass OprD is indicated 
by arrows.  
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4.3.4. MEROPENEM ACCUMULATION  
In the presence of high-concentration (4xMIC) of meropenem, P. 
aeruginosa was able to survive forming long rods; when meropenem 
pressure was suppressed, long-rods recovered their original shape (Fig. 
26).  
Accumulation of meropenem was 15% higher in regular morphological 
rods than in long ones.  
 
  a)                                             b)                                 c) 
 
 
Fig. 26. Effects of high-concentration (4xMIC) meropenem depending on P. aeruginosa 
shape. a) P. aeruginosa rods grown without antibiotic. b) P. aeruginosa rods grown with 
4xMIC of meropenem. c) P. aeruginosa rods after removing antibiotic.  
 
4.3.5. CLASS 1 INTEGRONS  
PCR amplification from MDRPA yielded amplicons of 750 bp (Fig. 27). 
Class 1 integrons detected in all of the MDRPA strains tested were 
sequenced and resulted to be identical. The cassette contained the aadB 
(also called ant(2″)-Ia) aminoglycoside resistance gene that confers 
gentamicin, kanamycin and tobramycin resistance (Fig. 28). 
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Fig. 27. PCR amplification, using the 5’-CS and 3’-CS primers, of variable regions of 
integrons from MDRPA isolates. The PCR products were separated by electrophoresis in 
0.7% agarose. Lane 1, 1-kb DNA ladder; lane 2, P. aeruginosa 459; lane 3, P. aeruginosa 
162; lane 4, P. aeruginosa 527 and lane 5, P. aeruginosa 133.  
 
 
 
3’-CS  
         intI1          aadB        orf5  qacE∆1  sul1 
5’-CS  
variable region 
 
 
Fig. 28. Schematic representation of  class 1 integron with an aadB gene cassette; arrows 
show direction of transcription. 
 
4.3.6. EFFLUX PUMP-MEDIATED FLUOROQUINOLONE RESISTANCE  
All the strains had a MIC of ciprofloxacin of 64 mg/L and subsequently 
should be considered clinically resistant. Those strains which MIC of 
ciprofloxacin decreases at least two fold after addition of PAßN are known 
as efflux pump overexpressed phenotype (EPO). We have tested such 
reduction in the strains studied. Results are indicated in figure 29.   
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Fig. 29. MIC reduction by the efflux pump inhibitor PAßN; all the strains were tested over the 
same range of ciprofloxacin concentrations (0.125 to 128 µg/mL) with and without PAßN, 
and showed a 4-fold decrease in MIC with the EPI. 
 
4.3.7. DETECTION OF A FUNCTIONING MEXXY-OPRM EFFLUX PUMP  
All MDRPA strains, exhibiting high tobramycin MIC values, showed 
outstanding antagonism with PAßN (at 40 µg/mL). MIC values increased 
at least 4-fold as can be seen in Fig. 30.  
 
 
Fig. 30. Effect of the efflux pump inhibitor PAßN on tobramycin susceptibility; all the strains 
were tested over the same range of tobramycin concentrations (0.25 to 256 µg/mL), and 
showed antagonism with the PAßN.  
 
4.3.8. ANTIBIOTICS COMBINATIONS AND EFFLUX 
Many reports have suggested the convenience of the rescue of “old” 
antibiotics to build synergistic combinations of different antimicrobials that 
can be useful in the treatment of infections due to multidrug-resistant 
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microorganisms. Thus, we performed experiments to explore the 
convenience of such approach. First, a measure of the MICs reduction in 
the presence of PAßN was done. Slight reductions of MIC values of  
ceftazidime and meropenem were observed in the presence of PAßN 
without tobramycin (Fig. 31). Furthermore combinations of pairs of 
antibiotics were tested.       
      
Fig. 31. Effect of the efflux pump inhibitor PAßN on ceftazidime and meropenem 
susceptibility; all the strains were tested over the same range of ceftazidime and meropenem 
concentrations (128-0.125 µg/mL) with and without PAßN, and showed a trivial decrease in 
MIC with the EPI. 
 
As we pointed out before tobramycin antagonizes PAßN irrespective of its 
concentration. Combinations of tobramycin with either ceftazidime or 
meropenem resulted to be synergistic. On the other hand when PAßN was 
added (40 µg/mL) significant increased MIC values were determined, 
demonstrating again the antagonism between PAßN and tobramycin 
(Table 16). 
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 Table 16. MICs of combinations of antibiotics with and without PAßN. 
 
  Meropenem MIC (µg/ml) 
Concentrations tested:         
256-0.125 (µg/ml) 
Ceftazidime MIC (µg/ml) 
Concentrations tested:      
256-0.125 (µg/ml) 
  Isolates  Isolates 
Fixed 
concentration 
of tobramycin 
(µg/ml) 
PAßN 
(µg/ml) 459 133 162 527  459 133 162 527 
0 0 8 8 8 8  128 64 64 64 
0 40 4 8 4 4  32 32 32 32 
8 0 0.5 1 1 1  4 2 4 4 
8 40 8 8 8 16  32 32 64 32 
16 0 0.125 0.5 0.25 0.5  0.125 0.5 1 1 
16 40 8 8 8 8  32 32 32 32 
32 0 0.125 0.125 0.125 0.125  0.125 0.125 0.125 0.125 
32 40 8 8 8 8  8 32 32 32 
64 0 0.125 0.125 0.125 0.125  0.125 0.125 0.125 0.125 
64 40 8 8 8 16  16 32 32 16 
128 0 0.125 0.125 0.125 0.125  0.125 0.125 0.125 0.125 
128 40 8 4 8 8  16 32 32 16 
 
 
The high incidence of P. aeruginosa resistant to multiple drugs, the 
difficulties in treating infections due to such bacteria and the extensive use 
of antibiotics, leading to spread of resistance genes make this species in 
the center of objectives to control the spread, avoid infections, enlarge 
treatment strategies, and reduce mortality [146]. Table 15 shows that the 
four P. aeruginosa isolates presented high resistance to all the 
antimicrobial drugs tested and were therefore considered as MDRPA, i.e., 
resistant to at least three different classes of antimicrobial agents, mainly 
aminoglycosides, carbapenems, antipseudomonal penicillins, quinolones, 
and cephalosporins [147]. 
Carbapenems, such as meropenem and imipenem, are potent 
antimicrobial agents used to treat infections due to MDRPA isolates. 
These antibiotics bind to critical penicillin-binding proteins, disrupting the 
growth and structural integrity of walls of bacteria. They provide better 
anaerobic and Gram-negative coverage than other beta-lactams and their 
stability against extended-spectrum beta-lactamases (ESBLs) makes 
them an effective treatment option. Both antibiotics have broad-spectrum 
activity, including activity against non-fermenting and Gram-negative 
bacteria. 
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However, among non-fermenting Gram-negative bacteria, resistance to 
imipenem and meropenem is increasing [148]. Several mechanisms 
conferring P. aeruginosa resistance to carbapenems have been reported, 
such as diminished permeability, overexpression of the intrinsic efflux 
systems and production of carbapenem hydrolyzing ß-lactamases [149].  
Additionally, the observation that P. aeruginosa survives in the presence of 
high concentrations of meropenem (4xMIC) by forming long rod-shaped 
bacteria and its capability to return to the original shape when the 
antimicrobial was removed suggested that accumulation of meropenem 
probably differs depending on bacterial shape. Experiments to measure 
meropenem accumulation revealed that only a 15 % difference could be 
demonstrated. Meropenem has a great affinity for the PBP3. This protein is 
involved in the final steps of the wall building during bacterial division. 
When PBP3 is blocked the separation of daughter bacteria does not take 
place as it has been shown in other works. This leads to the formation of 
long filaments having a non-functional PBP3 but able to survive for a 
relatively long time periods, and also capable to restore original 
morphotypes.  
The reduced OprD expression in MDRPA compared with the wild-type 
strain (ATCC 27853) could be related with the decreased susceptibility to 
both imipenem and meropenem. However, it is difficult to measure the 
quantitative role of the OM and their porins when an antibiotic is applied in 
vivo, since both the bacterial physiological states and the OM protein 
expression strongly depend on the environmental conditions [89]. 
Rodríguez-Martínez et al. [150], reported that OprD gene downregulation 
and OprD protein inactivation contributed to resistance to imipenem and 
reduced susceptibility to meropenem. Whereas OprD inactivation alone is 
the source of resistance to imipenem, the mechanisms leading to 
meropenem resistance seem to be more complex and are very likely 
multifactorial, involving overproduction of AmpC or overexpression of the 
efflux pumps MexAB-OprM, MexXY-OprM, and MexCD-OprM. The efflux 
systems MexAB-OprM and MexXY-OprM directly affect meropenem 
activity in P. aeruginosa [151]. Ikonomidis et al. [152] found that 
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heterogeneous populations had upregulation of efflux with increased levels 
of transcription of mexB and mexY genes and low intensity of oprD protein 
band (46 kDa) compared to native populations [152]. 
Strains 459, 133, 162 and 527 also produced OXA-1 and OXA-2 enzymes, 
which contribute to carbapenem resistance. (Segura et al., unpublished 
data).  
Our results from the study of efflux pumps using PAßN suggested that all 
the MDRPA strains belong to a phenotype that overexpresses MexAB-
OprM and contain a functioning MexXY-OprM efflux pump. Moreover, 
overexpression of MexXY-OprM has been related with carbapenem 
resistance. Mao et al. [163] demonstrated that PAßN antagonizes the 
activity of aminoglycosides only in strains that contained a functioning 
MexXY-OprM, and the degree of antagonism was higher in strains with a 
high level of MexXY-OprM expression. Structural changes in target 
enzymes and active efflux are the major mechanisms that lead to 
fluoroquinolone resistance in P. aeruginosa. 
Two mutations were also found in the strains studied, one in parC and one 
in gyrA (Segura et al., unpublished data). These results correlate with 
quinolone resistance in Enterobacteriaceae being generally caused by a 
cooperative effect between mutations in the genes gyrA and parC and 
efflux pumps, mostly acrAB [152, 88, 153, 154]. 
The basis of multiple resistance of P. aeruginosa is complicated because 
several mechanisms are involved on it. Class 1 integrons have been 
strongly associated with the presence of MDRPA. Nemec et al. found that 
among 108 clinical isolates of P. aeruginosa, the ones that were resistant 
to less than three agents were intI1-negative, whereas almost all those 
resistant to more than two agents were intI1-positive [155]. 
All of the MDRPA strains examined, which belong to serotype O4, had a 
class 1 integron with the gene cassette array aadB. The aadB product is 
aminoglycoside (2”) adenylyltransferase (ANT(2”)-Ia), associated with 
resistance to kanamycin, gentamicin, and tobramycin [156]. 
This type of integron was previously found in our laboratory in some 
clinical P. aeruginosa strains from Bellvitge Hospital [65], however, this 
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kind of integrons has not only been found in Spain. In a recent study from 
Iran, 78% of 41 MDRPA isolates from five hospitals had an integron 
containing the aadB gene and amplifications of internal variable regions 
(IVRs) of class 1 integrons confirmed a high prevalence of class 1 
integrons with limited diversity of gene cassette arrays including aadB, 
aadA6–orfD, and blaOXA10–aacA4 [157].   
Syrmis et al. observed a high prevalence of the class 1 integron-
associated aadB gene cassette in P. aeruginosa isolates from an 
Australian cystic fibrosis patient population. However, some of the strains 
that possessed the aadB gene were tobramycin sensitive. Thus, position 
of the aadB gene alone does not confer tobramycin resistance [158]. In 
Brazil, 106 P. aeruginosa clinical isolates were analyzed and none of the 
class 1 integrons detected had the aadB gene cassette [159].  
Other studies showed that some class 1 integrons with more than one 
gene of resistance also contained the aadB gene. For instance, many 
MDRPA isolates (serotype O4) from various hospitals in the Czech 
Republic and Hungary shared an integron variable region with the gene-
cassette array of aadB-aadA13, which may indicate recent international 
dissemination. In China and Iran, several P. aeruginosa clinical isolates 
had the aadB gene cassette array [155, 157, 160].  
Although integron associated gene cassettes harbored by P. aeruginosa 
can vary between different geographic locations [158], it is important to 
take clonal dissemination of the MDRPA strains into account and 
establish effective measures to prevent their transmission. In addition to 
integrons, multiresistant bacteria serve as hosts for other genetic 
elements such as transposons and plasmids. These elements are 
involved in the development of antibiotic resistance phenotypes and 
consequently bacteria that contain these elements could be extremely 
effective vehicles for the dissemination of these resistance elements 
[146]. 
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4.4. CCCP TOXICITY FOR P. aeruginosa 
Antimicrobial resistance of P. aeruginosa has been shown to be due to 
several mechanisms and particularly to a series of active efflux pumps 
such as MexAB-OprM, MexXY-OprM, MexCD-OprJ. When analyzing the 
actual role of efflux mechanisms in determining bacterial susceptibility it is 
crucial not only to measure the levels of expression of genes involved, 
but also to determine the efflux activity by comparing antimicrobial 
accumulation on bacteria both in the presence and absence of efflux 
pump inhibitors (EPIs). Among EPIs, the most currently used is carbonyl 
cyanide m-chlorophenylhydrazone (CCCP). CCCP is a proton ionophore 
acting as an inhibitor of proton motive force. CCCP is currently used to 
measure active efflux in Gram-negative bacteria including P. aeruginosa 
[161, 162]. 
In the course of our work we tried to measure the active efflux in different 
environmental conditions by using the method of Beyer et al. with some 
modifications (section 3.8) [105].  
In experiments with CCCP (10 mg/L concentration), the results 
apparently showed a predominant role of efflux pumps. However, when 
comparing with controls in the absence of antibiotics, lethality was 
indistinguishable, demonstrating that CCCP is highly toxic for P. 
aeruginosa (Fig. 32). 
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Fig. 32. Growth inhibition assay of a MDR P. aeruginosa using CCCP as efflux pump 
inhibitor. C+ is the control of P. aeruginosa without antibiotic nor CCCP. 
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When inhibition experiments were repeated using the efflux pump 
inhibitor PAßN (40 mg/L concentration), that competes with antibiotics for 
binding to the same target or generates steric hindrances that impairs 
antibiotic binding the results showed active efflux and it was easy to 
demonstrate extrusion for the different antibiotics assayed but for 
tobramycin which antagonizes with PAßN [163] (Fig. 33). 
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Fig. 33. Growth inhibition assay of a MDR P. aeruginosa using PAßN as efflux pump 
inhibitor. 
We were able to demonstrate that  CCCP is toxic for P. aeruginosa since 
it inhibits their growth. Therefore its use should be avoided in experiments 
done with P. aeruginosa. Furthermore, although we did not perform 
experiments it is possible that it should be avoided when studying other 
respiratory bacteria. It is feasible that the effect of inhibition of proton 
motive force in a strictly respiratory organism produces such a metabolic 
alteration that no data obtained in these conditions can be considered as 
reliable enough. Piddock et al. already pointed that accumulation of most 
quinolones in E. coli and S. aureus proceeds by simple diffusion, but that 
P. aeruginosa behaves differently. They observed that using CCCP, 
apparent saturation of quinolone accumulation by P. aeruginosa was 
faster than in other species such as E. coli and S. aureus. They 
suggested this could be due to more than one factor such as 
experimental artefacts because of long periods of time exposure, lysis of 
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P. aeruginosa due to the chelation of divalent cations in the presence of 
high quinolone concentrations or transport of quinolones into P. 
aeruginosa mediated by a cytoplasmic membrane carrier protein. Less 
likely, the apparent saturation of quinolone accumulation could be 
attributed to structural differences of bacteria [164].  
We discourage the use of CCCP and we believe that special caution 
should be exercised when analyzing reports in which results were 
obtained from experiments using CCCP with aerobic microorganisms 
[165, 166, 167]. Furthermore the eventual role of active respiration in the 
extrusion measurements in facultative microbes should be also revised. 
 
4.5. RESISTANCE TO COLISTIN IN P. aeruginosa 
4.5.1. DRUG SUSCEPTIBILITY TESTING  
Preliminary antibiotic susceptibility testing of P. aeruginosa clinical 
isolates was done initially by using the MicroScan system. Table 17. 
shows the values, and Table 18 shows their antibiotic susceptibility 
patterns.  
Table 17. MICs obtained by using the MicroScan System for P. aeruginosa clinical isolates. 
 
Isolates 
Drug 296 362 017 493 264 025 
 MICs (mg/L) 
Amikacin  32 >32 32 >32 ≤16 32 
Aztreonam  8 8 8 8 8 8 
Ceftazidime  16 8 16 16 8 8 
Ciprofloxacin  >2 >2 >2 >2 >2 >2 
Cefepime  16 16 16 16 16 >16 
Gentamicin  >8 >8 >8 >8 >8 >8 
Imipenem  >8 >8 >8 >8 8 >8 
Pip-Taz  32 16 32 >64 ≤16 32 
Tobramycin >8 >8 >8 >8 >8 >8 
Levofloxacin  - >4  >4 >4 - - 
Meropenem - >8 8 16 - 8 
Colistin 4 >4 4 >4 8 >4 
Pip-Taz= Piperacillin/Tazobactam; - No results from MicroScan system 
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Table 18. Antibiotic susceptibility patterns of P. aeruginosa clinical isolates to the 
antimicrobial agents tested by MicroScan System. S= clinically susceptible; R= clinically 
resistant; I= clinically intermediate; 
                                           Isolates 
Antibiotic EUCAST/CLSI 296 362 017 493 264 025 
AMK EU R R R R S R 
CL I R I R S I 
ATM EU I I I I I I 
CL S S S S S S 
CAZ EU R S R R S S 
CL I S I I S S 
CIP EU R R R R R R 
CL R R R R R R 
CPM EU R R R R R R 
CL I I I I I I 
GENTA EU R R R R R R 
CL R R R R R R 
IMI EU R R R R R R 
CL R R R R R R 
PIP-TAZ EU R S R R S R 
CL - - - - - - 
TOBRA EU R R R R R R 
CL R R R R R R 
LEVO EU - R R R - - 
CL - R R R - - 
MERO EU - R I R - I 
CL - R I R - I 
COLIS EU S R S R R R 
 
CL I R I R R R 
EU= Clinical breakpoints by EUCAST; CL= Clinical breakpoints by CLSI  
AMK= amikacin; ATM= aztreonam; CAZ= ceftazidime; CIP= ciprofloxacin; CPM= cefepime; 
GENTA= Gentamicin; IMI= imipenem; PIZ-TAZ= Piperacillin/Tazobactam; TOBRA= 
tobramycin; LEVO= levofloxacin; MERO= meropenem; COLIS = colistin 
Then, these strains and four more clinical isolates of P. aeruginosa 
isolated in the Laboratori de referència de Catalunya as colistin-resistant 
isolates plus a colistin-susceptible strain, were used to explore the 
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resistance to colistin. This was done by adding EDTA and subsequent 
MIC determination.  
MICs of colistin, EDTA and colistin plus 1 mM of EDTA are shown in table 
19.  
Table 19. Minimum inhibitory concentration of EDTA, colistin and colistin plus 1 mM of 
EDTA 
Strain: MICs of EDTA 
(mM) 
MICs of Colistin 
(µg/mL) 
MICs of Colistin 
(µg/mL) plus  
1 mM EDTA  
296  20  8 <0.0625 
362  20 8 <0.0625 
017  20 8 <0.0625 
493  20 32 <0.0625 
264  20 8 <0.0625 
025  20 8 <0.0625 
401  20 8 <0.0625 
732   20 8 <0.0625 
780  20 8 <0.0625 
328S  20 0.5 <0.0625 
328R  20 16 <0.0625 
 
These results clearly show that addition of EDTA enhances the 
susceptibility of P. aeruginosa to colistin, whereas MIC values decreased 
more than 100-fold in the presence of 1 mM of EDTA.  
Both EDTA and colistin are considered OM permeabilizers [54]. 
Mechanisms of action of polymyxins and EDTA are quite different: 
whereas EDTA acts through cation chelation (mostly divalent cations), 
polymyxins in general produce disruption of outer membrane (blebs) 
although they can be taken up by some negatively-charged site in the 
external layers [168]. Stability of lipid bilayers is based on the role of 
divalent cations (Mg2+ and Ca2+). Polymyxins, and particularly colistin, 
compete with divalent cations, thus, phospholipids tend to bound to 
polycation instead its normal divalent cation. 
The enhancement of colistin action by EDTA could be explained on the 
basis that EDTA chelates divalent cation Ca2+ and Mg2+ and induces 
drastic disorganization of the OM structure. Thus colistin can act in the 
absence of their normal competitors. The final outcome resulted in a 
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complete disorganization of  the membranes and obviously it facilitates 
that colistin can reach the cytoplasmic membrane much easier [169].  
This is consistent with the idea that LPS composition, length and electric 
charges can be significant in the appearance of colistin-resistant variants 
as well as resistant derivatives to other polycationic compounds.  
Moreover, the eventual role of total amount of LPS on polymyxin 
susceptibility should be carefully analyzed.  
4.5.2. PFGE  
Strains 328S and 328R were isolated from the sputum of the same patient 
being one of them susceptible and the other resistant. Initially we 
speculated that such phenomena could be also due to some kind of 
epigenetic mechanism, thus, in order to explore eventual genetic 
relationship between strains PFGE analysis was performed. Results 
showed a significant degree of genetic diversity between both strains (Fig. 
34). This indicates that at least in this case resistance did not seemed to 
be caused by an epigenetic mechanism, unless the transient effect of the 
polycation modifies drastically the expression of a big number of genes. 
Further experimental work to perform transcriptomics should be done 
before one can obtain some conclusions.  
M  328S 328R 
 
Fig 34. PFGE profiles of SpeI-digested chromosomal DNA of MDRPA 
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4.5.3. ROLE OF SELECTIVE PRESSURE ON COLISTIN RESISTANCE 
EMERGENCE 
Four clinical isolates of MDRPA (all resistant to colistin) were used to test 
whether it was possible to reverse the resistance when the drug-selective 
pressure is removed. Susceptibilities to various antibiotics were tested by 
broth microdilution method at the beginning of the experiment and after 
several serial passages in antibiotic-free media. 
Moreover, strains 328S, 328R and 493 were used to explore the ability of 
bacteria to become adapted to higher concentrations of colistin. To do 
this, bacteria were cultivated under conditions in which antibiotic 
concentration was gradually increased.  Results are shown in tables 20 
and 21.  
Table 20.  Evolution of MIC values of P. aeruginosa clinical isolates in antibiotic-free 
conditions. 
 Isolates 
 401 780 328R 493 ATCC 
27853 
 MICs by broth microdilution method (mg/L) 
Drug B A B A B A B A QC 
Meropenem 8 8 1 1 8 8 16 16 1 
Ciprofloxacin 128 64 32 16 64 64 32 32 0.12 
Tobramycin 128 64 64 32 128 128 128 128 0.5 
Gentamicin >256 >256 >256 >256 >256 >256 >256 >256 0.5 
Ceftazidime  32 32 8 8 16 16 8 8 1 
Colistin 4 1 4 2 16 2 32 8 1 
        B = MICs at the beginning A = MICs after several passages without antibiotic  
These results suggest that adaptative resistance evolve much faster for 
colistin than for the rest of the antimicrobial agents tested. After 
subsequent drug-free passages, there was a four-fold/ eight-fold reduction 
in colistin MIC, while only a slight reduction was seen in ciprofloxacin MIC, 
and no reduction in meropenem, tobramycin, gentamicin and ceftazidime 
MICs.  
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Table 21. Evolution of colistin-MIC values of P. aeruginosa clinical isolates in both antibiotic-
free conditions and increasing concentrations of colistin.  
                                   MICs (mg/L)  
Isolates t=0 20 passages 
antibiotic-free  
20 passages 
increasing colistin 
concentration 
328S 0.5 - 1000 
328R 16 2 2000 
493 32 8 2000 
 
Effect of colistin on P. aeruginosa was analyzed by comparing 
morphological and topographical changes. Colistin-susceptible (328S) 
and colistin-resistant (328R) strains were examined by atomic force 
microscopy (AFM).  
Imaging of both colistin-susceptible and colistin-resistant P. aeruginosa 
after incubation for 36 hours in MHA and MHA supplemented with 
different concentrations of colistin (0, 4 or 500 µg/mL) were obtained. 
Visualization showed an increase in outer membrane damage as the 
concentration of this antimicrobial agent was higher (Fig. 35).  
Furthermore, substantial topographical changes such as marked bulges 
and surface deformations were observed in bacteria upon treatment with 
500 µg/mL of colistin (Fig. 35). These alterations were consistent with a 
remarkable increase in surface roughness of bacteria growth with 500 
µg/mL of colistin (24.93 ± 2.1 for strain 328S and 28.58 ± 2.3 for strain 
328R) compared with untreated bacteria or bacteria growth with low 
concentrations of colistin (9.22 ± 3.9 for strain 328S growth without 
colistin; 11.21 ± 1.8 for strain 328S growth with 4 µg/mL of colistin and 
16.9 ± 2.3 for strain 328R growth with 4 µg/mL of colistin).  
Mortensen et al. [170] evaluated the changes in P. aeruginosa 
morphology and nanomechanical properties due to exposure to colistin in 
a liquid  environment, and found that treatment  with this cationic peptide 
caused an increase in the rigidity of the bacterial cell wall and their 
surface changed morphologically from smooth to wrinkled. These 
morphological changes were suggested to be due to the loss of surface 
Results and discussion  
  
140
proteins or LPS since lipopolysaccharide is necessary for the initial 
interaction needed for colistin uptake. 
Soon et al. [171, 172] observed that surface of colistin-resistant A. 
baumanii  strains exposed to high concentration of colistin (32 µg/mL) 
were smoother than colistin-susceptible ones when exposed to the same 
concentration of colistin. In our case, surface roughness of both 328R and 
328S P. aeruginosa able to growth at 500 µg/mL of colistin do not exhibit 
remarkable differences. 
These authors already pointed out that surface of colistin-resistant A. 
baumanii when treated with colistin exhibit similar alterations than the one 
of  susceptible strains. In other words, the ability of colistin to interact with 
the OM seems to be independent from the final output of 
antimicrobial/bacteria interaction. This is in agreement with the results 
observed in intrinsically resistant species. For instance, S. marcescens, 
which is naturally resistant to polymyxins can modify some behaviors in 
the presence of colistin and related antimicrobials. Viñas et al. [173], 
demonstrated that addition of polymyxin enhances the synthesis of 
prodigiosin in the presence of L-proline in non proliferating cultures. This 
strongly suggests that injuries in outer membrane are needed for 
antimicrobial effect of polymyxins but are not enough to limit the viability of 
treated bacteria. In summary, although it seems that interaction between 
colistin and LPS is the first step of colistin antimicrobial action, it becomes 
apparent that bactericidal effect is due to the injuries induced in 
cytoplasmic membrane.  Thus, LPS role in resistance is probably a 
consequence of its capacity to prevent the entry of colistin and the 
subsequent interaction between the antimicrobial and the membrane.  
Our AFM results obtained for P. aeruginosa confirmed this idea, since 
AFM images of colistin-susceptible and -resistant strains revealed similar 
surface disruptive effects.  
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          a)                              b)                              c) 
     
             0                         2.5 µm   0                          2.5 µm   0                           2.5 µm 
 
                     d)                                  e) 
   
0                              2.5 µm    0                               2.5 µm 
Fig. 35. AFM amplitude images of colistin-susceptible, colistin-resistant and ATCC 27853 P. 
aeruginosa. Bacteria were visualized in air by using the Atomic Force Microscope XE-70 
(Park Systems) previously air dried at RT in a dust-free environment and images were 
collected in Non-contact mode using pyramidal-shaped silicon cantilevers. a) P. aruginosa 
328S growth without colistin; b) P. aeruginosa 328S growth with 4 mg/L of colistin; c) P. 
aeruginosa 328R, growth with 4 mg/L of colistin; d) P. aeruginosa 328S, growth with 500 
mg/L of colistin and e) P. aeruginosa 328R, growth with 500 mg/L of colistin.  
 
Due to these morphological consequences of colistin action on the 
surface properties of treated bacteria, it seemed of interest to explore the 
composition of LPS in order to compare LPS molecules from resistant and 
susceptible isolates and or derivatives. Figure 36 shows that LPS profiles 
of “original” clinical isolates, isolates after several passages without 
antibiotic and isolates that survived a concentration of colistin of 500 
µg/mL were considerably different from that of ATCC 27853. O-side chain 
length from the control strain (ATCC 27853) resulted to be shorter than 
those from clinical isolates.  On the contrary LPS profiles of both 328S at 
the beginning grown without colistin, after several serial passages by 
increasing colistin concentrations up to 500 µg/mL, grown with 4mg/mL of 
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colistin, and after twenty passages without colistin did not show noticeable 
differences with its correspondent resistant derivative (328R)  after 
several serial passages increasing colistin concentration until 500 µg/mL, 
at the beginning growth with 4mg/mL of colistin, after twenty passages 
without colistin; and after several serial passages increasing colistin 
concentration until 500 µg/mL. Apparent differences are due to the 
differences in LPS concentration. Wells in the electrophoresis gels were 
filled with equivalent samples as determined by protein concentration 
(Bradford), thus, it seems that in the presence of colistin the amount of 
LPS is reduced and that at high concentrations (500 µg/mL) this reduction 
is drastic. This would be in agreement with conditions similar to the ones 
already described as heteroresistance. If one assume that both bacterial 
models (one with a regular LPS and another with a scarced LPS) already 
exists in the primary isolate, then the mechanism should be interpreted as 
a strict phenomenon of heteroresistance. In conditions in which scarced 
LPS are better adapted the rest is rapidly eliminated and replaced by 
resistant biotype. Whereas in non-selective conditions both models will 
survive. This is also in agreement with the fact that 328R and 328S were 
both isolated simultaneously from the same patient. We thus, hypothesize 
a heteroresistance phenomenon to explain colistin-resistance in 
Pseudomonas aeruginosa. A few months ago Bergen et al. [174] also 
pointed out a similar conclusion based on the study of synergism between 
imipenem and colistin.  
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Fig. 36. SDS-PAGE analysis of P. aeruginosa LPS. 1) 328S at the beginning growth without 
colistin; 2) 328S after several serial passages increasing colistin concentration until 500 µg/mL; 
3) 328S at the beginning growth with 4 mg/mL of colistin; 4) 328S after twenty passages without 
colistin; 5) 328R after several serial passages increasing colistin concentration until 500 µg/mL; 
6) 493 at the beginning growth with 4 mg/mL of colistin; 7) 493 after twenty passages without 
colistin; 8) 493 after several serial passages increasing colistin concentration until 500 µg/mL; 
9) ATCC 27853 
In order to see eventual differences between both strains in  protein-
profiles,  we  examined  OMPs by PAGE. No noticeable differences in 
OMP electrophoretic profiles were observed. Thus it seems unlikely that 
OMPs could play any significant role in colistin resistance.  
 
4.5.4. CONTRIBUTION OF EFFLUX PUMPS IN COLISTIN 
RESISTANCE  
For the analysis of the contribution of efflux pumps in colistin resistance, 
the two colistin-resistant isolates 328R and 493 were used.  
In the course of the study we tried to measure the active efflux by using 
the method of Beyer et al. with some modifications [105]. Inhibition 
experiments were performed with colistin (1/4 MIC) and colistin (1/4 MIC) 
plus PAßN (40 µg/mL). The efflux pump inhibitor CCCP was not used, as 
we previously demonstrated its toxicity for P. aeruginosa.   
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The results showed (Fig. 37) that colistin efflux does not exist, and 
therefore, it seems reasonable to suggest that efflux pumps do not play 
any role in resistance to colistin. 
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Fig. 37. Growth inhibition curves of colistin-resistant P. aeruginosa at a concentration of ¼ 
MIC of colistin in the presence and absence of PABN. a) P. aeruginosa 328R b) P. 
aeruginosa 493 
 
4.5.5. MODEL MEMBRANE STUDIES 
A possible approach to enlarge knowledge of the intimate mechanism of 
colistin action is to explore membrane damaging by electrophysiology. 
During the period of this research we had the possibility to initiate the 
exploration of colistin action on the artificial membranes by using the 
single channel conductance measurements technique. Membranes were 
constructed as described previously, using different proportions of the 
zwitterionic lipid DiphPC and the anionic lipid PS, both in n-decane. In Fig. 
38, some illustrative recordings of the channel-forming behavior of colistin 
in 1% DiphPC/n-decane membranes are presented. 
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Fig. 38. Chart recorder tracings of conductance events that occurred upon the addition of 
different concentrations of colistin to the solution (1 M KCl) bathing a planar lipid bilayer. The 
indicated voltages were applied. 1% DiphPC/n-decane membranes. Approximately 3 min of 
chart recordings is shown.  
 
Fig. 39. shows chart recording tracings of conductance events after 
addition of different concentrations of colistin in 0.8% DiphPC plus 0.2% 
PS/n-decane membranes.  
 
 
Fig. 39. Chart recorder tracings of conductance events that occurred upon the addition of 
different concentrations of colistin to the solution (1M KCl) bathing a planar lipid bilayer 
(0.8% DiphPC in n-decane). The indicated voltages were applied. Approximately 3 min of 
chart recordings is shown. Approximately 3 min of chart recordings is shown.  
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Similar to other studies with antimicrobial peptides [175], we observed that 
these peptides required large concentrations (approximately 1 µg/mL or 
more) to permit the observation of reasonable numbers of channels. All 
the studies in the present work were performed using concentrations of 
colistin between 1 and 32 µg/mL. Certain generalizations could be made 
regarding the observed activities. 
First, it is required a high voltage across the membrane. In general, 
voltages above +-180 mV initiated conductance events. When the applied 
voltage was subsequently decreased to +-130 mV, conductance events 
were still observed but often at a lower frequency.  
Second, contrary to other studies [175], conductance events in DiphPC 
planar bilayer membranes were initiated by both positive and negative 
applied voltages (e.g., +-180 mV). Other studies has obtained similar 
results for cationic antimicrobial peptides such as tritrpticin peptide [176], 
exhibiting ionic channel forming activity in both negative and positive 
voltages.  
Third, for the same concentrations of colistin, conductance events in 
DiphPC/n-decane planar lipid bilayers were observed less frequently and 
were less relevant than in planar lipid bilayers containing negatively 
charged lipid PS. This result seems reasonable given the positive charge 
on the peptide. 
Fourth, most of the events observed involved very rapid conductance 
alterations which were widely variable in magnitude (Figures 38 and 39). 
There were some situations where substantial increases in 
transmembrane conductance were observed for a short period of time, 
followed by a fast return to the conductance base line (Fig. 39).  
Fifth, some of the experiments performed clearly showed that channel-like 
conductance events increase with higher concentrations of colistin (Fig. 
40.a). However, the repeatability of these experiments was low, obtaining 
some contradictory results (Fig. 40.b). This would indicate the need to 
refine the method to obtain reliable data. 
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40.a) 
  Concentration  (µg/mL ) 
Voltage 
(mv) 0 8 16 32 
  
Conductance (pS) 
0 0 0 0 0 
50 0 4 36 44 
-50 -8 -4 -24 -36 
80 5  38 60 
-80 -5  -48 -15 
100 4 4 44 52 
-100 -4 -2 -52 -18 
150 5 46 45 117 
-150 -4 -40 -114 -94 
180 5 54 80 85 
-180 -5 -63 -141 -102 
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40.b)  
  Concentration  (µg/mL ) 
Voltage 
(mv) 0 8 16 32 
  
Conductance (pS) 
0 0 0 0 0 
50 8 4 12 -4 
-50 0 -4 -8 -8 
80 5 2 8 5 
-80 -5 -2 -10 5 
100 4 2 2 4 
-100 -2 -6 -10 -6 
150 4 58 17 4 
-150 -4 -4 -22 -4 
180 4 26 5 4 
-180 -4 -28 -11 -6 
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Figure 40.a and 40.b. Relationship between conductance and voltage of two independent 
experiments with 0.8% DiphPC plus 0.2% PS/n-decane and increasing concentrations of 
colistin. 
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It was also observed that conductance events begin at lower voltages 
when the concentration of colistin is higher.  Therefore, in membranes 
constructed from 0.8% DiphPC plus 0.2% PS/n-decane and a 
concentration of colistin of 8 µg/mL, no remarkable conductance events 
were observed until voltages equal or superior to +-150 mV, meanwhile 
for colistin concentrations of 32 µg/mL increments of conductance started 
at +-50 mV (Fig. 40). 
Polymyxins are old antimicrobials whose use was reintroduced a few 
years ago to treat severe infections caused by P. aeruginosa. Then, it 
seemed a promising group of molecules; however, adaptative resistance 
was promptly described. 
Many studies have been recently published with the aim to elucidate the 
main factors involved in this type of resistance. Modifications in the lipid A 
region of the LPS molecule as well as the recently identified two-
component regulator ParR-ParS [32], mutations in phoQ  and PmrB [177, 
178] have been suggested to play a decisive role in the acquisition of 
colistin-resistance. Moreover, ParR-S seems to play a significant role in 
determining resistance to at least four classes of antimicrobials 
(polymyxins, aminoglycosides, ß-lactams and fluoroquinolones) and its 
role seems to be played through the modification of three mechanisms of 
resistance (LPS modification, increase in drug efflux and reduction in 
porin pathway) and also by modifying the regulation of MexXY/OprM 
[179]. According to our results, LPS is modified, but not efflux machinery 
function. If there is some alteration in the protein pathway we were unable 
to visualize in electrophoresis analysis of porins.   
Our work suggests that the use of colistin for multidrug-resistant P. 
aeruginosa may contribute to the emergence of a colistin-heteroresistant 
phenotype. The presence of subpopulations in primary isolates with less 
amount of LPS and consequently less sites for polymyxin binding might 
proliferate preferentially during the colistin treatment and lead to the 
treatment failure or recurrence infection. Thus, treatments with colistin 
concentrations below the MIC of the microorganisms might increase the 
emergence of resistant bacteria during exposure to the drug.  
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The optimization of colistin administration regimens with appropriate 
higher dosages to suppress amplification of the colistin-resistant 
subpopulations or the use of synergic combinations of antimicrobial 
agents might significantly reduce the treatment failure.   
Conductance measurements in planar lipid membranes can be 
considered a useful tool for the study of the channel forming activity by 
both antimicrobial peptides and bacterial porins. One of the main 
advantages of these assays is its specificity and sensitivity, although in 
the case of antimicrobial peptides, the required concentration to observe a 
reasonable number of conductance events is larger (for example ≥ 8 
µg/mL for colistin; ≥ 1 µg/mL for Gramidicin [175]) than the concentration 
required for the analysis of porins (for example 5 ng/mL for K. oxytoca 
[180]; 50 ng/mL for the 28 kDa cell wall channel protein of Streptomyces 
griseus [181]).  
In the present study, the addition of colistin in 0.8% DiphPC (zwitterionic 
lipid) plus 0.2% PS (negatively charged lipid)/n-decane planar lipid 
bilayers induced irregular fluctuations of current.  
In general, increments in conductance for colistin and other antimicrobial 
peptides are irregular, unstable and present fast openings and closings of 
pores. This is in contrast to the conductance events observed for the 
majority of channel-forming proteins, which tend to be regular, stable and 
in the form of step (stepwise manner).  
Cationic peptides are generally able to interact electrostatically with the 
negatively charged headgroups of bacterial phospholipids and then insert 
into the cytoplasmic membrane, forming conductance events which are 
proposed to lead to the leakage of cell contents and cell death [175].  
In accordance with the general model proposed by Matsuzaki et al. [182], 
antimicrobial peptides bind to the outer leaflet of model membranes and 
flip inward, carrying lipids with them and creating brief disruptions in 
permeability.  
Besides, Wu et al. [175] suggested that these compounds contain 
irregular aggregates of peptide molecules within the membrane that will 
form in a concentration- and voltage-dependent manner creating informal 
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aqueous channels. These informal aqueous channels probably allow the 
passage of at least ions and possibly larger molecules. As long as these 
supramolecular complexes are of variable size and stability, this would 
explain the observed variations in both the magnitude and duration of 
conductance events observed in our and other planar bilayer studies. 
4.6. IMIPENEM RESISTANCE IN CLINICAL ISOLATES OF P. 
aeruginosa 
4.6.1. MINIMUM INHIBITORY CONCENTRATIONS  
Antimicrobial susceptibilities were determined for strains PA110514 and 
PA116136. Besides, to study the stability of the resistant phenotype in the 
absence of antimicrobial selective pressure, a single colony of the 
imipenem-resistant P. aeruginosa, PA116136, was serially transferred 30 
times on antibiotic-free medium (TSB) incubated overnight at 37 °C.  
Susceptibilities to imipenem and colistin were tested by both methods of 
disk diffusion test and broth microdilution test, and susceptibilities for the 
rest of antimicrobial agents were tested by the method of broth 
microdilution test. Results are in tables 22 and 23. 
 
Table 22. Susceptibilities to antimicrobial agents tested by broth microdilution test 
  
PA110514   PA116136 
 
Before imipenem  
treatment  
After imipenem 
treatment and before 
passages without 
antibiotic 
 
After 30 passages 
without antibiotic 
Antibiotics MIC (µg/mL) Suscept.  
MIC 
(µg/mL) Suscept.  
MIC 
(µg/mL) Suscept. 
Tobramycin  0.5 S   0.5 S  0.5 S 
Gentamicin  0.5 S  1 S  1 S 
Meropenem  4 S  4 S  4 S 
Ciprofloxacin 0.12 S  0.12 S  0.12          S 
Ceftazidime  1 S  1 S  1 S 
Imipenem  4 S  16 R  16 R 
Colistin 0.5 S   1 S   1 S 
 
S= Susceptible, I= Intermediate and R= Resistant by CLSI M100-S20 
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Table 23. Susceptibilities to antimicrobial agents tested by disk diffusion test 
 
PA110514  PA116136 
 
Before imipenem  
treatment  
 
After imipenem 
treatment and 
before passages 
without antibiotic  
 
After 30 cultures 
without antibiotic 
Antibiotic
s 
∅ 
(mm) 
Susceptibi
lity 
 ∅ 
(mm) 
Susceptibi
lity 
 ∅ 
(mm) 
Susceptibi
lity 
Imipenem 
10 µg 
 29*  S*  13 R  16 R 
Colistin 
10 µg 
20 S  20 S  16 S 
S= Susceptible, I= Intermediate and R= Resistant by CLSI M100-S20. (*) Some “satellite” 
colonies were observed at higher concentration of colistin.  
When susceptibility to imipenem 10 µg was tested for PA110514, it was 
observed that few bacteria were able to resist higher concentrations of 
imipenem. These observations indicated the possible heterogeneity of the 
strain.   
Some of the satellite colonies within imipenem inhibition zones (red arrow 
in  Fig. 41) were isolated and named as AR1, AR2, AR3 and AR4, and 
some of the bacteria grown at lower concentration of imipenem were also 
isolated and named as AS1, AS2, AS3 and AS4 to explore the 
evolutionary mechanism by which the clinical isolate PA110514 yields 
imipenem-resistant derivatives such as PA116136, AR1, AR2, AR3 and 
AR4, or imipenem-susceptible derivatives such as AS1, AS2, AS3 and 
AS4.  
 
 
 
 
                        Fig. 41.   Susceptibility to imipenem 10 µg of PA110514 
 
Using the method of disk diffusion test  AS1, AS2, AS3 and AS4 had the 
same antibiogram than strain PA110514, and using the method of broth 
“Satellite” colonies AR1-R4 
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microdilution test, all of them had a MIC for imipenem of 4 µg/mL, again 
the same result than the one obtained for the original strain PA110514. 
However, using the method of disk diffusion test, AR1, AR2, AR3 and 
AR4 had the same antibiogram than strain PA116136, which was isolated 
once the patient finished the treatment with imipenem (Fig. 42). Using 
broth microdilution test, all these isolates had a MIC for imipenem of 16 
µg/mL, again the same result than the one obtained for the original strain 
PA116136. 
                      
Fig. 42.  Disk diffusion test to imipenem 10 µg in strain PA116136. Results are the same for 
isolates AR1, AR2, AR3 and AR4. 
 
4.6.2. OUTER MEMBRANE PROTEIN PROFILES 
Electrophoretic comparisons of OMPs demonstrated that the susceptible 
strain PA110514 and their susceptible derivatives (AS1-AS4) showed a 
band corresponding to the porin OprD in the outer membrane that it was 
not visible in the resistant strain PA116136 and their derivatives (Fig. 43).  
97
66
45
31
21
14
A    AS1   AS2  AS3   AS4   M     A’ A’30    AR1   AR2   AR4
 
Fig. 43. SDS-PAGE analysis of Outer Membrane Proteins (OMPs) of P. aeruginosa. M: 
Molecular mass standards in KDa. Position of OprD is indicated by arrows on the left. A: 
PA110514. A’: PA116136. A’30: PA116136 after 30 cultures without antibiotic.  
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4.6.3. oprD AMPLIFICATION  
To investigate the mechanism responsible for the loss of OprD 
expression,  oprD genes of PA110514, PA116136 and their derivatives 
were amplified, sequenced and their sequences compared.   
Size of amplicons of oprD gene region from PA110514, AR1, AR2, AR3, 
AR4, AS1, AS2, AS3 and AS4 and PA116136 were larger than that of 
strain ATCC 27853 (Fig. 44). The predicted length of oprD is 1586 bp, 
while the amplicons from PA110514, AS1, AS2, AS3 and AS4 were 3000 
bp and from PA116136, AR1, AR2, AR3 and AR4 were 2000 bp.  
 
M     A     AR1    AR2    AR3  AR4   A’     AS1   AS2    AS3  AS4   A’1 0     ATCC2 78 5 3   
bp 
 
3500 
3000 
2500 
2000 
 
1500 
 
 
 
1000 
 
 
750 
 
 
 
500 
 
 
 
 
 
Fig. 44. PCR amplification products obtained with primers OprDSEQF1 and OprDSEQR1. 
Fragments were separated by electrophoresis through a 1.5% agarose gel. M: GeneRulerTM 
1kb DNA Ladder (Fermentas, Lithuania). A: PA110514. A’: PA116136. A’30: PA116136 after 
30 cultures without antibiotic. ATCC27853= strain ATCC 27853, used as control.  
Prior work in our laboratory [130] revealed that amplicons of PA110514 
and PA116136 had a long insert, 1300 bp approximately. The same insert 
was later found in amplicons of A’30, AS1, AS2, AS3, AS4, PA116136, 
AR1, AR2, AR3 and AR4. In all amplicons, insert had 59.6% G+C content. 
This insert was designated as ISPa133 and showed high homologies with 
the mobile elements included into the IS3 family of insertion sequences.  
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The similarities were not only in terms of the length of the ISPa133, that 
for members of the IS3 family is typically between 1200 and 1550 bp, but 
also due to the presence of two characteristic open reading frames (ORF), 
orfA and orfB, which did not overlap. The insertion element was flanked 
by 25-bp terminal inverted repeats (IRs), with TG at the 5’end and CA at 
the 3’end, as in other families of the IS3 family. However, short directly 
repeated sequences (DR) of the target DNA flanking the IS, were not 
detected on ISPa133 insertion.  
The first ORF (orfA) encoded a transposase. In the search for conserved 
domains [183], we determined that the protein includes a helix-turn-helix 
motif (HTH), a family of DNA-binding domains unique in bacteria, and that 
it showed high identity to the transposase 8 family, some of which are 
members of the IS3 family. The second ORF (orfB) encoded the central 
catalytic domain of an integrase (Fig. 45). 
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Fig. 45. Nucleotide sequence of the IS3-like element, ISPa133, present in PA110514, 
PA116136, A’30, AR1, AR2, AR3 and AR4, AS1, AS2, AS3 and AS4. The underlined 
sequences represent the 25-bp inverted repeats (IRs). Start codons of both orfs encoded by 
the mobile element are in red; the amino acid sequence of the two open reading frames are 
shown below the sequence. Sequence of OprD is indicated in green. 
Integrase mediates the integration of a DNA copy of the viral genome into 
the host chromosome. The enzyme is composed of three domains. The 
amino-terminal zinc-binding domain (pfam02022) is the central catalytic 
domain. The carboxyl terminal domain is a non-specific DNA-binding 
domain (pfarn00552). The catalytic domain acts as an endonuclease 
when two nucleotides are removed from the 3’ ends of the blunt-ended 
viral DNA resulting from reverse transcription. This domain also catalyzes 
the DNA-strand-transfer reaction of the 3’ ends of the viral DNA to the 5’ 
ends of the integration site. 
The large insert located in PA116136, A’30, AR1, AR2, AR3, AR4, AS1, 
AS2, AS3 and AS4 was 99% identical to that found in PA110514. 
However, the location of IS element into oprD was different. As we 
previously described, in PA110514, ISPa133 was located 56 nucleotides 
upstream of the translacional start codon, the same position where this 
insert was later found in AS1, AS2, AS3 and AS4.  
However, in PA116136 and A’30, the insert was located further down, 
immediately before the nucleotide 697, replacing them and therefore 
removing the first 232 amino acids of the porin OprD. In AR1, AR2, AR3 
and AR4 the insert was located some nucleotides before, removing the 
first 222 amino acids of the porin OprD.  
Schematic representation of the location of IS elements with respect to 
the oprD gene of P. aeruginosa PAO1 is shown in figure 46, and 
alignments of the amino acid sequences of OprD protein are shown in 
figure 47.   
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Fig. 46. Schematic diagram of the location of IS elements with respect to the oprD gene of 
P. aeruginosa PAO1. The solid arrow represents the oprD structural gene while the striped 
arrow represents the ISPa133.  
 
              L1 
PaO1      MKVMKWSAIALAVSAGSTQFAVADAFVSDQAEAKGFIEDSSLDLLLRNYYFNRDGKSGSG  60 
PA110514  MKVMKWSAIALAVSAGSTQFAVADAFVSDQAEAKGFIEDSSLDLLLRNYYFNRDGKSGSG  60 
PA116136  ------------------------------------------------------------  60 
A’30                ------------------------------------------------------------  60 
AS1,2,3,4 MKVMKWSAIALAVSAGSTQFAVADAFVSDQAEAKGFIEDSSLDLLLRNYYFNRDGKSGSG  60 
AR1,2,3,4 ------------------------------------------------------------  60 
 
       L2 
PaO1      DRVDWTQGFLTTYESGFTQGTVGFGVDAFGYLGLKLDGTSDKTGTGNLPVMNDGKPRDDY  120 
PA110514  DRVDWTQGFLTTYESGFTQGTVGFGVDAFGYLGLKLDGTSDKSGTGNLPVMNDGTPRDDY  120 
PA116136  ------------------------------------------------------------  120 
A’30                ------------------------------------------------------------  120 
AS1,2,3,4 DRVDWTQGFLTTYESGFTQGTVGFGVDAFGYLGLKLDGTSDKSGTGNLPVMNDGTPRDDY  120 
AR1,2,3,4 ------------------------------------------------------------  120 
 
       L3 
PaO1      SRAGGAVKVRISKTMLKWGEMQPTAPVFAAGGSRLFPQTATGFQLQSSEFEGLDLEAGHF  180 
PA110514  SRAGGAVKVRISKTMLKWGEMQPTAPVFAAGGSRLFPQTATGFQLQSSELEGLDLEAGHF  180 
PA116136  ------------------------------------------------------------  180 
A’30                ------------------------------------------------------------  180 
AS1,2,3,4 SRAGGAVKVRISKTMLKWGEMQPTAPVFAAGGSRLFPQTATGFQLQSSELEGLDLEAGHF  180 
AR1,2,3,4 ------------------------------------------------------------  180 
 
          L4 
PaO1      TEGKEPTTVKSRGELYATYAGETAKSADFIGGRYAITDNLSASLYGAELEDIYRQYYLNS  240 
PA110514  TEGKQGTTTKSRGELYATYAGETAKSADFIGGRYAITDNLSASLYGAELEDIYRQYYLNS  240 
PA116136  ----------------------------------------------------YRQYYLNS  240 
A’30                ----------------------------------------------------YRQYYLNS  240 
AS1,2,3,4 TEGKQGTTTKSRGELYATYAGETAKSADFIGGRYAITDNLSASLYGAELEDIYRQYYLNS  240 
AR1,2,3,4 ------------------------------------------SLYGAELEDIYRQYYLNS  240 
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         L5  
PaO1      NYTIPLASDQSLGFDFNIYRTNDEGKAKAGDISNTTWSLAAAYTLDAHTFTLAYQKVHGD  300   
 
      L6                                              
PaO1      QPFDYIGFGRNGSGAGGDSIFLANSVQYSDFNGPGEKSWQARYDLNLASYGVPGLTFMVR  360 
 
                   L7 
PaO1      YINGKDIDGTKMSDNNVGYKNYGYGEDGKHHETNLEAKYVVQSGPAKDLSFRIRQAWHRA  420 
 
              L8 
PaO1      NADQGEGDQNEFRLIVDYPLSIL 
 
 
Fig. 47.  Alignment of the amino acid sequence of OprD protein of PA110514, PA116136, 
A’30, PA110514R1 (AR1),  PA110514R2 (AR2), PA110514R3 (AR3) and PA110514R4 
(AR4), PA110514 (AS1), PA110514S2 (AS2), PA110514S3 (AS3) and PA110514S4 (AS4). 
In bold and underlined is indicated loops (L) position. Hyphens indicate absence of amino 
acids.  
As can be seen in the previous figure, insert ISPa133 in PA110514, AS1, 
AS2, AS3 and AS4 is located before oprD gen, thus OprD is not truncated 
and consequently, imipenem can enter inside bacteria via this porin. 
Nevertheless, OprD protein of PA116136 and A’30 begin in the last amino 
acid of the loop 4 and OprD protein of AR1, AR2, AR3 and AR4 begins in 
the third amino acid of the same loop, therefore, this protein is not able to 
arrive to the membrane and imipenem is not able to enter inside bacteria.   
Carbapenems are a class of β-lactam antibiotics with good antimicrobial 
activity against P. aeruginosa; they are often used as a last resource to 
treat infections due to multidrug-resistant strains [184]. However, the 
emergence and spread of acquired carbapenem resistance have 
challenged therapeutic and control efforts [185], thus, a better 
understanding of the molecular mechanisms underlying resistance is 
needed. Moreover, it seems likely that several mechanisms are involved 
in carbapenem resistance [186]. The two clinical isolates of this study, 
PA110514 and PA116136 and their susceptible and resistant derivatives, 
were identical in their PFGE profiles and in biochemical tests, suggesting 
their close relationship. The unique noticeable difference between the 
isolates was in their susceptibility to imipenem. We hypothesized that this 
difference involves OMPs. This is reinforced by the results of SDS-PAGE, 
which revealed the loss of OprD in PA116136 and derivatives. To 
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investigate the mechanism responsible for the loss of the porin, the oprD 
gene of each strain was amplified and sequenced. Examination of these 
sequences revealed the presence of a new insertion sequence, ISPa133, 
located 56 nucleotides upstream of the oprD start codon in PA110514, 
AS1, AS2, AS3 and AS4. However, since this isolate is imipenem-
susceptible, the presence of ISPa133 has no obvious effect on the 
upstream regulatory region of the gene, as oprD expression was normal 
(Fig. 37) as was the expression of the porin OprD. By contrast, in 
PA116136 and A’30 the insertion element (99% identity) is located 
immediately before nucleotide position 696, which causes the removal of 
the first 232 amino acids of OprD and in AR1, AR2, AR3 and AR4 the 
insert was located some nucleotides before, removing the first 222 amino 
acids of the porin OprD. 
Subsequently, the protein was not expressed and was not detectable in 
the gels (Fig. 36). Since loss of the protein prevents the entrance of 
imipenem, strain PA116136, A’30, AR1, AR2, AR3 and AR4 are fully 
resistant to the antibiotic. 
To date, the presence of ISs in OprD has been reported only once, 
although these elements have been detected in other genes of P. 
aeruginosa [187, 188, 65]. In those cases, the ISs were described in 
resistant isolates and thus assumed to be the cause of resistance, either 
via gene activation or by inducing 
the high level expression of a potential resistance gene. 
Based on the findings of this study, we propose that the identified 
insertion element ISPa133 acts as a switch, depending on the degree of 
selective pressure exerted by imipenem. In the absence of selective 
pressure, as was the case during isolation of strain PA110514 from an 
infected, untreated patient, OprD is found on the OM and the position of 
ISPa133 in the genome has no effect on oprD expression; however, 
selective pressure exerted by antibiotic therapy results in the selection of 
strains in which ISPa133 moves within the oprD gene, such that, in the 
case of strain PA116136, the first 232 amino acids are removed, thus 
preventing expression of the gene. A high rate of ISPa133 jumping would 
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therefore provide a major selective advantage, one that allows the 
bacterium to survive in the presence of carbapenems. 
It has been proposed that ISs without DRs may simply result from the 
homologous inter- or intra-molecular recombination between two IS 
elements, each with a different DR sequence, or from the formation of 
adjacent deletions arising from duplicative intramolecular transposition 
[189]. For ISPa133, this could explain the lack of DRs as well as the 
absence of a crossover region between orfA and orfB. As shown in other 
species, experiments mimicking natural conditions can provide insight into 
population phenomena [190]. This was the aim of experiments in which 
strain PA110514 was submitted to selective pressure by imipenen in 
culture flasks in order to obtain spontaneous resistant mutants in vitro with 
properties similar or identical to those of the strains isolated from a patient 
hospitalized with a P. aeruginosa infection. Indeed, mutants with levels of 
resistance similar to those of strain PA116136 were easily recovered. 
Moreover, when the experiments were prolonged, the MICs of the isolates 
were even higher (16 µg/mL) [130]. According to the above-proposed 
mechanism of action, removal of the selective pressure exerted by the 
antibiotic should restore bacterial susceptibility to carbapenems through 
the expression of the full-length OprD. However, after 30 passages 
without antibiotic, susceptibility to imipenem was not restored, and 
electrophoretic OMPs  did not showed the band corresponding to the 
porin OprD in the outer membrane. These results point out that recovery 
of susceptibility to imipenem is slower than acquisition of resistance, since 
the selective advantage conferred by imipenem resistance in the 
presence of the antimicrobial is strong whereas OprD expression is likely 
evolutionarily advantageous only under certain and unknown 
environmental conditions.  
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5. CONCLUSIONS 
 
1. The resistome of Serratia marcescens did not change significantly 
during the antibiotic era. 
2. Antibiotic withdrawing tends to restore original susceptible 
phenotypes, irrespective to the molecular mechanism involved in 
resistance. 
3. None of Serratia strains studied presented integrons, any 
extended spectrum ß-lactamases. 
4. Phenotypical determination of susceptibilities of old strains 
inactive during the last 60 years have confirmed results obtained 
by metagenomics i.e. the genes of resistance already existed 
before antibiotics discovery and use.  
5. Multiresistant Pseudomonas aeruginosa harbored class 1 
integrons containing a cassette encoding aminoglycoside 
adenylyltransferase (aadB). 
6. Multiresistant Pseudomonas aeruginosa overexpressed MexAB-
OprM and MexXY efflux machinery. 
7. CCCP use should be avoided in experiments performed with P. 
aeruginosa and probably in other aerobic bacteria. 
8. Meropenem induces the formation of aberrant long rods which 
can survive, accumulate less antibiotic than normal bacteria, and 
can revert to normal forma when antibiotic pressure disappears. 
9. Colistin, the last therapeutic option to fight against Pseudomonas 
infections in cystic fibrosis patients, is normally active although 
cases of resistance have arisen recently. 
10. Resistance to colistin seems to be mediated by 
lipopolysaccharide singular properties. 
11. Colistin induces injuries in lipid bilayers, which can be studied by 
means of planar black lipid bilayer techniques. Preliminary results 
showed the ability of colistin to induce transient channels in the 
bilayers, with some dependence to voltage.  
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12.  Recovery of susceptibility to imipenem is slower than acquision 
of resistance, since the selective advantage conferred by 
imipenem resistance in the presence of the antimicrobial is strong 
whereas OprD expression is likely evolutionarily advantageous 
only under certain and unknown environmental conditions. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Now this is not the end. 
It is not even the beginning of the end. 
But it is, perhaps, the end of the beginning.” 
 
Winston Churchill. London, 10 November 1942. 
   
 
   
167
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
                                                                      6. REFERENCES 
 
 
   
 
 
   
169
REFERENCES 
                                                 
1 Jablonka E, Lamb MJ. The changing concept of epigenetics. Ann N Y 
Acad Sci. 2002; 981: 82-96. 
 
2 Goldberg AD, Allis CD, Bernstein E. Epigenetics: A landscape takes 
shape Cell. 2007; 128: 635-8. 
 
3 Fraga MF, Esteller M. Epigenetics and aging: The targets and the 
marks. Trends Genet. 2007; 23: 413-8. 
 
4 Ledermann D.W. Pitágoras, Alejandro, Rafael y la Serratia marcescens. 
Revista chilena de infectología. 2003; 20: 71-3. 
 
5 Ledermann D.W. Shakespeare y la prodigiosa historia de Serratia 
marcescens como marcador biológico. Revista chilena de infectología. 
2003; 20: 74-5. 
 
6 Hejazi A, Falkiner FR. Serratia marcescens. J Med Microbiol. 1997; 46: 
903-12. 
 
7 Grimont F, Grimont PAD. The genus Serratia. In: Dworkin M, Falkow S, 
Rosenberg E, Schleifer K, and Stackebrandt E (ed.). The Prokaryotes. 
Springer; 2006. 
 
8 Holt JG, Bergey DH. Bergey's Manual of Determinative Bacteriology. 9th 
ed. Baltimore Ma. etc: Williams & Wilkins; 1994. 
 
9 Leranoz S, Orus P, Berlanga M, Dalet F, Viñas M. New fimbrial 
adhesins of Serratia marcescens isolated from urinary tract infections: 
Description and properties. J Urol. 1997; 157: 694-8. 
 
10 Kurz CL, Chauvet S, Andres E, Aurouze M, Vallet I, Michel GP, et al. 
Virulence factors of the human opportunistic pathogen Serratia 
marcescens identified by in vivo screening. EMBO J. 2003; 22: 1451-60. 
 
11 Moore, E. R. B., B. J. Tindall, V. A. P. Martins dos Santos, D. H. 
Pieper, J. L.Ramos, and N. J. Palleroni. Nonmedical: Pseudomonas. In: 
M.Dworkin, S. Falkow, E. Rosenberg, K. Schleifer, and E. Stackebrandt 
(ed.) The Prokaryotes. Springer; 2006. 
 
12 Murray PR, Baron EJ. Manual of clinical microbiology. 9th ed. 
Washington, D.C.: ASM Press; 2007. 
 
13 Yahr T, Parsek M. 2006. Pseudomonas aeruginosa. In: Dworkin M, 
Falkow S, Rosenberg E, Schleifer K, and Stackebrandt E(ed.), The 
Prokaryotes. Springer. 
 
   
170
                                                                                                               
 
14 Ruiz Martínez L. Pseudomonas aeruginosa: Aportación al 
conocimiento de su estructura y al de los mecanismos que contribuyen a 
su resistencia a los antimicrobianos [PhD thesis]. Barcelona: Universitat 
de Barcelona; 2008. 
 
15 Hall RM, Collis CM. Mobile gene cassettes and integrons: Capture and 
spread of genes by site-specific recombination. Mol Microbiol. 1995; 15: 
593-600. 
 
16 Rowe-Magnus DA, Guerout AM, Mazel D. Bacterial resistance 
evolution by recruitment of super-integron gene cassettes. Mol Microbiol. 
2002; 43: 1657-69. 
 
17 White DG, Alekshun MN, McDermott PF, editors. Frontiers in 
Antimicrobial Resistance: A Tribute to Stuart B. Levy. Washington D.C.: 
ASM Press; 2005.  
 
18 Hopper DC, Wolfson JS. Quinolone antimicrobial agents. 2nd ed. 
Washington D.C.: American Society for Microbiology; 1993. 
 
19 Mcchesney EW, Froelich EJ, Lesher GY, Crain AV, Rosi D. 
Absorption, excretion, and metabolism of a new antibacterial agent, 
nalidixic acid. Toxicol Appl Pharmacol. 1964; 6: 292-309. 
 
20 García Sánchez JE, López R, Prieto J. Antimicrobianos en medicina. 
2nd ed. Barcelona: Prous Science; 2006. 
 
21 Fenosa Bernadó A. La proteïna TolC de "klebsiella oxytoca" [PhD 
thesis]. Barcelona: Universitat de Barcelona; 2006. 
 
22 Berlanga M, Vazquez JL, Hernandez-Borrell J, Montero MT, Viñas M. 
Evidence of an efflux pump in Serratia marcescens. Microb Drug Resist. 
2000; 6: 111-7. 
 
23 Ruiz N, Montero T, Hernandez-Borrell J, Viñas M. The role of Serratia 
marcescens porins in antibiotic resistance. Microb Drug Resist. 2003; 9: 
257-64. 
 
24 Puig M, Palomar J, Lorén JG, Viñas M. Modification by analgesics of 
the susceptibility to antibiotics in Serratia marcescens. New Microbiol. 
1995; 385-90. 
 
25 Berlanga M, Viñas M. Salicylate induction of phenotypic resistance to 
quinolones in Serratia marcescens. J Antimicrob Chemother. 2000; 46: 
279-82. 
 
 
   
171
                                                                                                               
 
26 Begic S, Worobec EA. Fluoroquinolone resistance of Serratia 
marcescens: Sucrose, salicylate, temperature, and pH induction of 
phenotypic resistance. Can J Microbiol. 2007; 53: 1239-45. 
 
27 Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009; 
22: 535-43. 
 
28 Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et 
al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-
negative bacterial infections. Lancet Infect Dis. 2006; 6: 589-601. 
 
29 Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of 
colistin as an agent against multi-resistant Gram-negative bacteria. Int J 
Antimicrob Agents. 2005; 25: 11-25. 
 
30 Hancock RE. Peptide antibiotics. Lancet. 1997; 349: 418-22. 
 
31 Pogue JM, Marchaim D, Kaye D, Kaye KS. Revisiting "older" 
antimicrobials in the era of multidrug resistance. Pharmacotherapy 2011; 
9: 912-21.  
 
32 Fernandez L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, 
Hancock RE. Adaptive resistance to the "last hope" antibiotics polymyxin 
B and colistin in Pseudomonas aeruginosa is mediated by the novel two-
component regulatory system ParR-ParS. Antimicrob Agents Chemother. 
2010; 54: 3372-82. 
 
33 Brandon RN. Environment. In: Keller EF, lloyd EA, eds. Key words in 
evolutionary biology. Cambridge, Massachusetts: Harvard university 
press; 1992.  
 
34 Baquero F, Negri MC, Morosini MI, Blazquez J. Antibiotic-selective 
environments. Clin Infect Dis. 1998; 27 Suppl 1: S5-11.  
 
35 Adam M, Murali B, Glenn NO, Potter SS. Epigenetic inheritance based 
evolution of antibiotic resistance in bacteria. BMC Evol Biol. 2008; 8: 52. 
 
36 Fernandez L, Breidenstein EB, Hancock RE. Creeping baselines and 
adaptive resistance to antibiotics. Drug Resist Updat. 2011; 14: 1-21. 
 
37 Mawer SL, Greenwood D. Specific and non-specific resistance to 
aminoglycosides in Escherichia coli. J Clin Pathol. 1978; 31: 12-5. 
 
38 Davey ME, O'toole GA. Microbial biofilms: From ecology to molecular 
genetics. Microbiol Mol Biol Rev. 2000; 64: 847-67. 
 
   
172
                                                                                                               
 
39 Brazas MD, Hancock RE. Using microarray gene signatures to 
elucidate mechanisms of antibiotic action and resistance. Drug Discov 
Today. 2005; 10: 1245-52. 
 
40 Livermore DM, Chau PY, Wong AI, Leung YK. Beta-lactamase of 
Pseudomonas pseudomallei and its contribution to antibiotic resistance. J 
Antimicrob Chemother. 1987; 20: 313-21. 
 
41 Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold 
Spring Harb Perspect Biol. 2010; 2:a000414.  
 
42 Nikaido H, Vaara M. Molecular basis of bacterial outer membrane 
permeability. Microbiol Rev. 1985; 49: 1-32. 
 
43 Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification 
systems in Gram-negative bacteria. Annu Rev Biochem. 2007; 76: 295-
329.  
 
44 Kamio Y, Nikaido H. Outer membrane of Salmonella typhimurium: 
Accessibility of phospholipid head groups to phospholipase c and 
cyanogen bromide activated dextran in the external medium. 
Biochemistry. 1976; 15: 2561-70. 
 
45 Benz R. Structure and function of porins from Gram-negative bacteria. 
Annu Rev Microbiol. 1988; 42: 359-93. 
 
46 Heyde M, Laloi P, Portalier R. Involvement of carbon source and acetyl 
phosphate in the external-pH-dependent expression of porin genes in 
Escherichia coli. J Bacteriol. 2000; 182: 198-202. 
 
47 Zeth K, Thein M. Porins in prokaryotes and eukaryotes: common 
themes and variations. Biochem J. 2010; 431: 13-22. 
 
48 Braun V, Braun M. Iron transport and signalling in Escherichia coli. 
FEBS Lett. 2002; 529: 78-85. 
 
49 Kim EH, Nies DH, McEvoy MM, Rensing C. Switch or funnel: how 
RND-type transport systems control periplasmic metal homeostasis. J 
Bacteriol. 2011; 193: 2381-7. 
 
50 Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an 
update. Drugs. 2009; 69: 1555-623. 
 
51 Erridge C, Bennett-Guerrero E, Poxton IR. Structure and function of 
lipopolysaccharides. Microbes Infect. 2002; 4: 837-51. 
 
 
   
173
                                                                                                               
 
52 Lam JS, Taylor VL, Islam ST, Hao Y, Kocíncová D. Genetic and 
Functional Diversity of Pseudomonas aeruginosa Lipopolysaccharide. 
Front Microbiol. 2011; 2: 118 
 
53 Schneck E, Papp-Szabo E, Quinn BE, Konovalov OV, Beveridge TJ, 
Pink DA, Tanaka M. Calcium ions induce collapse of charged O-side 
chains of lipopolysaccharides from Pseudomonas aeruginosa. J R Soc 
Interface. 2009; 6 Suppl 5: S671-8. 
 
54 Kwon DH, Lu CD. Polyamines increase antibiotic susceptibility in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006; 50:1623-
7. 
 
55 Rowe-Magnus DA, Mazel D. Resistance gene capture. Curr Opin 
Microbiol. 1999; 2: 483-8. 
 
56 Kampranis SC, Maxwell A. Conformational changes in DNA gyrase 
revealed by limited proteolysis. J Biol Chem. 1998; 273: 22606-14. 
 
57 Partridge SR, Recchia GD, Scaramuzzi C, Collis CM, Stokes HW, Hall 
RM. Definition of the attI1 site of class 1 integrons. Microbiology. 2000; 
146: 2855-64. 
 
58 Levesque C, Piche L, Larose C, Roy PH. PCR mapping of integrons 
reveals several novel combinations of resistance genes. Antimicrob 
Agents Chemother. 1995; 39: 185-91. 
 
59 Collis CM, Grammaticopoulos G, Briton J, Stokes HW, Hall RM. Site-
specific insertion of gene cassettes into integrons. Mol Microbiol. 1993; 9: 
41-52. 
 
60 Stokes HW, Hall RM. A novel family of potentially mobile DNA 
elements encoding site-specific gene-integration functions: integrons. Mol 
Microbiol. 1989; 3: 1669-83. 
 
61 Recchia GD, Stokes HW, Hall RM. Characterisation of specific and 
secondary recombination sites recognised by the integron DNA integrase. 
Nucleic Acids Res. 1994; 22: 2071-8. 
 
62 Recchia GD, Hall RM. Gene cassettes: A new class of mobile element. 
Microbiology 1995;141:3015-27. 
 
63 Collis CM, Hall RM. Gene cassettes from the insert region of integrons 
are excised as covalently closed circles. Mol Microbiol. 1992; 6: 2875-85. 
 
 
 
   
174
                                                                                                               
 
64 Goldstein C, Lee MD, Sanchez S, Hudson C, Phillips B, Register B, et 
al. Incidence of class 1 and 2 integrases in clinical and commensal 
bacteria from livestock, companion animals, and exotics. Antimicrob 
Agents Chemother. 2001; 45: 723-6. 
 
65 Ruiz-Martinez L, Lopez-Jimenez L, Fusté E, Vinuesa T, Martinez JP, 
Viñas M. Class 1 integrons in environmental and clinical isolates of 
Pseudomonas aeruginosa. Int J Antimicrob Agents. 2011; 38: 398-402. 
 
66 Martinez-Freijo P, Fluit AC, Schmitz FJ, Grek VS, Verhoef J, Jones 
ME. Class I integrons in Gram-negative isolates from different European 
hospitals and association with decreased susceptibility to multiple 
antibiotic compounds. J Antimicrob Chemother. 1998; 42: 689-96. 
 
67 Leranoz AM, Fusté MC, Viñas M, Hull RA, Williams RP. Cloning and 
expression in escherichia coli of a gene encoding proline oxidase of 
Serratia marcescens. Microbios. 1991; 67: 87-94.  
 
68 Gargallo D, Loren JG, Guinea J, Viñas M. Glucose-6-phosphate 
dehydrogenase alloenzymes and their relationship to pigmentation in 
Serratia marcescens. Appl Environ Microbiol. 1987; 53: 1983-6.  
 
69 Viñas M, el-Ebiary A, Guinea J, Loren JG. Effect of gramicidin A and 
valinomycin on prodigiosin production by non-proliferating Serratia 
marcescens. J Antibiot (Tokyo). 1987; 40: 113-5.  
 
70 Lauferska U, Viñas M, Loren JG, Guinea J. Enhancement by 
polymyxin B of proline-induced prodigiosin biosynthesis in non-
proliferating cells of Serratia marcescens. Microbiologica.1983; 6: 155-62.  
 
71 Perez-Tomas R and Viñas M. New insights on the antitumoral 
properties of prodiginines Curr Med Chem. 2010; 17: 2222-31 
 
72 Trias J, Viñas M, Guinea J, Loren JG. Brown pigmentation in Serratia 
marcescens cultures associated with tyrosine metabolism. Can J 
Microbiol. 1989; 35: 1037-42.  
 
73 Trias J, Viñas M, Guinea J, Loren JG. Induction of yellow pigmentation 
in Serratia marcescens. Appl Environ Microbiol. 1988; 54: 3138-41. 
 
74 Montilla R, Williams RP, Loren JG, Viñas M. Lipopolysaccharide is the 
receptor for kappa phage in Serratia marcescens. Antonie Van 
Leeuwenhoek 1991; 59: 15-8.  
 
 
   
175
                                                                                                               
 
75 Palomar J, Montilla R, Fusté MC, Viñas M. The role of O-antigen in 
susceptibility of Serratia marcescens to non-immune serum. Microbios 
1993; 76: 189-96.  
 
76 Palomar J, Puig M, Montilla R, Loren JG, Viñas M. Lipopolysaccharide 
recovery restores susceptibility levels towards beta-lactams in Serratia 
marcescens. Microbios. 1995; 82: 21-6.  
 
77 Palomar J, Viñas M. The effect of O-antigen on transformation 
efficiency in Serratia marcescens. Microbiologia. 1996; 12: 435-8. 
 
78 Berlanga Herranz M. Mecanismos de resistencia a las quinolonas en 
Serratia marcescens [PhD thesis]. Barcelona: Universitat de 
Barcelona;1999.  
 
79 Berlanga M, Ruiz N, Hernandez-Borrell J, Montero T, Viñas M. Role of 
the outer membrane in the accumulation of quinolones by Serratia 
marcescens. Can J Microbiol. 2000; 46: 716-22.  
 
80 Berlanga M, Montero MT, Hernandez-Borrell J, Viñas M. Influence of 
the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-
negative and Gram-positive bacteria. Int J Antimicrob Agents. 2004; 23: 
627-30.  
 
81 Ruiz L, Dominguez MA, Ruiz N, Viñas M. Relationship between clinical 
and environmental isolates of Pseudomonas aeruginosa in a hospital 
setting. Arch Med Res. 2004; 35: 251-7.  
 
82 Puig M, Fusté C, Viñas M. Outer membrane proteins from Serratia 
marcescens. Can J Microbiol 1993;39:108-11. 
 
83 Puig M, Palomar J, Loren JG, Viñas M. Modification by analgesics of 
the susceptibility to antibiotics in Serratia marcescens. New Microbiol. 
1995; 18: 385-90.  
 
84 Regue M, Fabregat C, Viñas M. A generalized transducing 
bacteriophage for Serratia marcescens. Res Microbiol 1991; 142: 23-7. 
 
85 Ruiz N, Merino S, Viñas M, Domenech O, Montero MT, Hernandez-
Borrell J. Preliminary studies of the 2D crystallization of Omp1 of Serratia 
marcescens: Observation by atomic force microscopy in native 
membranes environment and reconstituted in proteolipid sheets. Biophys 
Chem. 2004; 111: 1-7. 
  
 
   
176
                                                                                                               
 
86 Ruiz N, Maier E, Andersen C, Benz R, Viñas M. Molecular and 
functional characterisation of the Serratia marcescens outer membrane 
protein Omp1. Biophys Chem. 2004; 109: 215-27.  
 
87 Sanchez L, Ruiz N, Leranoz S, Viñas M, Puig M. The role of outer 
membrane in Serratia marcescens intrinsic resistance to antibiotics. 
Microbiologia. 1997; 13: 315-20.  
 
88 Fenosa A, Fusté E, Ruiz L, Veiga-Crespo P, Vinuesa T, Guallar V, 
Viñas M. Role of TolC in Klebsiella oxytoca resistance to antibiotics. J 
Antimicrob Chemother. 2009; 63: 668-74. 
 
89 Veiga-Crespo P, Fusté E, Vinuesa T, Viñas M, Villa TG. Synergism 
between outer membrane proteins and antimicrobials. Antimicrob Agents 
Chemother 2011; 55: 2206-11. 
  
90 Palomar J, Guasch JF, Regué M, Viñas M. The effect of nuclease on 
transformation efficiency in Serratia marcescens. FEMS Microbiol Lett. 
1990; 57: 255-8. 
 
91 Veron M. Nutrition and taxonomy of "Enterobacteriaceae" and related 
bacteria. I. technical procedure for auxanograms. Ann Microbiol. 1975; 
126: 267-74. 
 
92 Sambrook J, Russell DW. Molecular cloning: A laboratory manual. 3rd 
ed. Cold Spring Harbor N.Y.: Cold Spring Harbor Laboratory; 2001. 
 
93 Pages JM, Amaral L. Mechanisms of drug efflux and strategies to 
combat them: Challenging the efflux pump of Gram-negative bacteria. 
Biochim Biophys Acta. 2009; 1794: 826-33. 
 
94 Pages JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-
negative bacteria. Trends Mol Med. 2005; 11: 382-9. 
 
95  Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pages JM. 
Antibiotic efflux pumps in Gram-negative bacteria: The inhibitor response 
strategy. J Antimicrob Chemother. 2007; 59: 1223-9. 
 
96 Lomovskaya O, Bostian KA. Practical applications and feasibility of 
efflux pump inhibitors in the clinic-a vision for applied use. Biochem 
Pharmacol. 2006; 71: 910-8. 
 
 
 
 
   
177
                                                                                                               
 
97 Clinical and Laboratory Standards Institute. Performance standards for 
antimicrobial susceptibility testing; 20th informational supplement CLSI 
document M100-S20. Wayne, PA: Clinical and laboratory standards 
institute; 2010. 
 
98 Clinical and Laboratory Standards Institute. Methods for dilution 
antimicrobial tests for bacteria that grow aerobically. approved standards 
M7-A4. 1997. NCCLS, wayne, PA. 2010 
 
99 European Committee on Antimicrobial Susceptibility Testing. Data from 
the EUCAST MIC distribution website, http://www.eucast.org; last 
accessed 8 march 2011.  
 
100 Clinical and Laboratory Standards Institute. Performance standards 
for antimicrobial disk susceptibility tests. approved standard M2-A10. 
wayne, PA: Clinical and laboratory standards institute; 2009. 
 
101 Clinical and Laboratory Standards Institute. Methods for dilution 
antimicrobial susceptibility tests for bacteria that grow aerobically. 8th ed. 
CLSI M07–A8. wayne (PA): The institute; 2009. 
 
102 Kwon DH, Lu CD. Polyamines increase antibiotic susceptibility in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006; 50: 
1623-7. 
 
103 Jeong SH, Song W, Park MJ, Kim JS, Kim HS, Bae IK, et al. Boronic 
acid disk tests for identification of extended-spectrum beta-lactamase 
production in clinical isolates of Enterobacteriaceae producing 
chromosomal AmpC beta-lactamases. Int J Antimicrob Agents. 2008; 31: 
467-71.  
 
104 Coudron PE. Inhibitor-based methods for detection of plasmid-
mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and 
Proteus mirabilis. J Clin Microbiol. 2005; 43: 4163-7.  
 
105 Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. 
A convenient assay for estimating the possible involvement of efflux of 
fluoroquinolones by Streptococcus pneumoniae and Staphylococcus 
aureus: Evidence for diminished moxifloxacin, sparfloxacin, and 
trovafloxacin efflux. Antimicrob Agents Chemother. 2000; 44: 798-801. 
 
106 Kriengkauykiat J, Porter E, Lomovskaya O, Wong-Beringer A. Use of 
an efflux pump inhibitor to determine the prevalence of efflux pump-
mediated fluoroquinolone resistance and multidrug resistance in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005; 49: 565-
70. 
   
178
                                                                                                               
 
107 Mortimer PG, Piddock LJ. A comparison of methods used for 
measuring the accumulation of quinolones by Enterobacteriaceae, 
Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob 
Chemother. 1991; 28:639-53. 
 
108 Berlanga M, Ruiz N, Hernandez-Borrell J, Montero T, Viñas M. Role 
of the outer membrane in the accumulation of quinolones by Serratia 
marcescens. Can J Microbiol. 2000; 46: 716-22. 
 
109 Laemmli UK. Cleavage of structural proteins during the assembly of 
the head of bacteriophage T4. Nature. 197; 227: 680-5. 
110 Ames GF, Spudich EN, Nikaido H. Protein composition of the outer 
membrane of Salmonella typhimurium: Effect of lipopolysaccharide 
mutations. J Bacteriol. 1974; 117: 406-16. 
111 Hitchcock PJ, Brown TM. Morphological heterogeneity among 
Salmonella lipopolysaccharide chemotypes in silver-stained 
polyacrylamide gels. J Bacteriol. 1983; 154: 269-77. 
112 Palomar Montejo J. El lipopolisacárido de Serratia marcescens como 
factor de virulencia [PhD thesis]. Barcelona: Universitat de 
Barcelona;1994.  
 
113 Maslow JN, Slutsky AM, Arbeit RD. Application of pulsed-field gel 
electrophoresis to molecular epidemiology. In: Persing DH, Smith TF, 
Tenover FC, White TJ, editors. Diagnostic molecular microbiology: 
principles and applications. Washington, D.C.: American Society for 
Microbiology; 1993. pp. 563–572. 
 
114 Schwartz DC, Cantor CR. Separation of yeast chromosome-sized 
DNAs by pulsed field gradient gel electrophoresis. Cell. 1984; 37: 67-75. 
 
115 Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, 
Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction 
patterns produced by pulsed-field gel electrophoresis: criteria for bacterial 
strain typing. J Clin Microbiol. 1995; 33: 2233-9. 
 
116 Benz, R., and Hancock, R. E. W. Properties of the large ion-
permeable pores formed from protein F of Pseudomonas aeruginosa in 
lipid bilayer membranes .Biochim Biophys Acta.1981; 646: 298-308. 
 
117 Kordel M, Benz R, Sahl HGJ. Mode of action of the staphylococcinlike 
peptide Pep 5: voltage-dependent depolarization of bacterial and artificial 
membranes. Bacteriol. 1988; 170: 84-88. 
   
179
                                                                                                               
 
118  Marmur J. A procedure for the isolation of deoxyribonucleic acid from 
micro-organisms. J Mol Biol. 1961; 3: 208,218, IN1. 
 
119 Kieleczawa J. DNA sequencing II: Optimizing preparation and 
cleanup. Jones and Bartlett Publishers; 2006. 
 
120 Wolter DJ, Hanson ND, Lister PD. Insertional inactivation of oprD in 
clinical isolates of Pseudomonas aeruginosa leading to carbapenem 
resistance. FEMS Microbiol Lett. 2004; 236: 137-43. 
 
121 Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et 
al. Gapped BLAST and PSI-BLAST: A new generation of protein database 
search programs. Nucleic Acids Res. 1997; 25: 3389-402.  
 
122  Pearson W. Finding protein and nucleotide similarities with FASTA. 
Curr Protoc Bioinformatics. 2004; Chapter 3: Unit 3.9. 
 
123 Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel 
RD, et al. Protein identification and analysis tools in the ExPASy server. 
Methods Mol Biol. 1999; 112: 531-52. 
 
124 Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: Improving the 
sensitivity of progressive multiple sequence alignment through sequence 
weighting, position-specific gap penalties and weight matrix choice. 
Nucleic Acids Res. 1994; 22: 4673-80. 
 
125 Chen H, Shu W, Chang X, Chen J, Guo Y, Tan Y. The profile of 
antibiotics resistance and integrons of extended-spectrum beta-lactamase 
producing thermotolerant coliforms isolated from the Yangtze River basin 
in Chongqing. Environmental Pollution. 2010; 158: 2459-2464. 
 
126 Hu Z and Zhao W. Identification of plasmid- and integron-borne 
blaIMP-1and bla IMP-10 in clinical isolates of Serratia marcescens. 
Journal of Medical Microbiology. 2009; 58: 217-221. 
 
127 Bagattini M, Crispino M, Gentile F, Barretta E, Schiavone D, Boccia 
MC et al. A nosocomial outbreak of Serratia marcescens producing 
inducible Amp C-type beta-lactamase enzyme and carrying antimicrobial 
resistance genes within a class 1 integron. J Hosp Infect. 2004; 56: 29-36. 
 
128 Centrón D, Roy PH. Presence of a group II intron in a multiresistant 
Serratia marcescens strain that harbors three integrons and a novel gene 
fusion. Antimicrob Agents Chemother. 2002; 46: 1402-409. 
 
 
   
180
                                                                                                               
 
129 Quiroga C, Roy PH, Centrón D. The S.ma.I2 class C group II intron 
inserts at integron attC sites. Microbiology. 2008; 154: 1341-53. 
 
130 Ruiz-Martínez L, López-Jiménez L, d'Ostuni V, Fusté E, Vinuesa T, 
Viñas M. A mechanism of carbapenem resistance due to a new insertion 
element (ISPa133) in Pseudomonas aeruginosa. Int Microbiol. 2011; 
14:51-58. 
 
131 D'Costa VM, King CE, Kalan L et al.  Antibiotic resistance is ancient. 
Nature. 2011; 477: 457-461. 
 
132 Schmieder R, Edwards R. Insights into antibiotic resistance through 
metagenomic approaches. Future Microbiol. 2012; 7: 73-89. 
 
133 Russell AD. Antibiotic and biocide resistance in bacteria: introduction. 
Symp Ser Soc Appl Microbiol 2002; 1S-3S. 
 
134 Kyd JM, McGrath J, Krishnamurthy A. Mechanisms of bacterial 
resistance to antibiotics in infections of COPD patients.Curr Drug Targets. 
2011; 12: 521-30. 
 
135 Musk DJ Jr, Hergenrother PJ. Chemical countermeasures for the 
control of bacterial biofilms: effective compounds and promising targets. 
Curr Med Chem. 2006; 13: 2163-77. 
 
136 Hentzer M, Eberl L, Nielsen J, Givskov M. Quorum sensing : a novel 
target for the treatment of biofilm infections. BioDrugs. 2003; 17: 241-50. 
 
137 Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 
2001; 45: 999-1007. 
 
138 Anderl JN, Franklin MJ., Stewart PS. Role of Antibiotic Penetration 
Limitation in Klebsiella pneumoniae Biofilm Resistance to Ampicillin and 
Ciprofloxacin. Antimicrob Agents Chemother. 2000; 44: 1818–1824. 
 
139 Levy SB. Active efflux mechanisms for antimicrobial resistance. 
Antimicrob Agents Chemother. 1992; 36: 695-703. 
 
140 Dechene M, Leying H, Cullmann W. Role of the outer membrane for 
quinolone resistance in Enterobacteria. Chemotherapy. 1990; 36: 13-23. 
 
141 Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes 
bacterial biofilm formation. Appl Environ Microbiol. 2008; 74: 7376-82.  
 
 
 
   
181
                                                                                                               
 
142 Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski 
BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa 
biofilms. Antimicrob. Agents Chemother. 2005; 49: 3858-3867. 
 
143 Lynch SV, Dixon L, Benoit MR, Brodie EL, Keyhan M, Hu P, et.al . 
Role of the rapA gene in controlling antibiotic resistance of Escherichia 
coli biofilms. Antimicrob. Agents Chemother. 2007; 51: 3650-3658. 
 
144 De Kievit TR, Parkins MD, Gillis RJ, Srikumar R, Ceri H, Poole K et 
al. Multidrug efflux pumps: expression patterns and contribution to 
antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. 
Agents Chemother. 2001; 45: 1761-1770 
 
145 Lai S, Tremblay J, Déziel E. Swarming motility: a multicellular 
behaviour conferring antimicrobial resistance. Environ Microbiol. 2009; 1: 
126-36.  
 
146  Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative 
bacteria: The role of high-risk clones in the dissemination of antibiotic 
resistance. FEMS Microbiol Rev. 2011; 35: 736-55 
 
147 Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of 
multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter 
baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006; 55: 
1619-29. 
 
148 Nicolau DP. Carbapenems: A potent class of antibiotics. Expert Opin 
Pharmacother. 2008; 9: 23-37. 
 
149 Livermore DM, Woodford N. The beta-lactamase threat in 
Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 
2006; 14: 413-20. 
 
150 Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular 
epidemiology and mechanisms of carbapenem resistance in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53: 
4783-8. 
 
151 Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. 
Clin Microbiol Infect. 2004; 10: 12-26. 
 
152 Ikonomidis A, Tsakris A, Kantzanou M, Spanakis N, Maniatis AN, 
Pournaras S. Efflux system overexpression and decreased OprD 
contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. 
FEMS Microbiol Lett. 2008; 279: 36-9. 
 
 
   
182
                                                                                                               
 
153 Nakajima A, Sugimoto Y, Yoneyama H, Nakae T. High-level 
fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of 
the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol 
Immunol. 2002; 46: 391-5. 
 
154 Wang DD, Sun TY, Hu YJ. Contributions of efflux pumps to high level 
resistance of Pseudomonas aeruginosa to ciprofloxacin. Chin Med J. 
2007; 120: 68-70. 
 
155 Nemec A, Krizova L, Maixnerova M, Musilek M. Multidrug-resistant 
epidemic clones among bloodstream isolates of Pseudomonas 
aeruginosa in the Czech republic. Res Microbiol. 2010; 161: 234-42. 
 
156 Azucena E, Mobashery S. Aminoglycoside-modifying enzymes: 
Mechanisms of catalytic processes and inhibition. Drug Resist Updat. 
2001; 4: 106-17. 
 
157 Shahcheraghi F, Badmasti F, Feizabadi MM. Molecular 
characterization of class 1 integrons in MDR Pseudomonas aeruginosa 
isolated from clinical settings in Iran, Tehran. FEMS Immunol Med 
Microbiol. 2010; 58: 421-5. 
 
158 Syrmis M, Bell S, Bye P, Coulter C, Harbour C, Iredell J, et al. High 
prevalence of a class 1 integron-associated aadB gene cassette in 
Pseudomonas aeruginosa isolates from an australian cystic fibrosis 
patient population. Pathology. 2008; 40: 524-5. 
 
159 Fonseca EL, Vieira VV, Cipriano R, Vicente AC. Class 1 integrons in 
Pseudomonas aeruginosa isolates from clinical settings in Amazon 
region, Brazil. FEMS Immunol Med Microbiol. 2005; 44: 303-9. 
 
160 Chen J, Su Z, Liu Y, Wang S, Dai X, Li Y, et al. Identification and 
characterization of class 1 integrons among Pseudomonas aeruginosa 
isolates from patients in Zhenjiang, China. Int J Infect Dis. 2009; 13: 717-
21. 
 
161 Abdel Malek SM, Al-Adham IS, Matalka KZ, Collier PJ. Pseudomonas 
aeruginosa PAO1 resistance to zinc pyrithione: Phenotypic changes 
suggest the involvement of efflux pumps. Curr Microbiol. 2009; 59: 95-
100. 
 
162 Nallathamby PD, Lee KJ, Desai T, Xu XH. Study of the multidrug 
membrane transporter of single living Pseudomonas aeruginosa cells 
using size-dependent plasmonic nanoparticle optical probes. 
Biochemistry. 2010; 49: 5942-53. 
 
 
   
183
                                                                                                               
 
163 Mao W, Warren MS, Lee A, Mistry A, Lomovskaya O. MexXY-OprM 
efflux pump is required for antagonism of aminoglycosides by divalent 
cations in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 
2001; 45: 2001-7. 
164 Piddock LJ, Jin YF, Ricci V, Asuquo AE. Quinolone accumulation by 
Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J 
Antimicrob Chemother. 1999; 43: 61-70.  
 
165 Abdel Malek SM, Al-Adham IS, Matalka KZ, Collier PJ. Pseudomonas 
aeruginosa PAO1 resistance to Zinc pyrithione: phenotypic changes 
suggest the involvement of efflux pumps. Curr Microbiol. 2009; 59: 95-
100.  
 
166 Ikonomidis A, Tsakris A, Kanellopoulou M, Maniatis AN, Pournaras S. 
Effect of the proton motive force inhibitor carbonyl cyanide-m-
chlorophenylhydrazone (CCCP) on Pseudomonas aeruginosa biofilm 
development. Lett Appl Microbiol. 2008; 47: 298-302. 
 
167 Abdi-Ali A, Rahmani-Badi A, Falsafi T, Nikname V. Study of antibiotic 
resistance by efflux in clinical isolates of Pseudomonas aeruginosa. Pak J 
Biol Sci. 2007; 10: 924-7. 
 
168 Brown MR, Melling J. Role of divalent cations in the action of 
polymyxin B and EDTA on Pseudomonas aeruginosa. J Gen Microbiol. 
1969; 59: 263-74. 
 
169 Vaara M. Agents that Increase the Permeability of the Outer 
Membrane. Microbiological Reviews. 1992; 395-411 
 
170 Mortensen NP, Fowlkes JD, Sullivan CJ, Allison DP, Larsen NB, 
Molin S, Doktycz MJ. Effects of colistin on surface ultrastructure and 
nanomechanics of Pseudomonas aeruginosa cells. Langmuir. 2009; 25: 
3728-33. 
 
171  Soon RL, Nation RL, Harper M, Adler B, Boyce JD, Tan CH, Li J, 
Larson I. Effect of colistin exposure and growth phase on the surface 
properties of live Acinetobacter baumannii cells examined by atomic force 
microscopy. Int J Antimicrob Agents. 2011; 38: 493-501.  
 
172 Soon RL, Nation RL, Hartley PG, Larson I, Li J. Atomic force 
microscopy investigation of the morphology and topography of colistin-
heteroresistant Acinetobacter baumannii strains as a function of growth 
phase and in response to colistin treatment. Antimicrob Agents 
Chemother. 2009; 53: 4979-86.  
 
   
184
                                                                                                               
 
173 Lauferska U, Viñas M, Lorén JG, Guinea J. Enhancement by 
polymyxin B of proline-induced prodigiosin biosynthesis in non-
proliferating cells of Serratia marcescens. Microbiologica. 1983; 6: 155-62. 
 
174 Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL 
et al. Clinically relevant plasma concentrations of colistin in combination 
with imipenem enhance pharmacodynamic activity against multidrug-
resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents 
Chemother. 2011; 55: 5134-42.  
 
175 Wu M, Maier E, Benz R, Hancock RE. Mechanism of interaction of 
different classes of cationic antimicrobial peptides with planar bilayers and 
with the cytoplasmic membrane of Escherichia coli. Biochemistry. 1999; 
38: 7235-42. 
 
176 Salay LC, Procopio J, Oliveira E, Nakaie CR, Schreier S. Ion channel-
like activity of the antimicrobial peptide tritrpticin in planar lipid bilayers. 
FEBS Letters. 2004; 565: 171-175. 
 
177 Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller 
SI, et al. PhoQ mutations promote lipid A modification and polymyxin 
resistance of Pseudomonas aeruginosa found in colistin-treated cystic 
fibrosis patients. Antimicrob Agents Chemother. 2011; 55: 5761-9.  
 
178 Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller 
AK, et al. PmrB mutations promote polymyxin resistance of Pseudomonas 
aeruginosa isolated from colistin-treated cystic fibrosis patients. 
Antimicrob Agents Chemother. 2012; 56: 1019-30.  
 
179 Muller C, Plésiat P, Jeannot K. A two-component regulatory system 
interconnects resistance to polymyxins, aminoglycosides, 
fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob 
Agents Chemother. 201; 55: 1211-21.  
 
180 Pajatsch M, Anderson C, Mathes A, Böck A, Benz R, Engelhardt H. 
Properties of a cyclodextrin-specific, unusual porin from Klebsiella 
oxytoca. J. Biol. Chem. 1999; 274: 25159-25166. 
 
181 Bong-Hui K, Andersen C and Benz R. Identification of a cell wall 
channel of 
Streptomyces griseus: the channel contains a binding site for 
streptomycin. Molecular Microbiology. 2001; 41: 665–673 
 
182 Matsuzaki K, Mitani Y, Akada KY, Murase O, Yoneyama S, Zasloff M, 
Miyajima K. Mechanism of synergism between antimicrobial peptides 
magainin 2 and PGLa. Biochemistry. 1998; 37: 15144-53. 
 
   
185
                                                                                                               
 
183 Marchler-Bauer A, Anderson JB, Chitsaz F, Derbyshire MK, 
DeWeese-Scott C, Fong JH et al. CDD: specific functional annotation with 
the Conserved Domain Database. Nucleic Acids Res. 2009; 37: 205-210 
 
184 Poissy J, Senneville E. New Antibiotics for Severe ICU-Aquired 
Bacterial Infections. Infect Disord Drug Targets. 2011; 11: 401-12. 
 
185 Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ.  The 
effects of group 1 versus group 2 carbapenems on imipenem-resistant 
Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis.  
2011; 70: 367-372 
 
186 El-Amin N, Giske CG, Jalal S, Keisjser B, Kronvall G, Wretlind B. 
Carbapenem resistance mechanisms in Pseudomonas aeruginosa: 
alterations of porin OprD and efflux proteins do not fully explain resistance 
patterns observed in clinical isolates. APMIS 113: 187-196 
 
187 Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N. 
Constitutive high expression of chromosomal β-lactamase in 
Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) 
located in ampD. Antimicrob Agents Chemother. 2002; 46: 3406-3411 
 
188  Boonkerd N, Pibalpakdi P, Tiloklurs M, Niumsup PR. Class 1 
integron containing metallo β-lactamase gene IMP-1 in 
carbapenemresistant Pseudomonas aeruginosa in Thailand. J Infect 
Chemother. 2009; 15: 257-261 
 
189 Turlan C, Chandler M. IS1-mediated intramolecular rearrangements: 
formation of excised transposon circles and replicative deletions EMBO J. 
1995;  14: 5410-5421 
 
190 Orús P, Viñas M. Transfer of penicillin resistance between Neisseriae 
in microcosm. Microb Drug Resist. 2000; 6: 99-104 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   6. PUBLICATIONS 
 
 
   
 
 







 











 
RESEARCH ARTICLE
Summary. This study explored the evolutionary mechanism by which the clinical isolate PA110514 yields the imipenem-
resistant derivative PA116136. Both isolates were examined by PFGE and SDS-PAGE, which led to the identification of a
new insertion sequence, ISPa133. This element was shown to have distinct chromosomal locations in each of the original iso-
lates that appeared to explain the differences in imipenem susceptibilty. In strain PA110514, ISPa133 is located 56 nucleotides
upstream of the translational start codon, which has no effect on expression of the porin OprD. However, in strain PA116136
ISPa133 it is located in front of nucleotide 696 and, by interrupting the coding region, causes a loss of OprD expression, thus
conferring imipenem resistance. In vitro experiments mimicking the natural conditions of selective pressure yielded imipen-
em-resistant strains in which ISPa133 similarly interrupted oprD. Amechanism is proposed whereby ISPa133 acts as a mobile
switch, with its position in oprD depending on the degree of selective pressure exerted by imipenem. [Int Microbiol 2011;
14(1):51-58]
Keywords: Pseudomonas aeruginosa · protein OprD · carbapenems · imipenem · insertion elements · antimicrobial resistance
Introduction
Infections by Pseudomonas aeruginosa are a serious clinical
problem, particularly in immune compromised hosts in hos-
pital settings [9,29,33]. Moreover, the treatment of these
infections is often difficult because of the limited number of
effective antimicrobial agents, due to the intrinsic resistance
of P. aeruginosa strains and their different modes of growth
[10]. These properties reflect the synergy between the bac-
terium’s low outer-membrane permeability [2,6,38], its chro-
mosomally encoded AmpC β-lactamase [14], and its broadly
specific drug efflux pump [11,17,22,23]. Furthermore, P. ae-
ruginosa readily acquires resistance to most antimicrobials
through mutations in its chromosomal genes and through
extrachromosomal elements carrying resistance determi-
nants [14,25]. Although there are several antimicrobials (car-
bapenems, cefepime, ceftazidime, tobramycin and amikacin)
that continue to be effective against P. aeruginosa, in the last
few years the bacterium’s increasing resistance to many others
has been reported [4,13,18,28,30]. 
Carbapenems are a class of β-lactam antibiotics with
good antimicrobial activity against P. aeruginosa but the
emergence and spread of acquired carbapenem resistance in
this species have challenged the success of therapeutic and
control efforts. Since carbapenems, especially imipenen, are
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widely used in the clinical setting [26], investigation of the
molecular mechanisms leading to resistance is crucial.
Imipenem resistance can involve low permeability, the activ-
ity of an inducible β-lactamase [15], and multidrug efflux
systems, but the most widely accepted mechanism involves
the loss of the porin OprD from the outer membrane [37],
which can occur at the transcriptional or translational level or
through the emergence of mutations in the oprD gene [20].
For example, in one report, the down-regulation of oprD
transcription in clinical isolates of P. aeruginosa was shown
to have occurred by a mechanism involving inactivation of
the gene due to the presence of insertion sequence elements
(IS) [36]. Additional mechanisms of carbapenem resistance
include repressed OprD expression, as is the case in nfxC-
type mutants, which simultaneously overexpress the MexEF-
oprN efflux pump. 
The present study resulted from the isolation of two
strains of P. aeruginosa from the same patient in the course
of a chronic respiratory infection. The first strain was
obtained soon after the patient was admitted to the University
Hospital of Bellvitge (L’Hospitalet, Barcelona, Spain). The
infection was successfully treated with imipenem. The sec-
ond strain was obtained 6 days later, from the patient’s rec-
tum. Pulsed-field gel electrophoresis (PFGE) profiles of the
two isolates were identical, as were the results of biochemi-
cal tests aimed at their identification. However, determina-
tion of antibiotics susceptibility demonstrated that the iso-
lates were identical for all antibiotics tested except imipen-
em: the first isolate was imipenem susceptible whereas the
second was imipenem resistant. Thus, aim of this study was
to search for underlying changes in the isolates’ DNA that
could account for the difference in imipenem susceptibility,
starting from the hypothesis that resistance was mediated by
a loss of OprD expression on the outer membrane. 
Materials and methods
Bacterial strains. The two studied clinical isolates of P. aeruginosa
were isolated from a patient at the Servei de Microbiologia of the Hospital
Universitari de Bellvitge. PA110514 was isolated before imipenem treat-
ment was started, and strain PA116136 after the patient had received the full
course of the antibiotic. P. aeruginosa PA9 was used as the positive control
for amplification of the oprD gene. Strains PA132325 and PA138635, sus-
ceptible and resistant to imipenem, respectively, were used as controls in
preparing extracts of outer membrane proteins (OMPs). P. aeruginosa
strains PAFL2, PAFL4, PAFL8, PAFL12, and PAFL16 are the resistant
mutants obtained in this study. All of the bacterial strains were cultured in
trypticase soy broth (TSB) or on trypticase soy agar (TSA). Bacteriological
media were purchased from Scharlab (Barcelona, Spain). 
Pulsed-field gel electrophoresis. To compare the different strains,
PFGE was carried out as follows: DNA was extracted and purified as
described elsewhere [28,31]. SpeI, a low-frequency restriction enzyme, was
used according to the manufacturer’s specifications (New England Biolabs,
Beverly, MA, USA). The SpeI DNA restriction fragments were separated in
a CHEF-DR III unit (Bio Rad, Hercules, CA, USA) for 20 h at 14ºC and 6
Volts/cm, with pulse times ranging from 0.5 to 25 s. Strain relatedness was
assigned in accordance with published criteria [32]. Pseudomonas aerugi-
nosa PAO1 was used as the control in sequence analysis (accession number
Z14065.1)
Minimum inhibitory concentration (MIC) determinations.
Antimicrobial susceptibility was tested using the microdilution method, with
Mueller-Hinton broth (Scharlab, Barcelona, Spain), according to the guide-
lines of the Clinical and Laboratory Standards Institute (CLSI). The follow-
ing antimicrobials were tested: piperacillin, piperacillin/tazobactam, ticar-
cillin, aztreonam, gentamicin, tobramicin, amikacin, trimethoprim/sulfame-
toxazol, ciprofloxacin, ofloxacin, ceftazidime, cefepime, imipenem, and
meropenem. The antibiotics were purchased from Sigma Chemical Co. (St
Louis, MO, USA).
Outer membrane preparations and SDS-PAGE. Whole bacter-
ial proteins and OMPs were obtained as described elsewhere [24,27]. SDS-
PAGE was performed, using a modification of the method of Laemmli, in a
Bio-Rad apparatus (Mini-Protean II). Gels were stained with 0.25%
Coomassie brilliant blue, destained, and then dried on a gel dryer (Biorad
543) [8,12].
Gene oprD amplification. To obtain P. aeruginosa genomic DNA, 5
ml of Luria broth inoculated with a single colony was incubated overnight at
37°C. Bacteria were harvested by centrifugation and suspended in 180 µl of
ATL buffer from the DNeasy Tissue kit (Qiagen, Germany), which was used
for DNA purification following the manufacturer’s instructions. A modified
version of the PCR assay previously described [36] was used to amplify
oprD. Reaction mixtures had a final volume of 50 µl and contained 2 µl
(1/10th volume) of genomic DNA, 0.5 µM of the OprDSEQF1 forward
primer (5′-CTACGCAGATGCGACATGC-3′), 0.5 µM of the OprDSEQR1
reverse primer (5′-CCTTTATAGGCGCGTTGCC-3′) (Invitrogen, USA), 1 U
of Taq DNA polymerase (Fermentas, Vilnius, Lithuania), 0.2 mM of each
deoxynucleoside triphosphate (Fermentas, Lithuania), 1× PCR buffer, and 2
mM MgCl2. Amplification was achieved in a Techne (Staffordshire, UK)
thermocycler model TC-312 during 25 cycles, each consisting of 30 s at
95°C, 30 s at 56°C, and 2 min at 72°C. Final extension was performed at
72°C for 10 min. PCR products were separated by agarose-gel (1.5% w/v)
electrophoresis in Tris-borate buffer (TBE) at 9 Volts/cm for 1.5 h and visu-
alized using ethidium bromide. 
DNA sequencing and analysis of sequence data. Sequence
data for oprD were obtained by using the primers OprDSEQF1 and
OprDSEQR1. PCR products were purified with the MinElute PCR purifi-
cation kit (Qiagen, Germany) prior to sequencing. The ABI PRISM
BigDye Terminator (version 3.1) Cycle Sequencing Ready Reaction kit
and ABI PRISM(R) 3700 DNA analyzer were used (Applied Biosystems,
USA). Database searches were conducted using the basic local alignment
search tool (BLAST) [1] and multiple alignments carried out with
CLUSTAL W [34]. 
In vitro generation of imipenem-resistant mutants of
Pseudomonas aeruginosa. Approximately 105 P. aeruginosa
PA110514 cells were used to inoculate 20 ml of MHB medium with imipen-
em concentrations ranging from 0.5 to 16 µg/ml. After 24 h of incubation at
37°C, resistant derivatives (MICs = 6–16 µg/ml) were selected by spreading
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0.01 ml of the overnight culture onto MHA plates (Scharlab, Barcelona,
Spain) containing the appropriate concentration of imipenem. Repeated
exposure to the antibiotic was continued with the most resistant derivatives
until an increase in the minimum inhibitory concentration (MIC) of imipen-
em to 16 µg/ml was achieved.
Nucleotide sequences accession numbers. The nucleotide
sequences reported herein have been submitted to GenBank databases. The
accession numbers for the ISPa133 found in strains PA110514 and
PA116136 are FJ387165.2 and FJ387166.2, respectively. 
Results
Minimum inhibitory concentration determina-
tions. Antimicrobial susceptibilities were determined in
MIC tests, with the results shown in Table 1. P. aeruginosa
strain PA110514 was found to be susceptible to all tested
antibiotics while P. aeruginosa strain PA116136 was resistant
to trimethoprim/sulfamethoxazole and imipenem. 
Outer-membrane protein profile. Electrophoretic
comparisons of OMPs from both strains demonstrated, as
expected, that the susceptible strain, P. aeruginosa
PA110514, but not the resistant strain, PA116136, showed a
visible band corresponding to the porin OprD in the outer
membrane (Fig. 1). To investigate the mechanism responsi-
ble for the loss of OprD expression, the oprD genes of both
strains were amplified and sequenced and their sequences
compared. 
Gene oprD amplification. The amplicons obtained
from the oprD gene region of strains PA110514 and
PA116136 were larger than that of strain PA9 used as positive
control (Fig. 2). The predicted length of oprD is 1586 bp,
while the amplicons from PA110514 and PA116136 were
3000 and 2000 bp, respectively. Sequence analysis of both
amplicons revealed the presence of a long insert, approxi-
mately 1300 bp, with a 59.6% G + C content. The insert, des-
ignated ISPa133, showed high homologies with the mobile
elements of the IS3 family of insertion sequences. The simi-
larities were not only in terms of the length of the ISPa133,
which for members of the IS3 family is typically between
1200 and 1550 bp, but due to the presence of two character-
istic open reading frames (ORF), orfA and orfB, which, unusu-
ally, did not overlap (Fig. 3). The insertion element was
flanked by 25-bp terminal inverted repeats (IRs), with TG at
the 5′ end and CA at the 3′ end, as in other members of the
IS3 family. Another general feature of IS elements is that, on
insertion, most generate short directly repeated sequences
(DR) of the target DNA flanking the IS, but these were not
detected in ISPa133.
The first ORF (orfA) encodes a transposase (Fig. 3). In
the search for conserved domains [16], we determined that
CARBAPEM RESISTANCE IN P. AERUGINOSA
Table 1. Susceptibilities to antimicrobial agents tested against Pseudomonas aeruginosa PA110514 and PA116136
Strain  PA110514 Strain  PA116136
Antibiotics MIC* Susceptibility MIC Susceptibility
piperacillin <16 S <16 S
piperacillin/tazobactam <16 S <16 S
ticarcillin <16 S <16 S
aztreonam 2 S 2 S
gentamicin <4 S <4 S
tobramicin <4 S <4 S
amikacin <8 S <8 S
trimethoprim/sulfametoxazol <2/38 S >2/38 R
ciprofloxacin <0.12 S <0.12 S
ofloxacin <0.5 S <0.5 S
ceftazidime <1 S <1 S
cefepime <1 S <1 S
imipenem <1 S >8 R
meropenem <4 S <4 S
*MICs are expressed in µg/ml.
54 INT. MICROBIOL. Vol. 14, 2011
the protein includes a helix-turn-helix motif (HTH), a family
of DNA-binding domains unique in bacteria, and that it
showed high identity to the transposase 8 family, some of
which are members of the IS3 family. The second ORF, orfB,
encodes the central catalytic domain of an integrase from the
rve super-family [http://pfam.sanger.ac.uk/family PF00665].
Integrase mediates the integration of a DNA copy of the viral
genome into the host chromosome. The enzyme is composed
of three domains. The amino-terminal zinc-binding domain
(pfam02022) is the central catalytic domain. The carboxyl
terminal domain is a non-specific DNA binding domain
(pfam00552). The catalytic domain acts as an endonuclease
when two nucleotides are removed from the 3′ ends of the
blunt-ended viral DNA resulting from reverse transcription.
This domain also catalyzes the DNA-strand-transfer reaction
of the 3′ ends of the viral DNA to the 5′ ends of the integra-
tion site. 
While the large insert located in PA116136 was 99%
identical to that found in PA110514, its location in oprD was
different. In PA110514, ISPa133 was located 56 nucleotides
upstream of the translational start codon, but in PA116136 it
occurred immediately before nucleotide position 697, effec-
tively replacing this nucleotide and causing the removal of
the first 232 amino acids of the porin OprD (Fig. 4). 
In vitro generation of imipenem-resistant
mutants of Pseudomonas  aeruginosa. Repeated
exposure of P. aeruginosa PA110514 to imipenem allowed
the selection of several defective OprD mutants. When oprD
was amplified using DNA from cultures resistant to imipen-
RUIZ-MARTÍNEZ ET AL.
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Fig. 1. Outer membrane protein profiles. Black arrows indicate the position of OprD. Lane 1: SDS-PAGE standards, (Low
Range, Bio-RAD, USA); lane 2: strain PA110514; lane 3: strain PA116136; lane 4: strain PA138635 (imipenem-resistant
control); lane 5: strain PA132325 (imipenem-susceptible control).
Fig. 2. PCR amplification products obtained with primers OprDSEQF1
and OprDSEQR1. Fragments were separated by electrophoresis through
a 1.5% agarose gel. Lane 1: GeneRuler 1 kb DNA Ladder (Fermentas,
Vilnius, Lithuania). Lane 2: strain PA110514. Lane 3: strain PA116136.
Lane 4: strain PAFL2. Lane 5: strain PAFL4. Lane 6: strain PAFL8.
Lane 7: strain PAFL12. Lane 8: strain PAFL16. Lane 9: strain PA9, used
as positive control.
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em concentrations 2, 4, 8, 12, and 16 times higher than the
MIC value for PA110514, an amplicon of 2000 bp was
obtained, i.e., identical in size to the amplicon of the resistant
clinical isolate PA116136. Sequencing of the amplicon
revealed the presence of ISPa133. The position of the inser-
tion element in the mutants was not the same as in PA110514
and PA116136. In the mutant strain PAFL2, ISPa133 was
located immediately before nucleotide position 667, replac-
CARBAPEM RESISTANCE IN P. AERUGINOSA
Fig. 3. Nucleotide sequence of de novel IS3-like element, ISPa133, present in strain PA110514 and its proposed derivative PA116136. The underlined
sequences represent the 25-bp inverted repeats (IRs). Bold letters within the IRs indicate mismatches between left and right IRs. Translational start and stop
codons of both orfs encoded by the mobile element are boxed; the amino acid sequence of the two open reading frames are shown below the sequence.
Shaded regions represent the sequence of the oprD gene flanking the IS element. 
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ing the first 222 amino acids of the porin, but in PAFL4 and
in the rest of resistant strains, it was located just before
nucleotide 703, causing the removal of the first 234 amino
acids of OprD (Fig. 4).
Discussion
Carbapenems are a class of β-lactam antibiotics with good
antimicrobial activity against P. aeruginosa; as such, they are
often used as a last resort in infections due to multidrug-
resistant strains of the bacterium [21]. However, the emer-
gence and spread of acquired carbapenem resistance have
challenged therapeutic and control efforts [5], necessitating a
better understanding of the molecular mechanisms underly-
ing resistance. Moreover, it seems likely that several mecha-
nisms are involved in carbapenem resistance [7]. 
The two clinical isolates of this study, PA110514 and
PA116136, were identical in their PFGE profiles and in bio-
chemical tests, suggesting their close relationship. The
unique noticeable difference between the isolates was in their
susceptibility to imipenem. Our hypothesis, that this differ-
ence involved the OMPs, was supported by the results of
SDS-PAGE, which revealed the loss of OprD in PA116136
(Fig. 1) and suggested that this strain was a PA110514 deriv-
ative. To investigate the mechanism responsible for the loss
of the porin, the oprD gene of each strain was amplified and
sequenced. Examination of these sequences revealed the
presence of a new insertion sequence, ISPa133, located 56
nucleotides upstream of the oprD start codon in PA110514.
However, since this isolate is imipenem-susceptible, the
presence of ISPa133 has no obvious effect on the upstream
regulatory region of the gene, as oprD expression was normal
(Fig. 1) as was the expression of the porin OprD. By contrast,
in PA116136, the insertion element (99% identity) is located
immediately before nucleotide position 696, which causes
the removal of the first 232 amino acids of OprD.
Consequently, the protein is not expressed and was not
detectable in the gels (Fig. 1). Since loss of the protein pre-
vents the entrance of imipenem, strain PA116136 is resistant
to the antibiotic.
To date, the presence of ISs in OprD has been reported
only once , although these elements have been detected in
other genes of P. aeruginosa [3,4,28]. In those cases, the ISs
were described in resistant isolates and thus assumed to be
the cause of resistance, either via gene activation or by induc-
ing the high level expression of a potential resistance gene.
Based on the findings in the two clinical isolates analyzed in
this study, we propose that the newly identified insertion ele-
ment ISPa133 acts as a switch, depending on the degree of
selective pressure exerted by imipenem. In the absence of
selective pressure, as was the case during isolation of strain
PA110514 from an infected, untreated patient, OprD is found
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Fig. 4. Schematic diagram of the locations of the ISPa133 element with respect to the oprD gene. The solid arrow represents the oprD
structural gene while the striped arrow represents ISPa133.
57INT. MICROBIOL. Vol.14, 2011
on the OM and the position of ISPa133 in the genome has no
effect on oprD expression; however, selective pressure exerted
by antibiotic therapy results in the selection of strains in
which ISPa133 moves within the oprD gene, such that, in the
case of strain PA116136, the first 232 amino acids are
removed, thus preventing expression of the gene. A high rate
of ISPa133 jumping would therefore provide a major selec-
tive advantage, one that allows the bacterium to survive in
the presence of carbapenems.
It has been proposed that ISs without DRs may simply
result from the homologous inter- or intra-molecular recom-
bination between two IS elements, each with a different DR
sequence, or from the formation of adjacent deletions arising
from duplicative intramolecular transposition [35]. For
ISPa133, this could explain the lack of DRs as well as the
absence of a crossover region between orfA and orfB.
As shown in other species, experiments mimicking natu-
ral conditions can provide insight into population phenome-
na [19]. This was the aim of our experiments in which strain
PA110514 was submitted to selective pressure by imipenen
in culture flasks in order to obtain spontaneous resistant
mutants in vitro with properties similar or identical to those
of the strains isolated from a patient hospitalized with a P. ae-
ruginosa infection. Indeed, mutants with levels of resistance
similar to those of strain PA116136 were easily recovered.
Moreover, when the experiments were prolonged, the MICs
of the isolates were even higher (16 µg/ml). 
Note that, according to the above-proposed mechanism of
action, removal of the selective pressure exerted by the
antibiotic should restore bacterial susceptibility to carbapen-
ems through the expression of the full-length OprD; whether
this is the case remains to be determined. However, this
change would not be expected to occur as quickly as the
acquisition of resistance, since the selective advantage con-
ferred by imipenem resistance in the presence of the antimi-
crobial is severe whereas OprD expression is likely to be
evolutionarily advantageous only under certain environmen-
tal conditions. 
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The prevalence of Gram-negative multidrug-resistant Pseudomonas 
aeruginosa (MDRPA) has increased in recent years. Clonal 
dissemination of this antibiotic-resistant pathogen is a major 
concern worldwide. The aim of this study was to explore 
carbapenem mechanisms leading to this resistance in an endemic 
clone. Outer membrane proteins were resolved in SDS-PAGE 
electrophoresis after outer membranes isolation. A bioassay 
method was used to measure meropenem accumulation depending 
on bacterial shape (bacilli or filaments). PCR was used for class 1 
integron detection. Efflux pumps were studied for several 
antimicrobial agents and synergic combinations in the presence or 
absence of Phe-Arg-ß-naphthylamide (PAßN) at a final concentration 
of 40 µg/mL. MDRPA showed a reduction of OprD porin in OMP 
electrophoretic profiles. Accumulation of meropenem was 15% 
higher in bacilli than in filaments. All the strains had a class 1 
integron with a cassette encoding aminoglycoside 
adenyltransferase B (aadB). Overexpression of the efflux pump 
MexAB-OprM and a functional MexXY-OprM were detected in all the 
strains explored.  
 
Key words: Multidrug-resistant Pseudomonas aeruginosa (MDRPA), 
carbapenem resistance, OprD, integrons, morphological changes and 
efflux pumps.  
  
 
 
Introduction  
Pseudomonas aeruginosa is a major nosocomial pathogen worldwide. It 
causes several infections, such as wound and burn infections as well as 
respiratory tract infections that mostly affect cystic fibrosis patients. 
Moreover, increasing prevalence of infections caused by multidrug-
resistant isolates has been reported in many countries and is now a 
cause of concern [1, 2]. Some of the classic antimicrobial drugs used to 
treat these pathogens are out of date and bacterial mechanisms of 
resistance have already affected the efficacy of several of the newly-
available drugs [3]. High-level antibiotic resistance in P. aeruginosa 
involves several mechanisms including overexpression of active efflux 
systems, the production of modifying enzymes, a decrease in outer 
membrane permeability and structural alterations of topoisomerases II 
and IV which are involved in quinolone resistance [4]. 
One of the main mechanisms of carbapenem resistance in P. aeruginosa 
is the reduction of outer membrane permeability through alterations in or 
decreased production of outer membrane protein OprD. This outer 
membrane porin allows entry of carbapenems, especially imipenem, into 
the cell [5].  
While imipenem does not have any influence on the bacterial shape of P. 
aeruginosa, meropenem, at high concentrations it induces the formation 
of bacterial filaments. Previous in vitro studies have shown that 
morphological changes induced by meropenem in P. aeruginosa depend 
on the concentration and the exposure period [6, 7]. Furthermore, Horii et 
al. [8] demonstrated that meropenem induces the release of greater 
amounts of endotoxin than other carbapenems. This phenomenon is 
correlated with bacterial shape just before cell lysis. We measure the 
accumulation of meropenem in cells depending on the cell shape.  
In P. aeruginosa, resistance to carbapenems, other ß-lactam antibiotics 
and aminoglycosides, has been strongly related to enzyme production. 
Production of the following enzymes is particularly noteworthy: ß-
lactamase such as AmpC ß-lactamase, class A carbenicillin hydrolyzing 
  
 
 
ß-lactamases (PSE-1 (CARB-2); PSE-4 (CARB-1); CARB 3 and CARB-
4)), class A ESBLs (TEM, SHV, PER, VEB, GES/IBC and BEL types), 
class D ß-lactamases (oxacillinases), carbapenemases or MBLs (IMP, 
VIM, SPM and GIM types) and aminoglycoside-modifying enzymes or 
AMEs (APHs, AADs or ANTs and AACs). Some of the antibiotic resistant 
genes found in multidrug-resistant P. aeruginosa (MDRPA) had been 
reported to occur as a cassette carried by class 1 integron [9]. The 
current study explored the presence of these genetic elements that 
contribute actively to the dissemination of resistance determinants to 
aminoglycosides and ß-lactams among gram-negative species, and 
notably among P. aeruginosa multi-resistant isolates.  
Other mechanisms are needed in addition to outer membrane barrier low 
permeability, hydrolysis by ß-lactamase and genetic elements to explain 
the intrinsic and acquired resistance in P. aeruginosa. Multidrug efflux 
makes a major contribution to the resistance of gram-negative bacteria. 
Several studies with clinical isolates including epidemic clones support 
the role of the drug efflux pumps in multidrug-resistant (MDR) strains [10, 
11]. Moreover, elevation of their expression levels can frequently produce 
high levels of antibiotic resistance [12]. 
The ten P. aeruginosa pumps (excluding the metal cation transporters) 
that belong to the resistance–nodulation–division (RND) family are: 
MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY, MexJK, MexGHI-
OpmD, MexVW, MexPQ-OpmE, MexMN, and TriABC [10, 11]. 
Nowadays, a new molecular route for fighting against the increasing 
problem of antibiotic efflux is via efflux pump inhibitors (EPIs) to block 
efflux and restore drug susceptibility to resistant clinical strains. The 
recently discovered inhibitor PAßN, which is highly effective against P. 
aeruginosa efflux mechanisms, has an interesting efflux-inhibitory 
capacity associated with a reversal of fluoroquinolone resistance and has 
potent broad-spectrum activity [13-15]. Some of the mechanisms leading 
to resistance in four multidrug-resistant P. aeruginosa belonging to an 
endemic clone at the Hospital del Mar (Barcelona) were studied. 
  
 
 
Materials and methods 
Bacterial strains, media and antibiotics 
Four MDRPA isolates belonging to an endemic clone selected between 
2005 and 2008 in Hospital del Mar (Barcelona, Spain) were considered. 
These clinical strains were isolated from a blood culture, urine, a surgical 
wound and sputum. P. aeruginosa ATCC 27853 was also used as a test 
strain. 
Ceftazidime, ciprofloxacin and the EPI, Phe-Arg-naphthylamide (MC-
207,110, also termed PAßN) were purchased from Sigma Chemical Co. 
(St Louis, MO, USA). Meropenem was from Astra Zeneca UK Ltd. 
(Macclesfield, UK), imipenem was from Merck (Rahway, NJ, USA) and 
tobramycin was obtained from Fagron Iberica, S.A.U (Barcelona, Spain). 
All the bacteriological media were obtained from Scharlab (Barcelona, 
Spain). 
Drug susceptibility testing 
Susceptibility to antimicrobial agents was determined using the broth 
microdilution method in Mueller-Hinton broth as recommended by the 
CLSI and expressed as MIC (minimal inhibitory concentration) [16]. The 
breakpoints were those recommended by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) [17]. 
Outer membrane (OM) isolation 
Outer membranes were isolated from 100 mL of stationary-phase 
cultures. The cells were harvested, and the cell pellet resuspended in a 
30 mL of Ringer 1/4. The cells were centrifuged at 6,000 x g at room 
temperature for 15 min and the pellet was resuspended in 30 mL HEPES 
10 mM pH 7.4. Bacterial cells were disrupted at a pressure of 30 kPa 
(constant cell disruption systems) followed by a sedimentation of whole 
cells at 3,000 x g for 15 min at 21ºC. Sedimentation of whole membranes 
was performed at 60,000 x g for 90 min at 21ºC.  
  
 
 
The pellets were resuspended in 2 mL of SLS 1% in HEPES 10 mM pH 
7.4, and the suspensions were incubated at room temperature for 20 min. 
Sedimentation of the outer membranes was performed at 60,000 x g for 
60 min and the pellets were resuspended in sample buffer.  
Proteins were resolved by SDS-PAGE electrophoresis following a 
modification of the Laemmli method. Outer membrane proteins (OMPs) 
were compared with a size standard marker purchased from Bio-Rad 
(Hercules, CA, USA).  
Bioassay for the measurement of meropenem accumulation  
Long rods of Pseudomonas aeruginosa formed in the presence of four 
times the MIC and short rods from cultures without an antibiotic were 
washed with PBS pH 7.4 and resuspended in 30 mL of the same buffer. 
The total protein in both samples was measured using a Pierce BCA 
Protein Assay Kit (Thermo Scientific, Rockford, USA).  
Meropenem was added while the cells were centrifuged at 20,000 x g for 
1 min. The supernatant was used for the measurement of the 
meropenem that did not penetrate the cells.  
Measurements were taken using a meropenem susceptible strain of 
Escherichia coli. The standard curve ranged from 25 to 0 ng/mL of 
meropenem. After incubation of the samples at 37ºC for approximately 2 
hours, the optical density at 550 nm was measured.  
Detection of class 1 integrons and PCR amplification 
Bacteria were grown in 4 mL of brain heart infusion (BHI; Difco, Detroit, 
MI, USA)-10% glycerol at 30 ºC overnight. Then, 200 µl was added to 
800 µl of distilled water and boiled for 10 min. The bacterial suspension 
was then centrifuged at 12,000 x g for 2 min, and the supernatant was 
used for PCR. 
PCR was performed in 100-µl volumes containing 30 µl of template DNA 
and 70 µl of the mix (2.5 pmol oligonucleotides, 1 U Taq DNA 
polymerase, 200 µM deoxynucleoside triphosphate, 3 mM MgCl2, 10 mM 
Tris-HCl pH 8, 50 mM KCl, 0.001% gelatin and distilled water). The 
  
 
 
primers used were those reported by Lévesque et al. [18]. All the PCR 
products used were purchased from Fermentas (Vilnius, Lithuania) 
except the primers, which were purchased from Invitrogen (Camarillo, 
CA, USA). To amplify the DNA in the thermal cycler, we used a three-
step profile: 1 min of denaturation at 94ºC, 1 min of annealing at 55ºC, 
and 5 min of extension at 72ºC for a total of 35 cycles. All completed 
reactions were maintained at 4ºC. The PCR products were visualized 
using 0.7% agarose gel electrophoresis (85 V for 2 h). The gels were 
stained with ethidium bromide.  
DNA sequencing and submission 
MinElute PCR Purification Kit (Qiagen, Crawley, UK) was used to purify 
the PCR products obtained for integron variable regions (IVRs). The 
purified amplicons were sequenced using the ABI PRISM BigDye® 
Terminator version 3.1 Cycle Sequencing Ready Reaction Kit and ABI 
PRISM(R) 3700 DNA Analyzer (Applied Biosystems, Foster City, CA, 
USA).  
The sequences were compared using online blast software 
(http://www.ncbi.nlm.nih.gov/BLAST/). 
Study of efflux pump-mediated fluoroquinolone resistance   
To establish the prevalence of efflux pump-mediated fluoroquinolone 
resistance in the MDRPA strains, MICs were determined in 96-well 
microtiter plates using a twofold standard broth microdilution method [19] 
in Mueller-Hinton broth either with or without a fixed concentration of EPI 
Phe-Arg-naphthylamide (PAßN) as described by Kriengkauykiat et al. 
[15]. 
Ciprofloxacin was tested at 11 concentrations (128-0.25 µg/ml) and PAßN 
at 40 µg/ml, based on previous studies [14]. A confirmation test was also 
performed during our research. 
 
 
 
  
 
 
Detection of a functioning MexXY-OprM efflux pump  
To detect the presence of a functioning MexXY-OprM efflux pump in the 
MDRPA strains, the MIC of aminoglycoside tobramycin was determined 
in 96-well microtiter plates using a twofold standard broth microdilution 
method in Mueller-Hinton broth in the absence and in the presence of 40 
µg/mL of PAßN [20]. 
Effect of the efflux pump inhibitor PAßN on ceftazidime and 
meropenem MICs alone and in combination with tobramycin 
A checkerboard titration assay was performed to assess the interaction 
between ceftazidime and meropenem plus tobramycin (concentrations 
ranging from 0 to 128 µg/ml), alone and in combination with 40 µg/mL of 
PAßN.  
 
 
  
 
 
Results  
Drug susceptibility testing 
MIC data for the ATCC 27853 and MDRPA strains for several 
antimicrobial agents are shown in Table 1. Clinical breakpoints are listed 
below the table in accordance with the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) recommendations [17]. 
Analysis of outer membrane proteins (OMPs) 
OMPs were analyzed in all the strains. No great differences in OMP 
electrophoretic profiles were observed between the MDRPA strains and 
ATCC 27853. MDRPA showed a reduction of OprD porin (46 kDa) in 
comparison to ATCC 27853 (Fig. 1). This protein is a specific porin which 
facilitates the uptake of basic amino acids and imipenem [21]. 
Bioassay for measuring meropenem accumulation  
In the presence of high-concentration (4xMIC) meropenem, P. 
aeruginosa was able to survive in long, undivided rods; when the 
meropenem antibiotic pressure was eliminated, the rods returned to their 
original shape. (Fig. 2) 
Accumulation of meropenem was 15% superior in short rods than in long 
ones. Therefore, accumulation of meropenem revealed marked 
differences between regular bacilli and filaments.  
Detection of class 1 Integrons  
PCR amplification from all MDRPA endemic clones yielded a product of 
750 bp (Fig. 3). The class 1 integrons mapped from all the MDRPA 
strains were identical and carried only one resistance gene involved in 
aminoglycoside resistance (Fig. 4). 
The cassette contained the aadB (also called ant(2″)-Ia) aminoglycoside 
resistance gene that confers gentamicin, kanamycin and tobramycin 
resistance. 
  
 
 
Efflux pump-mediated fluoroquinolone resistance   
All the strains had a ciprofloxacin MIC of 64 mg/L and were interpreted as 
resistant according to EUCAST [17]. The efflux pump overexpressed 
phenotype (EPO) was defined with at least a twofold decrease in 
ciprofloxacin MIC when tested in the presence of the EPI PAßN [22] and 
was observed in all the MDRPA strains. Table 2 shows the decrease in 
ciprofloxacin MIC in the presence of 40 mg/L the EPI PAßN. 
Detection of a functioning MexXY-OprM efflux pump  
All the MDR strains, which had a high tobramycin MIC, showed 
outstanding antagonism in the presence of 40 µg/mL of the EPI, PAßN. 
There was a minimum 8-fold increase in tobramycin MIC when combined 
with this EPI (Table 2).  
Effect of PAßN on ceftazidime and meropenem MIC alone and in 
combination with tobramycin 
A trivial reduction in ceftazidime and meropenem MICs was observed in 
the presence of PAßN. Regardless of the ß-lactam concentration, the 
combination of tobramycin and ceftazidime or meropenem presented 
similar antagonism in the presence of PAßN (Table 2).  
Discussion 
P. aeruginosa is considered one of the more problematic drug-resistant 
pathogens, and many strains have developed resistance to multiple 
drugs, probably due to the large amount of antibiotics used to treat 
humans, farm animals and in aquiculture [23, 24]. It is extremely 
important to control the spread of multiresistant bacteria to avoid 
infections, increase the treatments that are available for patients and 
reduce patient mortality [25]. Table 1 shows that the four P. aeruginosa 
strains used presented high resistance to all the antimicrobial drugs 
tested in the present study and were therefore considered as MDRPA, 
i.e., resistant to at least three different classes of antimicrobial agents, 
  
 
 
mainly aminoglycosides, carbapenems, antipseudomonal penicillins, 
quinolones, and cephalosporins [26]. 
Carbapenems, such as meropenem and imipenem, are potent 
antimicrobial agents of infections due to MDRPA isolates. These 
antibiotics bind to critical penicillin-binding proteins, disrupting the growth 
and structural integrity of bacterial cell walls. They provide better 
anaerobic and Gram-negative coverage than other beta-lactams and 
their stability against extended-spectrum beta-lactamases (ESBLs) 
makes them an effective treatment option. Both antibiotics have broad-
spectrum activity, including activity against non-fermenting and Gram-
negative bacteria.  
However, among non-fermenting Gram-negative bacteria, resistance to 
imipenem and meropenem is increasing [27]. Several mechanisms that 
confer P. aeruginosa resistance to carbapenems have been reported, 
such as diminished permeability, overexpression of the intrinsic efflux 
systems and production of carbapenem hydrolyzing ß-lactamases [28].  
Additionally, the observation that P. aeruginosa survives in the presence 
of high concentrations of meropenem (4xMIC) by forming long undivided 
rods and its subsequent return to the original shape when the pressure 
was eliminated suggests that accumulation of meropenem probably 
differs depending on bacterial shape. 
Our study revealed marked differences between regular bacilli and 
filaments. 
These morphological changes could contribute to explaining the lack of 
success of antibiotic treatments, since long rods can survive treatment 
and become an origin of recidivisms when “normal” morphology is 
restored. 
The reduction of OprD porin seen in all of the endemic clones compared 
to the wild-type strain (ATCC 27853) could be related with the decreased 
susceptibility to both imipenem and meropenem [4]. However, it is difficult 
to measure the quantitative role of the OM and their porins when an 
antibiotic is applied in vivo, since both the bacterial physiological states 
and the OM protein expression strongly depend on the environmental 
  
 
 
conditions [29]. Rodríguez-Martínez et al. [30], reported that OprD gene 
downregulation and OprD protein inactivation contributed to resistance to 
imipenem and reduced susceptibility to meropenem. Whereas OprD 
inactivation alone is the source of intermediate susceptibility or resistance 
to imipenem, the mechanisms leading to meropenem resistance seem to 
be more complex and are very likely multifactorial, involving 
overproduction of AmpC or overexpression of the efflux pumps MexAB-
OprM, MexXY-OprM, and MexCD-OprM. The efflux systems MexAB-
OprM and MexXY-OprM directly affect meropenem activity in P. 
aeruginosa [31]. Ikonomidis et al. [32] found that heterogeneous 
populations had upregulation of efflux with increased levels of 
transcription of mexB and mexY genes and low intensity of oprD protein 
band (46 kDa) compared to native populations [4]. The aforementioned 
strains also produced OXA-1 and OXA-2 enzymes, which contribute to 
carbapenem resistance. (Segura et al., unpublished data).  
Our results from the study of efflux pumps using the EPI, PAßN 
suggested that all the MDRPA strains belong to a phenotype that 
overexpresses MexAB-OprM and contain a functioning MexXY-OprM 
efflux pump. However, structural changes in target enzymes and active 
efflux are the major mechanisms that lead to fluoroquinolone resistance 
in P. aeruginosa. Moreover, overexpression of MexXY-OprM has been 
related with carbapenem resistance. Mao et al. [20] demonstrated that 
PAßN antagonizes the activity of aminoglycosides only in strains that 
contained a functioning MexXY-OprM efflux pump, and the degree of 
antagonism was higher in strains with an elevated level of MexXY-OprM 
expression.  
Furthermore, two mutations were found in the strains studied, one in parC 
and one in gyrA (Segura et al., unpublished data). These results correlate 
with quinolone resistance in Enterobacteriaceae being generally caused 
by a cooperative effect between mutations in the genes gyrA and parC 
and efflux pumps, mostly acrAB [4, 33, 34, 35]. 
The multiple resistance mechanism of P. aeruginosa is extremely 
complicated, and many mechanisms are involved on it, including 
  
 
 
integrons and gene cassette-mediated resistance [36]. Class 1 integrons 
have been strongly associated with the presence of MDRPA, as 
indicated by the fact that all the isolates that are not susceptible to less 
than three agents were intI1-negative, whereas almost all those non-
susceptible to more than two agents were intI1-positive [37]. 
All of the MDRPA strains examined, which belong to serotype O4, had a 
class 1 integron with the gene cassette array aadB. The aadB product is 
aminoglycoside (2”) adenylyltransferase (ANT(2”)-Ia), associated with 
resistance to kanamycin, gentamicin, and tobramycin [38]. 
This type of integron was previously found in our laboratory in some 
clinical P. aeruginosa strains from Bellvitge Hospital, in Barcelona [39], 
however, this kind of integron has not only been found in Spain. In a 
recent study from Iran, 78% of a number of 41 MDRPA isolates from five 
hospitals had an integron containing the aadB gene and amplifications of 
internal variable regions (IVRs) of class 1 integrons confirmed a high 
prevalence of class 1 integrons with limited diversity of gene cassette 
arrays including aadB, aadA6–orfD, and blaOXA10–aacA4 [40].   
Syrmis et al. observed a high prevalence of the class 1 integron-
associated aadB gene cassette in P. aeruginosa isolates from an 
Australian cystic fibrosis patient population. However, some of the 
strains that possessed the aadB gene were tobramycin sensitive. Thus, 
position of the aadB gene alone does not confer tobramycin resistance 
[41]. In Brazil, 106 P. aeruginosa clinical isolates were analyzed and 
none of the class 1 integrons detected had the aadB gene cassette [42].  
Other studies showed that some class 1 integrons with more than one 
gene of resistance also contained the aadB gene. For instance, many 
MDRPA isolates (serotype O4) from various hospitals in the Czech 
Republic and Hungary shared an integron variable region with the gene-
cassette array of aadB-aadA13, which may indicate recent international 
dissemination. In China and Iran, several P. aeruginosa clinical isolates 
had the aadB gene cassette array [37, 40, 43].  
Although integron associated gene cassettes harbored by P. aeruginosa 
can vary between different geographic locations [41], it is important to 
  
 
 
take clonal dissemination of the MDRPA strains into account and 
establish effective measures to prevent their transmission. In addition to 
integrons, multiresistant bacteria serve as hosts for other genetic 
elements such as transposons and plasmids. These elements are 
involved in the development of antibiotic resistance phenotypes and 
consequently bacteria that contain these elements could be extremely 
effective vehicles for the dissemination of these resistance elements 
[25]. 
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Table 1. MICs (mg/L) of ATCC 27853 and MDRPA strains determined by 
a microdilution method.  
 
 Strains  
Drug Family  459 133 162 527 ATCC 
27853 
  MIC (mg/L) 
Meropenem Carbapenem 8 8 8 8 1 
Imipenem Carbapenem 8 8 8 8 2 
Ciprofloxacin Fluoroquinolone 64 64 64 64 0.5 
Tobramycin Aminoglycoside 32 64 64 64 0.5 
Ceftazidime  Cephalosporin 128 64 64 64 4 
 
Clinical breakpoints, according to European Committee on Antimicrobial Susceptibility 
Testing (EUCAST): Meropenem, susceptible ≤2 mg/L, resistant >8 mg/L; Imipenem, 
susceptible ≤4 mg/L, resistant >8 mg/L; Ciprofloxacin, susceptible ≤0.5 mg/L, resistant >1 
mg/L; Tobramycin, susceptible ≤4 mg/L, resistant >4 mg/L; Ceftazidime, susceptible ≤ 8 
mg/L, resistant >8 mg/L. 
 
 
Figure 1. SDS-PAGE analysis of Outer Membrane Proteins (OMPs) of P. aeruginosa. 
Positions of molecular mass standards in KDa are shown on the left. Position of OprD is 
indicated by arrows on the left. 
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Figure 2. Effects of high-concentration (4xMIC) meropenem on P. aeruginosa cell shape. 
(A) P. aeruginosa rods grown without antibiotic. (B) P. aeruginosa rods grown with 4xMIC of 
meropenem. (C) P. aeruginosa rods after elimination of antibiotic pressure.  
 
 
Figure 3. PCR amplification, using the 5’-CS and 3’-CS primers, of variable regions of 
integrons from MDRPA isolates. The PCR products were separated by electrophoresis in 
0.7% agarose. Lane 1, 1-kb DNA ladder; lane 2, P. aeruginosa 459; lane 3, P. aeruginosa 
162; lane 4, P. aeruginosa 527 and lane 5, P. aeruginosa 133.  
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Figure 4. Schematic representation of a class 1 integron with an aadB gene cassette; 
arrows show direction of transcription of genes. 
 
 
Figure 5. Effects of inhibition of efflux by the efflux pump inhibitor PAßN on ciprofloxacin 
susceptibility; all the strains were tested over the same range of ciprofloxacin 
concentrations (0.125 to 128 µg/ml) with and without PAßN, and showed a 4-fold decrease 
in MIC with the EPI. 
 
 
Figure 6. Effects of the efflux pump inhibitor PAßN on tobramycin susceptibility; all the 
strains were tested over the same range of tobramycin concentrations (0.25 to 256 µg/ml), 
and showed antagonism with the PAßN.  
 
Table 1. MICs (mg/L) of ATCC 27853 and MDRPA strains determined by microdilution 
method.  
 
3’-CS  
         intI1          aadB        orf5  qacE∆1  sul1 
5’-CS  
variable region 
  
 
 
 
 Strains  
Drug Family  2404459 1449133 2908162 1169527 ATCC 
27853 
  MICs (mg/L) 
Meropenem Carbapenem 8 8 8 8 1 
Imipenem Carbapenem 8 8 8 8 2 
Ciprofloxacin Fluoroquinolone 64 64 64 64 0.5 
Tobramycin Aminoglycoside 32 64 64 64 0.5 
Ceftazidime  Cephalosporin 128 64 64 64 4 
 
Clinical breakpoints according to European Committee on Antimicrobial Susceptibilities 
Testing (EUCAST): Meropenem, susceptible ≤ 2 mg/L, resistant >8 mg/L; Imipenem, 
susceptible ≤ 4 mg/L, resistant >8 mg/L; Ciprofloxacin, susceptible ≤ 0.5 mg/L, resistant > 1 
mg/L; Tobramycin, susceptible ≤ 4 mg/L, resistant > 4 mg/L; Ceftazidime, susceptible ≤  8 
mg/L, resistant > 8 mg/L; 
 
 
Table 2. MICs of synergic combinations of antibiotic with and without PAßN 
  
PA110514   PA116136 
 
Before imipenem  
treatment  
After imipenem 
treatment and before 
passages without 
antibiotic 
 
After 30 passages 
without antibiotic 
Antibiotics MIC (µg/mL) Suscept.  
MIC 
(µg/mL) Suscept.  
MIC 
(µg/mL) Suscept. 
Tobramycin  0.5 S   0.5 S  0.5 S 
Gentamicin  0.5 S  1 S  1 S 
Meropenem  4 S  4 S  4 S 
Ciprofloxacin 0.12 S  0.12 S  0.12          S 
Ceftazidime  1 S  1 S  1 S 
Imipenem  4 S  16 R  16 R 
Colistin 0.5 S   1 S   1 S 
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Abstract.  Therapeutic options to fight against infections caused by multiresistant (MR) Pseudomonas aeruginosa
strains are restricted to a few antimicrobials such as colistimethate and amikacin. The purpose of this study was to compare 
in vitro synergy testing by epsilometric (E-test) and the checkerboard (CB) methods with time-kill analysis in MR P. 
aeruginosa clinical isolates. Four isolates belonging to a MR endemic clone were selected. Their resistance mechanisms 
were studied. Susceptibility to ceftazidime (CAZ) and meropenem (MEM) in combination with tobramycin (TOB) and 
ciprofloxacin (CIP) were tested. Synergy was consistently detected in CAZ plus TOB as well as in MEM plus TOB com-
binations. The E-test method was comparable to CB method. Synergy and bactericidal activity were observed at 1/4 or 1/8 
MIC TOB concentration combined with 1 MIC of CAZ or 1 MIC of MEM by time kill curves, with slight differences in 
the two isolates tested. These findings indicate the possibility of designing therapies based on combinations of a -lactam 
and an aminoglycoside as a therapeutic option in infections caused by MR P. aeruginosa. 
Keywords  Pseudomonas aeruginosa, synergy, time-kill, FICI, SPBI 
1. Introduction 
Pseudomonas aeruginosa is naturally resistant to a 
wide variety of antimicrobials and can easily become 
resistant to many more; this constitutes a serious and 
growing therapeutic challenge, particularly in hospital 
setting. In addition, the natural capacity of P. aerugi-
nosa to survive in adverse conditions and their mini-
mal nutritional requirements, as well as their cosmo-
politan distribution, enables this bacterium to be a si-
lent nosocomial inhabitant.  
A large number of publications have pointed out the 
increasing resistance rates, with special concern on the 
increase of isolation of multiresistant and panresistant 
strains [1, 2, 3].  
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As a result, endemic situations with variable inci-
dences have emerged in many hospitals [4, 5, 6]. The 
lack of pipeline antipseudomonal agents available get 
the situation worse at short-term.  
This has enhanced the interest in exploring the use of 
associations of several antibiotics and also in the res-
cue of old antimicrobials whose use had ceased sev-
eral decades ago because of its potential toxicity; 
some of them have been used and assayed in several 
antibacterial combinations to achieve synergy [7]. 
The aim of this study was to assess synergistic effect 
of several antibiotic combinations as well as to ex-
plore bactericidal effect on P. aeruginosa isolates be-
longing to this endemic clone, thus, we explored the 
combinations of ceftazidime and meropenem with to-
bramycin and ciprofloxacin in four representative 
multiresistant P. aeruginosa isolates belonging to a 
nosocomial endemic clone of the Hospital del Mar, in 
Barcelona. Preliminary experiments to explore the 
mechanisms of resistance in these isolates were also  
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2. Materials and methods
Bacterial strains: Four representative MR  P. 
aeruginosa isolates belonging to an endemic clone 
from the Hospital del Mar at Barcelona (Spain) were 
selected.  
Susceptibility tests: Susceptibility tests were done by 
diffusion or microdilution using the gramnegative 
breakpoint panel 38 for non-fermenter gramnegative 
bacilli of MicroScan® Walkaway system (Siemens 
Diagnostic Inc., CA) [Clinical Laboratory Standards 
Institute. Performance Standards for Antimicrobial 
Susceptibility Testing: Twenty-first Informational 
Supplement M100-S21. CLSI, Wayne, PA, USA, 2011. 
Clinical Laboratory Standards Institute. Performance 
Standards for Antimicrobial Disk Susceptibility Tests 
-Tenth Edition; Approved Standard M02-A10. CLSI, 
Wayne, PA, USA, 2009.]. 
Clonal identification: Serotyping and pulse-field gel 
electrophoresis (PFGE) were done. DNA for PFGE 
was digested with 40 U of xbal.  
Characterization of the mechanisms of resistance in-
volved: Expanded spectrum ß-lactamases (ESBLs), 
AmpC ß-lactamases (AmpCs), oxacillinases (OXA-1t, 
OXA-2t, OXA-10t, OXA-20t, OXA-23t, OXA-24t, 
OXA-46, OXA-48, OXA-51t and OXA-58t), carbap-
enemases (GES, IMI, KPC, NMC, SME, GIM, IMP, 
SPM, VIM), aminoglycosides (ANT-2"Ia, ACC-3'-IIa, 
ACC-6'-Ia, ACC-6'-Ib, ACC-6'-Ic, ANT-4"-IIa, 
AAC-3'-Ia, AAC-3'-Ib, AAC-2'-Ia), and quinolones 
(parC, gyrA were determined by PCR and sequencing 
(Macrogen Inc, Seoul, Korea) using the primers de-
scribed in table 1 or in Aragon et al. [8]  
Outer membrane proteins (OMPs). OMP extracts ob-
tained and electrophoresed as previously described [9]  
Mechanisms of efflux. The growth inhibition assays 
were performed as described [10]  with some modi-
fications. P. aeruginosa isolates were inoculated at 1 - 
2 x 10
6
 cfu/ml into tubes containing TSB with antibi-
otics at concentrations one-fourth the previously de-
termined MIC, either in the presence or absence of 
PAßN (10 mg/L final concentration). Bacteria were 
incubated at 37ºC, and optical density values at a 
wavelength of 550 nm were registered over 8 hours. 
The OD550 values were measured after 7 h. 
Combination of Antibiotics: Antibiotic powders were 
provided by their manufacturers (Ceftazidima Com-
bino Pharm®, Spain; Meropenem AstraZeneca, Spain; 
Tobramycin sulfate Fagron® Ciprofloxacino Combino 
Pharm, Spain).  
Synergy tests: Synergy testing was performed using 
the checkerboard [11] and the epsilometric (E-test) 
methods [12]. Determinations by E-test were per-
formed by duplicate, since the variation of concentra-
tion range on E-test strips, a MIC-to-MIC placement 
of the strips was easier to perform and seemed to give 
a more accurate diffusion of the two drugs [12]. E-test 
strips were placed on  the bacterial lawn sequentially, 
the first E-test strip (strip A) was incubated for 1 h at 
room temperature, then removed, and the second 
E-test strip (strip B) was added immediately over the 
imprint of the strip A. Plates were incubated for 18 h 
at 37°C. Respective MIC strips/scales were used to 
read MICs by placing them in each gradient’s position.  
The summation operator Fractional Inhibitory Con-
centration Index (FICI) was calculated for each set of 
MICs, and the mean FICI was used to compare with 
the checkerboard test. High-off scale MICs (>256 
mg/L) were converted to the next two-fold dilution 
(512 mg/L). The following formulas were used to 
calculate the FICI: (i) FIC of drug A = MIC of drug A 
in combination/MIC of drug A alone; (ii) FIC of drug 
B = MIC of drug B in combination/MIC of drug B 
alone; (iii) FICI = FIC of drug A + FIC of drug B. 
Synergy was defined by a FICI  0.5. Antagonism was 
defined by a FICI 4. Values of FICI between 0.5 and 
1 were termed additive and those from1 to  4 indif-
ferent [13].  
The Susceptible Breakpoint Index (SBPI) [14] was 
also calculated. SBPI= (susceptible breakpoint A/MIC 
of A in combination) + (susceptible breakpoint B/MIC 
of B in combination). A SBPI of 2 indicates that the 
MICs of antimicrobials A and B in combination are 
either equivalent to their respective breakpoints or that 
the combination MIC of one of the antimicrobials is 
lower than its susceptible breakpoint.  
Time-kill analysis: Time-kill assays were performed 
by the broth macrodilution technique [11] only for 
those antibiotic combinations showing synergy by 
both checkerboard and E-test. Each organism was 
tested against each antimicrobial agent, alone and in 
combination. The combinations tested against each 
organism were the -lactam (CAZ or MEM) with 
TOB (i.e., CAZ plus TOB, MEM plus TOB). The 
concentrations of each antimicrobial agent tested 
alone or in combination were 1, 1/2, 1/4 and 1/8 of 
MIC values. Volumes of 10 mL tubes inoculated at 6 x 
10
5
 cfu/ml. were incubated at 37ºC aliquots of 0.1 ml 
were withdrawn from each tube at 0, 6, and 24 h, and 
10-fold dilutions were prepared and inoculated onto 
blood agar plates. Plates were incubated for 24 h/48 h 
at 37ºC and colony counted, lower limit of detection 
was 40 cfu/ml. 
Synergy was defined as decreases 10
2
 cfu/ml (2-log 
10) at 6 or 24 h in the combination compared with that 
of the most active single agent. Indifference as a 
10-fold change in colony count at 6 or 24 h in the 
combination compared with that of the most active 
single agent and Antagonism as a 100-fold increase in 
colony count at 6 or 24 h in the combination compared 
with that of the most active drug alone. Bactericidal 
activity was defined as a  3 log10 cfu/ml decrease in 
the starting inoculum.  P. aeruginosa ATCC 27853 
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was used as quality control strain in all susceptibility 
tests by microdilution technique, in all checkerboards, 
time-kill tests, and in every lot of E-tests strips . ATCC 
27853 is a susceptible strain (CAZ 1 µg/ml; MEM 
0.25 µ/ml; TOB 0.5µg/ml and CIP 0.25 µg/ml) 
3. Results 
MicroScan® susceptibility results expressed in MIC 
values (mg/L) were: Aztreonam 16; Ceftazidime 16 
and >16; Cefepime 16; Piperacilline + tazobactam 32
and 64; Imipenem 8 and >8; CIP >2; Gentamicin >8; 
TOB >8; Amikacine 8 and 16; Colistine  2.  
The four selected representative multiresistant P. 
aeruginosa gave identical PFGE pattern and all be-
longed to the O:4 serotype. In all of them the same 
resistance mechanisms were detected: 
bla-OXA-1-type, bla-OXA-2-type, ant(2”)-Ia and 
ant(4”)-IIb. Moreover two mutations on parC 
(Leu87Trp and Leu168Gln) one in gyrA (Asn87Asp) 
as well as an important reduction of OmpD porin ex-
pression were detected.  
Fig 1 shows the effect of inhibition of efflux by the 
efflux pump inhibitor (EPI) PAßN on (1) CIP suscep-
tibility showing 4-fold decrease in MIC with the EPI; 
(2) CAZ susceptibility to which 2 and 4-fold decrease 
in MIC with the EPI were measured; (3) MEM sus-
ceptibility demonstrating 0 and 2-fold decrease in 
MIC with the EPI and finally (4) TOB in this case the 
antagonism between TOB and the EPI does not allow 
to measure the effect. 
By both checkerboard and E-test, combinations of 
CAZ and MEM with TOB resulted to be synergistic 
against the isolates (Table 2). The combinations with 
CIP resulted to be additive or indifferent by the two 
methods, in the two isolates tested (Table 2). SBPI 
values were in concordance with FICI interpretation 
except in MEM + TOB combination.  
Time-kill experiments done showed in two of the iso-
lates synergy in the TOB--lactam combinations. 
CAZ+TOB as well MEM+TOB combinations showed 
synergy and bactericidal activity at different concen-
trations (Table 3).  
  
Fig 1. Effect of inhibition of efflux by the efflux pump 
inhibitor (EPI) PAßN on (1)ciprofloxacin susceptibil-
ity; all the strains were tested over the same range of 
ciprofloxacin concentrations (0.125 to 128 µg/ml), and 
showed 4-fold decrease in MIC with the EPI; (2) cef-
tazidime the strains were tested over the same range of 
ceftazidime concentrations (0.125 to 128 µg/ml), and 
showed 2 and 4-fold decrease in MIC with the EPI; (3) 
meropenem susceptibility, strains were tested over the 
same range of meropenem concentrations (0.125 to 
128 µg/ml), and showed 0 and 2-fold decrease in MIC 
with the EPI and (4) tobramycin susceptibility. All the 
strains were tested over the same range of tobramycin 
concentrations (0.125 to 128 µg/ml), in this case the 
antagonism between tobramycin and the EPI does not 
allow to measure the effect 
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Enzyme Primer name Primer sequence  GenBank number 
OXA-1t OXA1/4 CAGCAGCGCCAGTGCATC  J02967 
 OXB1/4 TCCTGTAAGTGCGGACAC              
OXA-2t OXA-2 up GCCAAAGGCACGATAGTTGT        X07260 
 OXA-2 dn ATAGAGCGAAGGATTGCCCG       
OXA-10t OXA-10 up GAGTTCTCTGCCGAAGCCG  J03427 
 OXA-10 dn GCCACCAATGATGCCCTCAC   
OXA-20t OXA-20 up CAGCTGTTGTACTTGTCTCTC  AF024602 
 OXA-20 dn CGGATTGAAGAATAGCACGCG  
OXA-23t OXA-23 up CTTGCTATGTGGTTGCTTCT  AJ132105 
 OXA-23 dn CATTACGTATAGATGCCGGC   
OXA-24t OXA-24 up CTCTCAGTGCATGTTCATCT  AJ239129 
 OXA-24 dn CGAATAGAACCAGACATTCC  
OXA-46 OXA-46 up ATGGCAATCCGATTCTTCAC  AJ969237 
 OXA-46 dn TTAGTTGGGTGGCAATGCGT   
OXA-48 OXA-48 up CGTTATGCGTGTATTAGCCTTAT  AY236073 
 OXA-48 dn TTTTTCCTGTTTGAGCACTTCTTT    
OXA-51t OXA-51 up ATGAACATTAAAACACTCT  AJ309734 
 OXA-51 dn TTAAGGGAGAACGCTACA   
OXA-58t OXA-58 up CTTGTGCTGAGCATAGTATGAG  EU642594 
 OXA-58 dn ACCAATACGTTGCAATTCAC   
GES GES-1-up ATGCGCTTCATTCACGCAC GU831563 
 GES-1-dn CTATTTGTCCGTGCTCAGG  
IMI IMI-up GTCACTTAATGTAAAACC  U50278 
 IMI-dn TTAAGGTTATCAATTGCG   
KPC KPC-up TGTCACTGTATCGCCGTC  AF297554 
 KPC-dn TTACTGCCCGTTGACGCC   
NMC NMCA-up GTCACTTAATGTAAAGCA  Z21956 
 NMCA-dn GGTTATCAATTGCAATTC   
SME SME-up CAATTGCCTGAATTGCAAT AY584237 
 SME-dn CGGCTTCATTTTTGTTTA  
GIM GIM-up ACTTGTAGCGTTGCCAGC AJ620678 
 GIM-dn AATCAGCCGACGCTTCAG  
IMP IMP up GAAGGCGTTTATGTTCATAC DQ842025 
 IMP dn GTAAGTTTCAAGAGTGATGC   
SPM SPM-1 A CTGCTTGGATTCATGGGCGC  DQ145284 
 SPM-1 B CCTTTTCCGCGACCTTGATC   
VIM VIMB ATGGTGTTTGGTCGCATATC DQ489717 
 VIMF TGGGCCATTCAGCCAGATC   
ANT-2"Ia ANT-2"Ia FW ACGCCGTGGGTCGATGTTTGATGT X04555 
 ANT-2"Ia R CTTTTCCGCCCCGAGTGAGGTG  
ACC-3'-IIa AAC-3'-IIa FW GGCAATAACG- X13543 
GAGGCGCTTCAAAA 
 AAC-3'-IIa R TTCCAGGCATCGGCATCTCATACG  
ACC-6'-Ia ACC-6'-Ia FW ATGAATTATCAAATTGTG M18967 
 ACC-6'-Ia R TTACTCTTTGATTAAACT  
ACC-6'-Ib ACC-6'-Ib FW CAAAGTTAGGCATCACA M21682 
 ACC-6'-Ib R ACCTGTACAGGATGGAC  
ACC-6'-Ic ACC-6'-Ic FW CTACGATTACGTCAACGGCTGC M94066 
 ACC-6'-Ic R TTGCTTCGCCCACTCCTGCACC  
ANT-4"-IIa ANT-4"-IIa FW CCGGGGCGAGGCGAGTGC M98270 
 ANT-4"-IIa R TACGTGGGCGGATT-
GATGGGAACC 
AAC-3'-Ia AAC-3'-Ia FW GCAGTCGCCCTAAAACAAA X15852 
 AAC-3'-Ia R CACTTCTTCCCGTATGCCCAACTT  
AAC-3'-Ib AAC-3'-Ib FW GCAGTCGCCCTAAAACAAA L06157 
 AAC-3'-Ib R GGATCGTCACCGTAGTCTGC  
AAC-2'-Ia AAC-2'-Ia FW AGAAGCGCTTTACGATTTATTA L06156 
  AAC-2'-Ia R GACTCCGCCTTCTTCTTCAA  
parC Ps parC up CTATCTGAACTATTCCATGTACGT AE004091 
 Ps parC dn ACGCGACTTCCCGCAGGTTG  
gyrA Ps gyrA up ATCGTCGGGCGGGCCCTGCCG AE004091 
 Ps gyrA dn GGGGTTGTCCATCAGCGCCA  
Table 1. Primers used to detect different genes involved in  
antimicrobial resistance. 
4. Discussion 
In our hospital a prolonged endemism of MR  P. 
aeruginosa has been observed. Colistine resistant or 
intermediate isolates were encountered, albeit in low 
number; the treatment of infections caused by such 
isolates is difficult and nowadays restricted to colistine 
and amikacine. 
On the other hand we tried to validate synergy testing 
by E-test as a rapid and easier tool to demonstrate 
synergy compared with the CB. Studied isolates 
showed resistance against all available antipseudo-
monal antibiotics except amikacin and colistine. Anti-
biotics for synergy testing were selected after review-
ing the literature on the potentially active and less 
toxic antibiotic combinations for MR P. aeruginosa. 
The resistance pattern and the lack of carbapenemases 
and extended spectrum betalactamases suggested that 
resistance was mainly due to a derepresion of AmpC 
enhanced by OXA type betalactamases , up-regulation 
efflux system showed by the pump inhibitor effect of 
PAßN, reduction of OprD expression and alteration of 
topoisomerases and two aminoglycoside-modifying 
enzymes encoding resistance to kanamycin, gentamy-
cin and tobramycin.  
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Synergy, was observed in combinations of CAZ and 
MEM with TOB both by E -test and checkerboard test. 
In the present study, as stated by other authors [12] , 
checkerboard and E-test methods yielded equivalent 
results, making the E- test, by its simplicity, a suitable 
method in clinical laboratories for synergy studies. 
The SBPI values were in concordance with FIC index 
in all combinations but for MEM+TOB. In some 
combinations SPBI values were higher when CLSI 
susceptibility breakpoints instead EUCAST 
[http://www.eucast.org/clinical_breakpoints] were 
used. The SBPI was more discriminatory than FIC 
because it uses the susceptible breakpoint MICs and 
likely has more clinical relevance [14]. 
Time-kill results showed synergy in most of the com-
binations. Bactericidal activity was also observed in a 
lesser extent. Synergy and bactericidal activities ob-
served with TOB concentrations lower than MIC val-
ues when combined with CAZ or MEM at 1 MIC. The 
bactericidal activity at 6 hours but not at 24 hours ob-
served in most of meropenem combinations could be 
the consequence of meropenem degradation and the 
low TOB concentration that can’t prevent regrown. 
 In P. aeruginosa, synergistic activities between 
-lactam and aminoglycosides were described previ-
ously [15, 16], but variable synergy rates were de-
scribed depending on the -lactam antibiotic and on 
the characteristics of the  P. aeruginosa strains in-
cluded (susceptible, resistant or multiresistant strains). 
The mechanism of synergy between -lactam and 
aminoglycosides is believed to be due to the increase 
of aminoglycoside penetration due to  the activity of 
the -lactam and, in turn, to the increase of entry of 
the -lactam due to the cationic displacement caused 
by aminoglycosides [17]. The mechanisms of resis-
tance have a critical role in the interaction of the dif-
ferent antibiotics and the absence of synergy observed 
in the ciprofloxacin combinations, unlike other studies, 
may be due to the presence of a resistance mechanism 
in our isolates [18]. It should be noticed that in our 
experiments synergy with antibiotics whose resistance 
mechanisms are chromosomally encoded resulted to 
be less evident that for those antibiotics whose resis-
tance mechanisms are related to acquisition of genetic 
material. 
Meropenem is commonly prescribed in nosocomial 
infections when the presence of  P. aeruginosa is sus-
pected. A peak plasma concentration of 53-62 mg/L 
were yielded after a dose of 1g meropenem in ICU 
patients [19], which is higher than all MIC values ob-
served in the present study. 
Table 2. In vitro interaction between ceftazidime and meropenem with tobramycin and ciprofloxacin, expressed by means of FICI  
(checkerboard and E-test methods) and SBPI. FICI: Synergy  0.5; Additive >0.5 -1Indifferent: >1 - <4; Antagonism 4; b: SBPI: Sus-
ceptible Breakpoint Index: SBPI CLSI/ SBPI EUCAST if different values were present; ND: Not done 
Meropenem shows a time-dependent killing above 
MIC activity and its administration in continuous 
infusion could improve clinical results. Both strate-
gies have shown concentrations above MIC in 
clinical studies [20]. Only maximum serum concen-
trations of ceftazidime administered in intermittent 
intravenous administration in human experiences 
[21] were in excess of the all MIC values of the 
studied isolates. 
The pharmacodynamic profile of the aminoglyco- 
CAZ+TOB MEM+TOB CAZ+CIP MEM+CIP 
E-test 
Check. 
test 
 E-test Check. test E-test 
Check. 
test 
E-test 
Check. 
test 
Isolate 
number 
a
FICI 
b
SBPI FICI FICI SBPI FICI FICI SBPI FICI FICI SBPI FICI 
1449133 
0.36 2.12 0.34 0.35 1.33/0.83 0.31 1-1.5 0.69/0.67 1 >1 0.19/0.17 1 
2404459 
0.25 2.12 0.25 0.41 1.12/0.62 0.5 ND ND ND ND ND ND 
1169527 
0.31 1.83 0.37 0.25 1.66/0.99 0.37 2 0.26/0.25 1 1-1.5 0.19/0.17 1 
2908162 
0.29 2.33 0.37 0.5 1.12/0.62 0.37 ND ND ND ND ND ND 
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Isolate number Antibiotic combina-
tions 
1449133 1169527 
1 TOB + 1 CAZ S B S B 
1/2 TOB + 1 CAZ S B S B 
1/4 TOB + 1 CAZ S B S B 
1/4 TOB + 1/2 CAZ S NB S NB 
1/8 TOB + 1 CAZ S B S NB 
1 TOB + 1 MEM S B S B 
1/2 TOB + 1 MEM S NB S B 
1/4 TOB + 1 MEM NSa NB S NBb
1/8 TOB + 1 MEM NS NB S NBb
Table 3. Time-kill results at 24 h. Antibiotic combinations ex-
pressed as MIC’s fractions Synergy: S; Bactericidal activity: B; 
No synergy: NS; No Bactericidal: NB. Microdilution MIC 
values (mg/L): 1449133 CAZ 64, MEM 8, TOB 128; 1169527: 
CAZ 16, MEM 8, TOB 64; Synergy: 2-log 10 decrease in col-
ony count in the combination compared with that of most ac-
tive single agent; Bactericidal:  3 log 10 cfu/ml decrease in the 
starting inoculum. a: Synergy at 6 h; b: Bactericidal at 6 h  
sides has been characterized both in vitro and in 
vivo. Since these antibiotics eliminate bacteria more 
rapidly when their concentrations are above the 
MIC of the bacteria, their killing activity is referred 
to as concentration or dose-dependent bactericidal 
activity [22]. Concentrations of 8 to 10 times MIC 
value have been proposed to achieve the optimal 
bactericidal activity of aminoglycosides [23]. 
Once-daily dose of nearly 7mg/Kg tobramycin has 
been associated with peak concentrations of 30 
mg/L in adult and pediatric patients with cystic fi-
brosis [24, 25]. This concentration matches with 1/2, 
1/4 and 1/8 MIC values of tobramycin included in 
our in vitro study. Synergy and bactericidal activity 
against 1449133 P. aeruginosa isolate was mainly 
observed with these MIC tobramycin values com-
bined with 1 MIC ceftazidime at 6h and 24h assay. 
However, tobramycin and meropenem combina-
tions showed better results at 6 h, possibly, as stated 
above, as a consequence of meropenem degrada-
tion.  
Recently, a mathematical simulation in combination 
therapy based on quantitative methods in a neutro-
penic murine pneumonia model have shown high 
consistence with the predictions of this in vitro
model [26] .  
Other in vitro studies as antibiotic degradation, 
more antibiotic combinations and also more isolates 
with different resistance mechanisms are in pro-
gress before initiating the studies in animal models 
in order to find a combination active on P. aerugi-
nosa MR.  
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